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SUMMARY The human gut microbiota is engaged in multiple interactions affecting
host health during the host’s entire life span. Microbes colonize the neonatal gut
immediately following birth. The establishment and interactive development of this
early gut microbiota are believed to be (at least partially) driven and modulated by
speciﬁc compounds present in human milk. It has been shown that certain genomes
of infant gut commensals, in particular those of biﬁdobacterial species, are geneti-
cally adapted to utilize speciﬁc glycans of this human secretory ﬂuid, thus represent-
ing a very intriguing example of host-microbe coevolution, where both partners are
believed to beneﬁt. In recent years, various metagenomic studies have tried to dis-
sect the composition and functionality of the infant gut microbiome and to explore
the distribution across the different ecological niches of the infant gut biogeography
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of the corresponding microbial consortia, including those corresponding to bacteria
and viruses, in healthy and ill subjects. Such analyses have linked certain features of
the microbiota/microbiome, such as reduced diversity or aberrant composition, to
intestinal illnesses in infants or disease states that are manifested at later stages of
life, including asthma, inﬂammatory bowel disease, and metabolic disorders. Thus, a
growing number of studies have reported on how the early human gut microbiota
composition/development may affect risk factors related to adult health conditions.
This concept has fueled the development of strategies to shape the infant microbi-
ota composition based on various functional food products. In this review, we de-
scribe the infant microbiota, the mechanisms that drive its establishment and com-
position, and how microbial consortia may be molded by natural or artiﬁcial
interventions. Finally, we discuss the relevance of key microbial players of the infant
gut microbiota, in particular biﬁdobacteria, with respect to their role in health and
disease.
KEYWORDS microbiome, microbiota, infants, metagenomics, virome, biﬁdobacteria,
gut commensals, probiotics, gut microbiota
INTRODUCTION
General Features of the Infant Gut Microbiota
The human body harbors trillions of microbial cells whose coordinated actions arebelieved to be important for human life. Such microbial cell populations reach
their highest density in the intestinal compartment, where they collectively form a
complex microbial community known as the gut microbiota (1) which develops over
the course of host infancy to eventually reach its adult form (2–4). Gut microbiota
members may belong to any of the three domains of life, i.e., Archaea, Bacteria, and
Eukarya, and also include viruses, and they are known to establish complex trophic
relationships with each other and their human host, ranging from symbiosis to para-
sitism (5). The human gut microbiota is composed of autochthonous, also known as
indigenous, microorganisms and allochthonous or transient microorganisms (6). In this
context, only a relatively small number of (opportunistic) pathogens are considered to
be members of the gut microbiota, residing unperturbed within the enteric host
microbiota and becoming a health threat to the host only when the gut ecosystem is
disturbed and the gut microbiota homeostasis becomes disrupted (see below).
The gastrointestinal microbiota composition may be affected by a number of
environmental parameters, such as pH, oxygen levels/redox state, availability of nutri-
ents, water activity, and temperature, enabling various populations to thrive and exert
different activities while interacting with their environment, including that of the
human host (7).
The abundant and diverse members of the human gut microbiota exert critical roles
in the maintenance of human health by assisting in the breakdown of food substances
so as to liberate nutrients that would otherwise be inaccessible to the host, by
promoting host cell differentiation, by protecting the host from colonization of patho-
gens, and by stimulating/modulating the immune system. Various epidemiological
studies have established a clear correlation between factors that disrupt the gut
microbiota during childhood on the one hand and immune and metabolic disorders
later in life on the other (8–10). Thus, there are increasing experimental data that
support long-term health beneﬁts elicited by the infant gut microbiota and that also
implicate the early human gut microbiota in modulating risk factors related to partic-
ular adult health conditions (11). This realization has in turn fueled the development of
strategies to inﬂuence the development, composition, and activities of the infant
microbiota by use of nutraceutical products (e.g., probiotics and/or prebiotics).
An intriguing feature of the adult gut microbiota is that the development of such a
microbial assemblage reaches a climax status represented by the establishment of a
homeostasis among all its members (12). A wide range of factors can cause shifts in this
microbiota balance, thereby disrupting the gut microbiota homeostasis and causing a
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so-called state of dysbiosis. There is controversy on the exact meaning of dysbiosis,
simply because of the lack of an accurate description of a “normal” or healthy
microbiota. Dysbiosis is usually associated with harmful effects and may have long-term
consequences leading to disorders or diseases, including obesity, diabetes, and inﬂam-
matory bowel disease (IBD) (13–17). In addition, ﬂuctuations occur in the gut microbi-
ota composition throughout host development from infancy to early childhood, from
young to aging adulthood, and during pregnancy.
Gut Microbiota Development and Dynamics
Each individual can be viewed as an island that consists of various habitats which are
colonized by microbial communities and which follow rules that create and shape
diversity in local assemblages, including dispersal, in situ diversiﬁcation, environmental
selection, and ecological drift (18, 19) (Fig. 1).
Dispersal is a natural process causing an increase in diversity in local microbial
communities, consistent with the view of the human body as an ecological “island,” an
area of habitat, which is continually sampling the pool of available colonists (19).
Another ecological process that impacts microbial communities is local diversiﬁcation,
which is based on rapid microbial adaptation via mutation or recombination (19). In this
scenario, horizontal gene transfer events, often driven by phages, may represent one of
the main forces responsible for microbial diversiﬁcation, especially for those microbes
that share the same ecological niche (20).
Environmental selection represents another key ecological process which shapes
the human microbiota and which may be viewed as a “habitat ﬁlter” consisting of an
assemblage of resources and conditions that allow and/or support growth of certain
microorganisms but not others, underscoring the selection of microbial features that
permit survival and growth in the host. Such a scenario assumes that the host
determines the microbiota rather than the other way around. Notably, the overall
proﬁles that can originate from environmental selection (niche-based interactions) may
vary as a function of the spatial scale across which these processes occur (21).
In addition, the abundances of microbial taxa can change due to another ecological
process, identiﬁed as ecological drift or demographic stochasticity. Such an ecological
process is responsible for the disappearance of low-abundance species (e.g., antibiotic-
sensitive strains) unless they gain a competitive advantage across a different ecological
niche or become replenished by dispersal from outside the community (19).
Finally, the microbiota composition and relative abundance of each bacterial mem-
ber are also inﬂuenced by phage predation, which acts as a very powerful force that
impacts community structure and dynamics (see below).
FIG 1 Microbiota composition across the different infant body sites. A global overview of the relative
abundances of key phyla of the infant microbiota composition in different body sites and at different
stages of early life is shown. Concentric cake diagrams schematically represent interindividual variability.
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The Holobiont Concept Applied to Infants
The human body is considered a host symbiont or holobiont, which acts as an
ecosystem under selection to minimize conﬂict between individual members (22). The
holobiont concept does not consider macrobes as autonomous individuals but as
highly organized biological units, which not only consist of the entire eukaryotic cell
arsenal that makes up the host’s body but also include the microbiota contained on or
within the host (23, 24) (Fig. 1). The holobiont concept emphasizes the important role
of coevolution in the assembly and dynamics of the human ecosystem and highlights
that long- and short-term selective pressures on the human microbiota are not inevi-
tably aligned. In this context, genetic variation among the hologenomes, i.e., the
combined genetic content of the host, its organelles, and its associated microbiota, may
happen due to changes in the host genome or modiﬁcations of the genomes of the
constituent symbiotic microorganisms (25, 26). Overall, the microbiomes, and conse-
quently their encoded phenotypes, may change through variations in the relative
abundances of speciﬁc microorganisms, through modiﬁcation of the genomes of
existing resident microorganisms, or through loss or gain of microbial symbionts into
holobionts. Interestingly, the genetic variation that may occur within a microbiome
greatly exceeds that of the host genome, while it also develops much more rapidly than
that of the host genome. Therefore, microbial sources of hologenomic variation are
potential targets for evolution, and the microbiome should consequently be considered
in the overall study of human evolution.
An emerging perception from recent studies is that the microbial communities
which belong to the holobiont are particularly important for host health during the
establishment of the infant gut microbiota (27). This developmental trajectory involves
crucial steps such as choreographed gut colonization by bacterial populations, dynamic
alteration in the virome structure, and transkingdom interactions between host and
microbial cells.
Projects Directed To Assess the Composition/Functionality of the Infant Gut
Microbiota
As mentioned above, the microbial gut community plays an important role in
human health (28). Alterations and aberrations in the gut microbiota composition
during neonatal life, which represents the ﬁrst month of life from the moment of birth,
as well as during infancy, which spans 1 month until 2 years of age, have been
associated with pediatric disorders and the onset of disease in later life (29). We may
assume that the early gut microbiota contributes to disease progression later in life and
that the foundation for a stable adult gut microbiota is already established in infancy.
This notion explains the need for an in-depth comprehension of the infant microbiota
composition and development, the interactions of microbiota members with each
other and their infant host, and the mechanisms by which such host-microbiota
interactions maintain gut homeostasis. Indeed, a number of research efforts, in-
cluding the JPI-HDHL projects EarlyMicroHealth, EarlyVir, and GI-MDH and the French
Epiﬂore, the Irish Infantmet, and the NIH-funded MOMS-PI projects, in addition to other
publicly and privately funded initiatives, are aimed at understanding the factors that
determine the infant intestinal microbiota composition, establishment, and develop-
ment and their associated long-term health consequences.
In the following sections, we assess the current knowledge about the infant gut
microbiota by analyzing the technical approaches employed to catalogue infant gut
microbial consortia and reconstruct the functionalities exerted by these communities.
In addition, we discuss the mechanisms responsible for development, transmission,
establishment, and persistence of microorganisms in the infant gut and their implica-
tions for health in regard to early and long-lasting outcomes. We also analyze how the
microbial consortia can be modulated by natural and/or artiﬁcial interventions. Fur-
thermore, we discuss the relevance of some of the most dominant microbial members
of the infant gut in terms of current knowledge regarding their biological role(s).
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TECHNICAL APPROACHES FOR MICROBIOTA DETERMINATION
General Features
Although microorganisms are abundant and ubiquitous, we currently lack a funda-
mental mechanistic understanding of many of the key roles played by microorganisms
in nature, including those that reside in the human body (30). Until the recent
development of novel culturomics approaches (31), only a very small fraction of the
human gut microbiota had been isolated and studied in pure culture (30). The pre-
sumption that a large proportion of the human gut microbiota was uncultured (32)
prompted the development of culture-independent approaches, i.e., metagenomics,
metatranscriptomics, and metaproteomics, to discover the identities, activities, and
functional roles of the so-far-uncultivated members of the gut microbiota (Fig. 2).
High-throughput sequencing of (a portion of) the 16S rRNA gene (i.e., 16S rRNA
gene-based microbial proﬁling analysis) as a conserved phylogenetic marker represents
the current standard methodology for proﬁling complex microbial communities, al-
though shotgun metagenomics is progressively replacing 16S rRNA gene-based micro-
bial proﬁling analysis (see below). The 16S rRNA gene-based microbial proﬁling ap-
FIG 2 General overview of the bioinformatic pipelines for the 16S rRNA gene microbial proﬁling and shotgun metagenomics. Starting from DNA extraction of
a microbial community and subsequent sequencing, the pipeline generates taxonomic proﬁling of the microbiota and the reconstruction of microbial genomes
with corresponding functional analyses of the genes.
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proach relies on universal primers for ampliﬁcation of single or multiple hypervariable
regions of the 16S rRNA gene (33). Reads of the obtained amplicons, having been
retrieved from a next-generation sequencing (NGS) platform, are processed using
bioinformatic pipelines, such as the popular Qiime software suite (34) or Mothur (35),
thus allowing the reconstruction of the microbial composition of the analyzed envi-
ronmental sample. This methodology also facilitates identity assignment for unknown
members of microbial communities through discrimination based on the sequences of
their unique hypervariable regions (36). Furthermore, sequencing of a microbiome, an
approach called metagenomics, has been developed to conﬁrm both the phylogenetic
and the functional gene repertoire of the gut microbiota (37). However, one of the
limitations of metagenomic approaches is that the microbiome data do not provide
information on whether or not genes are expressed at any given time. Other omics
approaches have been developed to counteract these limitations, including the se-
quencing of the whole microbial RNA pool of a given sample, i.e., metatranscriptomics,
or analysis of the overall protein content or proteome, i.e., metaproteomics. Notably,
similar to the case for the metagenomics approach, the usefulness of the latter two
technologies is limited by the fact that many genes or their homologs (and thus their
products) are not functionally characterized. Finally, assessment of the (microbially)
produced metabolites, i.e., metabolomics, will generate an overall signature represent-
ing microbial activities.
The Gold Standard Methodology for Microbiota Determination
Many human gut microbiota studies have relied on 16S rRNA gene-based
microbial proﬁling analyses. The 16S rRNA gene encompasses nine different vari-
able regions, i.e., V1 to V9, each ﬂanked by highly conserved DNA sequences that
are suitable for PCR primer binding (38). However, no standard approach exists to
select the most appropriate PCR primer pair that is equally efﬁcient in amplifying
part of the 16S rRNA-encoding gene for all taxa and phylotypes present in biolog-
ical samples, and very often the decision to employ a particular primer pair is based
on historic use, anecdotal evidence, or/and current literature (39–42). In addition,
none of the currently available DNA sequencing technologies offers full-length
gene sequencing at sufﬁcient depth for cost-effective multiplexing of multiple
samples in a single run.
As mentioned above, an alternative to human gut microbiota cataloguing through
16S rRNA gene microbial proﬁling is shotgun metagenomic sequencing. This approach
bypasses gene-speciﬁc ampliﬁcation and potentially sequences all (fragmented) DNA
extracted from the analyzed environmental sample, including that from unclassiﬁed
bacteria and viruses. Shotgun metagenomics provides substantially more information,
including insights into functional aspects of the microbial community, than 16S rRNA
gene-based microbial proﬁling. In this regard, it does not suffer from the potential bias
of the ampliﬁcation reaction required for 16S rRNA gene-based proﬁling. More specif-
ically, shotgun data can be employed to explore the repertoire of genes partici-
pating in a wide range of metabolic processes, such as those involved in biosyn-
thesis of compounds, e.g., short-chain fatty acids, or in the catabolism of nutrients,
e.g., carbon sources. Functional classiﬁcation of the shotgun metagenomic reads
through the use of customized databases may also provide insights into a plethora
of functional aspects of the gut microbiome, such as antibiotic resistance, degra-
dation of conjugated bile salts, presence of (pro)phages, extracellular structures
responsible for adhesion, and immunomodulation. Moreover, an assembly-based
approach can be exploited to reconstruct complete or partial genomes of so-far-
uncultivated taxa, enabling the exploration of what until recently was referred to as
microbial dark matter (43).
However, interpretation of the enormous amount of data obtained from DNA
sequencing of complex bacterial communities, such as those residing in the gas-
trointestinal tract (GIT), requires substantial processing power and bioinformatic
pipelines for sequence information management, interrogation, and administration
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(30). Moreover, it should be mentioned that underpopulated reference databases
and poor functional characterization of many genes considerably limit the use-
fulness of the metagenomic approaches employed to investigate the gut micro-
biota.
Novel NGS-Based, Cutting-Edge Approaches To Achieve a High-Deﬁnition Image
of the Gut Microbiota Composition
16S rRNA gene-based microbial proﬁling analyses provide insights into the compo-
sition of the human gut microbiota at a taxonomic level that is mostly higher than
species level (44). Thus, in order to overcome this limitation and to obtain a more
detailed image of the composition of the human gut microbiota, i.e., at the species or
even subspecies level, it is necessary to target a molecular marker that is much more
variable at the interspecies level than the 16S rRNA gene. The internally transcribed
spacer (ITS) sequence, which represents a spacer region between the 16S rRNA and the
23S rRNA genes within the rRNA locus, represents a valuable genetic marker for such
a purpose. An ITS-based protocol known as ITS biﬁdobacterial proﬁling analysis was
applied to achieve a detailed image of biﬁdobacterial communities (45). This ITS-based
approach can differentiate between closely related biﬁdobacterial taxa at the subspe-
cies level and thus can resolve the biﬁdobacterial community composition in complex
ecosystems, including the human gut (45, 46). In this context, the ITS biﬁdobacterial
proﬁling approach was shown to identify biﬁdobacterial strains from the infant micro-
biota that apparently had been acquired by vertical transmission (from the correspond-
ing mother) (47).
Complete genome analysis of the human gut microbiome implies decoding the
complete genome sequence of each constituent strain. The possibility of achieving this
goal is very challenging because of the complexity of the gut microbiota, which may
include hundreds of operational taxonomic units (OTUs). In addition, the inability to
simulate, under in vitro testing, the essential conditions of the ecological niches renders
the cultivation of most members of the gut microbiota even more difﬁcult. Single-cell
genomics can productively contribute to the genomic characterization of the micro-
biome. Standard approaches to single-cell analyses involve the physical isolation of the
microbial cell, followed by extraction of chromosomal DNA from each cell and ampli-
ﬁcation of its genomic content (48). Notably, single-cell genome sequences can be
obtained directly from crude samples, thus generating reference genome sequences
for those gut microorganisms that are recalcitrant to cultivation (49, 50) or that
represent rare community members (51). However, the currently available single-
cell approaches are still not particularly efﬁcient, while the quality of the attained
data and the possibility of contamination may skew output data compared to that
obtained by standard genomic methods. Furthermore, single-cell data sets enable
the recovery of only about 35% of the genomic data. Single-cell genomics, in
particular if this technique can be further improved, is expected to ﬁll important
gaps in our understanding of the contents and structure of the human gut
microbiome. Nonetheless, despite promising developments of microﬂuidic technol-
ogies for microbial single-cell analysis, actual implementation of this approach
remains very challenging.
A recently applied approach to infer the gut microbiota composition at high
resolution down to the strain level without performing any isolation and cultivation of
bacterial strains involves the reconstruction of a genome sequence of an individual
microbiota member from shotgun metagenomic data (52). Such an NGS approach not
only provides taxonomic information about strain identity but also provides very useful
data related to the genetic makeup of the organism, thereby providing metabolic and
evolutionary insights (52).
An interesting tool aimed at determining the composition of the human gut
microbiota at high resolution (down to the strain level) is named MetaPhlAn (53). This
software relies on read mapping to a precomputed database of strain-speciﬁc marker
genes generated through comparative analysis of all publicly available bacterial ge-
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nome sequences. The main criticism of this approach is that only previously sequenced
species can be proﬁled, thus ignoring the presence of as-yet-unknown/uncultured
members in the population.
Culturomics Approaches
During the last decade, the above-mentioned culture-independent approaches have
been applied mostly in order to dissect the human gut microbiota composition,
whereas microbial cultivation techniques have, to a degree, been neglected (54). This
has caused a substantial knowledge gap between bacterial species that reside in the
human gut but have not yet been cultivated and those that have been isolated and
cultivated (54). It has been reported that approximately 56% of gut bacteria detected
by NGS approaches have cultured representatives (55, 56). With the advent of so-called
culturomic approaches, this gap is being closed. Culturomics employs high-throughput
cultivation conditions to investigate the human gut microbiota. Recently, various
culturomics studies of human stool samples involved the formulation of complex
growth media, which allowed the isolation and cultivation of a considerable number of
novel gut microorganisms (57–59).
ESTABLISHMENT AND DEVELOPMENT OF THE INFANT INTESTINAL MICROBIOTA
Microbial Colonization of the Infant Intestine
Colonization of the infant gut represents the de novo assembly of a complex
microbial community (19), a process that is inﬂuenced by several environmental and
host factors (60) (Fig. 3). Until recently this colonization process was thought to begin
at birth. However, this dogma of a sterile in utero environment has been challenged. A
growing body of scientiﬁc evidence has provided indications of bacterial presence in
the placenta, umbilical cord, and amniotic ﬂuid in healthy full-term pregnancies
(61–63). While these observations suggest that microbial exposure may start before
delivery, thereby allowing colonization of the fetus with early pioneers derived from the
maternal microbiota, several other studies have put forward arguments against such a
possibility of in utero gut colonization (for further details, see elsewhere in this review)
(64–66).
The development and maturation of gut microbiota constitute a dynamic and
nonrandom process, in which positive and negative interactions between key microbial
taxa take place (67, 68). This process is inﬂuenced by various perinatal conditions, such
as mode of delivery, type of feeding, and antibiotic usage. Diet, the mother’s age and
metabolic status, and family genetics and lifestyle have also been reported to impact
the infant microbiota, although these are more difﬁcult to determine and quantify in
FIG 3 Window of opportunity for microbiota modulation from gestation to childhood. The schematic
representation shows a list of prenatal, neonatal, and postnatal factors that contribute to the bacterial
gut composition in infants.
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humans. In the following section, we describe how these factors are thought to
inﬂuence the development of the infant gut microbiota.
Main Drivers of the Microbial Colonization of the Infant Intestine
Mode of delivery. As indicated above, in full-term infants, the delivery mode is
recognized as an important driver of the early gut microbiota composition (69).
Vaginally delivered infants come into contact with the maternal vaginal and fecal
microbiota, which results in neonatal gut colonization by vagina-associated microbes
such as Lactobacillus and Prevotella (70, 71). In contrast, caesarean section (C-section)-
delivered infants are not directly exposed to maternal microbes and are thus more
likely to become colonized by environmental microorganisms from maternal skin, the
hospital staff, or the hospital environment (2, 60, 71–73). Several studies using different
culture- and molecular-based methodologies, including the recently employed high-
throughput sequencing technologies and metagenomics approaches, have described a
deviating gut microbiota in these infants (2, 70, 73). Proteobacteria and Firmicutes were
reported to be the main phyla represented during the ﬁrst days of life, with Actino-
bacteria appearing in the feces of C-section-delivered babies at day 7 to 15 following
birth (74). Infants born by C-section also show a reduced complexity of the gut
microbiota and are less often colonized by microorganisms such as Biﬁdobacterium and
Bacteroides, while being more frequently colonized by members of Clostridium sensu
stricto (cluster I) and Clostridium difﬁcile (70, 71, 74–79).
These differences between vaginally and C-section-delivered babies gradually de-
crease, but C-section-delivered infants remain more heterogeneous than vaginally born
infants up to 12 months of life (73, 80). Notably, persistent differences in the gut
microbiota between C-section- and vaginally delivered children have been detected in
children as old as 7 years (77, 78, 81). In contrast, a very recent publication reported no
discernible effect of C-section on the early microbiota beyond the immediate neonatal
period (82, 83). The observed microbiota differences between vaginally delivered and
C-section-delivered babies have been associated with the protective effect of natural
birth, particularly since it has been suggested that C-section has long-term health
implications. In fact, the levels of various cytokines have been shown to be remarkably
reduced in infants born by C-section (76, 84), while C-section delivery has also been
associated with an increased risk of immune disorders such as asthma (85), allergy (86),
and type 1 diabetes (T1D) (87) and with a higher incidence of obesity (88). Notably, the
ﬁnding that the mode of delivery impacts the health status throughout adulthood,
while the effects on gut microbiota composition decrease after the ﬁrst years of life,
underlines the relevance of early gut microbiota in the maturation and development of
the host’s immune system.
Gestational age at birth. Gestational age is another important factor in the estab-
lishment of the infant gut microbiota. Neonates are termed preterm when they are
born prior to 37 full weeks of gestation (89). Preterm infants may initially, depending on
the degree of prematurity, have to overcome serious health challenges. They often
present with an immature gut and with immune, respiratory, and neurological issues,
while they suffer from exposure to extensive antibiotic and other drug treatments.
These neonates usually endure long stays in hospitals, frequently being put on artiﬁcial
respiration and fed artiﬁcially or parenterally. All these factors are likely to interfere with
the natural pattern of microbiota acquisition and development, thus resulting in an
aberrant establishment or deviating composition of the intestinal microbiota. Several
studies have reported differences in the fecal microbiotas of premature and full-term
neonates. Preterm neonates exhibit delayed gut colonization with commensal anaer-
obic microbes, such as Biﬁdobacterium or Bacteroides, where instead their stools contain
signiﬁcantly higher levels of Enterobacteriaceae, Enterococcus, and other (opportunistic)
pathogenic microorganisms than fecal material from full-term neonates (79, 90–94).
Gram-positive bacteria, such as Staphylococcus, Enterococcus, and clostridia, dominate
the gut microbiota of very premature infants during the ﬁrst month of life, while
Gram-negative microorganisms such as Enterobacteriaceae and Veillonella may be
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variably present in such cases (95). A pattern of colonization and succession of bacterial
classes from Bacilli to Gammaproteobacteria to Clostridia was observed in a very-low-
birth-weight (VLBW) premature population (96). In the latter study, the microbiota
seemed to evolve with periods of abrupt population changes and with a common
endpoint where the premature gut was shown to be colonized by anaerobes, partic-
ularly clostridia (96).
Although gestational age has been proposed to be the most important driver of the
premature gut microbiota establishment, a huge interindividual variability is observed,
likely related to the cooccurrence of a variety of factors cited above. It is important to
underline that the aberrancies observed render the preterm infant microbiota more
unstable than that of full-term equivalents, and a premature infant microbiota is
believed to be associated with a delay in the transition to and establishment of an
adult-type signature microbiota (97). These alterations may dramatically affect short-
and long-term health. Indeed, the interaction between the altered premature neonatal
microbiota and their immature immune system may cause inﬂammatory responses and
facilitate infectious disease (98, 99). In fact, the composition of the intestinal microbiota
of the preterm infant has been correlated to an increased risk of necrotizing entero-
colitis (NEC) or sepsis (100–102), as discussed below. Moreover, the premature gut
microbiota is different not only in composition but also in functionality. The main
short-chain fatty acids (SCFAs) produced by the intestinal microbiota were found at
lower levels in fecal samples from premature and VLBW infants than in the feces of
full-term babies (92, 103). Metabolic pathways potentially affected by prematurity have
also been identiﬁed by the use of functional inference analyses, with a higher frequency
of genes related to xenobiotic biodegradation and metabolism and lipid metabolism
and a lower frequency of genes related to energy metabolism and biosynthesis of
cofactors and vitamins being present in fecal samples of premature infants than in
those of full-term counterparts (103). Premature neonates were found to display an
enrichment of bile acid derivatives, showing an altered lipid metabolism (79). Moreover,
the metabolomes of urine samples from premature infants were shown to be higher in
vitamins D and E (79).
Infant feeding mode. Feeding type is another major factor determining early
microbial colonization and, therefore, inﬂuencing the neonatal gut microbiota compo-
sition and gastrointestinal function. The differences in the gut microbial composition
between breastfed and formula-fed infants are well documented (4, 104), with in-
creased levels of biﬁdobacteria being present in the former group of infants. Breast-
feeding provides a mix of nutrients and promicrobial and antimicrobial agents, which
favors the development of a so-called “milk-oriented microbiota.” IgAs obtained from
breast milk promote a regulatory and more “tolerogenic” immune system (105). Breast
milk also contains human milk oligosaccharides (HMOs), which can selectively shape
the growth and function of beneﬁcial microbes (see below).
The gut microbiota of breastfed infants exhibits lower diversity than that of bottle-
fed counterparts (106). Transcriptomic analyses of intestinal epithelial cells has shown
that the infant feeding type also affects host gene expression, with breastfeeding
enhancing transcription of genes that are associated with immunological and meta-
bolic activities (73, 107). Formula-fed infants are exposed to different carbohydrates,
bacteria, and (micro)nutrients, causing different microbial colonization patterns of the
gut. In this context, several publications have reported that stools of breastfed infants
contain higher levels of biﬁdobacteria and lactobacilli and lower levels of potential
pathogens than those of their formula-fed counterparts, with the latter being associ-
ated with a more diverse gut microbiota that is dominated by staphylococci, Bacte-
roides, clostridia, enterococci, enterobacteria, and the genus Atopobium (78, 80, 106,
108–110). As a consequence of these microbiota differences, the levels of SCFAs are
also different in the stools of breastfed versus formula-fed infants, with propionate and
butyrate being present at higher levels in the latter group (111). Furthermore, it seems
that infants fed with formula milk achieve an early divergence toward an adult-like
microbiota composition (73).
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During the exclusive milk-feeding period, the infant microbiota seems to ﬂuctuate
and the bacterial succession phenomenon continues, progressively diversifying until
weaning, when it changes toward the adult-like microbiota in becoming more stable
and complex (112–114). The impact of the weaning stage on microbiota development
has been considerably less investigated than that of the early (exclusively milk) feeding
stage (113, 114). During weaning, due to the complementary introduction of a variety
of novel food substances and nutrients, the alpha diversity increases, resulting in the
replacement of Proteobacteria and Actinobacteria by Firmicutes and Bacteroidetes phyla
as the dominant members of the infant microbiota (112, 113). A survey of the gut
microbiota development during the complementary feeding period, between the 9th
and 18th months following birth, revealed an increase in the relative abundances of
some major bacterial families, including Lachnospiraceae, Ruminococcaceae, Eubacteri-
aceae, Rikenellaceae, or Sutterellaceae (115). In contrast, the relative abundances of
Biﬁdobacteriaceae, Actinomycetaceae, Veillonellaceae, Enterobacteriaceae, Lactobacil-
laceae, Enterococcaceae, Clostridiales incertae sedis XI, Carnobacteriaceae, and Fusobac-
teriaceae decreased during the transition from the infant to the toddler stage (115),
which is in agreement with previous reports (3, 73, 80, 116, 117). Increased protein
intake was shown to be correlated with an increase in Lachnospiraceae and a decrease
in saccharolytic bacteria such as members of the Biﬁdobacteriaceae family, which are
generally associated with breast milk and early infant feeding, while ingestion of ﬁber
was demonstrated to be associated with higher levels of Prevotellaceae (115). Interest-
ingly, two species, Faecalibacterium prausnitzii and Akkermansia muciniphila, which are
either absent or present at very low levels during early infancy, increase in abundance
to adult levels at 12 months and 24 months, respectively (3). In the latter case, the
increase may reﬂect the gradual increase of the production of mucin, which is the main
carbohydrate fermented by A. muciniphila and which is present at very low level during
early infancy (see below).
The cessation of breastfeeding and the transition to more varied, solid foods is
considered to cause an increase in alpha diversity of the infant gut microbiota (73, 115,
118). Moreover, the changeover from human milk to formula (i.e., bovine) milk also
strongly inﬂuences the development of gut microbiota. Just 5 days after breast milk
cessation, an increase in the relative abundances of the Bacteroides, Blautia, and
Ruminococcus genera, among others, and a decrease in the relative abundances of
Biﬁdobacterium, Lactobacillus, and enterobacteria have been observed, with an increase
in alpha diversity and fecal pH (119). In addition, the observed bacterial diversity
increase contributes to functional changes. An increase in total levels of SCFAs, in
particular butyrate, has been reported (80, 113). The dietary shift from exclusively
milk-based to solid foods induces the development of a mature microbiota with genes
responsible for complex carbohydrate, starch, and xenobiotic degradation as well as
vitamin production (113). The adult-like microbiota is functionally more complex and is
structured to metabolize plant-derived polysaccharides from the adult diet, providing
mutual beneﬁts to host and microbe (116).
Maternal diet. There is growing interest in understanding the effects of maternal
body mass index (BMI) on the infant gut microbiota (72). Recently, it has been observed
that the infant’s fecal microbial composition is inﬂuenced by the BMI and weight gain
of the mother during pregnancy (120). Overall, fecal Bacteroides and Staphylococcus
concentrations were shown to be signiﬁcantly higher in infants of overweight mothers
during the ﬁrst 6 months of life; on the other hand, biﬁdobacterial counts were
determined to be higher in infants from nonobese mothers. These observations have
not, however, been conﬁrmed by other authors (121). Moreover, information regarding
the impact of breastfeeding and its correlation with the mother’s weight and number
of children is currently not available. These parameters may act as confounding factors,
thus indicating the need for further investigations.
Environment (family lifestyle and geographical location). Family members and
close relatives (siblings) have also been described as a relevant environmental factor
that may inﬂuence the pattern of infant gut microbiota colonization (60), but as yet,
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deﬁnitive evidence of the effects of family size, structure, and birth order has yet to be
established (72). Infants 1 month of age, who were recruited from the KOALA Birth
Cohort Study in The Netherlands, with older siblings were shown to have a higher
number of biﬁdobacteria in their gut microbiota than infants without siblings (78). It
was also reported, in this case as part of the ALLERGYFLORA study, that infants without
older siblings had increased proportions of non-Escherichia coli enterobacteria as well
as clostridia in the gut but also a lower anaerobe-to-facultative anaerobe ratio (75). In
a recent study performed with a Danish cohort, the presence of older siblings was
shown to be associated with increased gut microbial diversity and richness during early
childhood, while the presence of household pets had less-pronounced effects on the
gut microbiota (122). The concept of the “sibling effect,” which may contribute to the
substantiation of the hygiene hypothesis, remains controversial, and more studies in
this area are needed.
Geographical location may also have an impact on the microbiota, as microbiota
differences appear to be related to dietary patterns and lifestyle in a speciﬁc area (60).
Additionally, different ethno-geographic populations have distinct regional diets and
cultural practices (123). For example, children living in a rural village in Africa harbor a
microbiota different from that of children living in an urban region in Italy (124), while
several other studies have investigated the geographical effect, as linked to ethnicity
and/or diet, on microbial diversity and composition (4, 112, 125–128). Fecal sample
analyses of children living in an urban slum in Bangladesh point to a gut microbiota
signiﬁcantly different from that of children of the same age range in an upper-middle-
class suburban community in the United States. In particular, children from these two
different geographical locations had a distinct fecal bacterial community composition
and structure, with the microbiota of Bangladeshi children being enriched in Prevotella
and depleted in Bacteroides compared to that of U.S. children (126). Another analysis
comparing southeastern African and northern European infants reported distinctions in
bacterial group composition, with the genus Biﬁdobacterium and the group Bacteroides-
Prevotella being present at a higher abundance in African children (125). Overall, it
seems that home structure and family settings (rural versus urban) affect colonization
of the gut microbiota after birth, although more studies are needed to establish the
exact contributing factors.
Host genetics. There is growing scientiﬁc evidence indicating that host genetics
inﬂuences the acquisition and development of the infant gut microbiota (129–131). In
this context, the contribution of host genotype in shaping the microbiota composition
and structure has been assessed in human twins and family relatives. In this regard, a
study with children younger than 10 years old reported higher levels of microbial
similarity in genetically identical twins than in fraternal twins and unrelated controls
(132). However, subsequent analyses performed by other authors did not identify
signiﬁcant differences in bacterial diversity between monozygotic and dizygotic twins
(133, 134). Remarkably, a recent analysis of a large cohort (1,539 individuals; age range,
18 to 84 years) established a clear association between host genotype and the relative
abundances of different bacterial taxonomies in adulthood. In that work, the authors
(135) found that single nucleotide polymorphisms (SNPs) located in the LCT locus
(responsible for human lactase production) are related to varying abundance of Biﬁ-
dobacterium and found an association between host genetics and intake of dairy
products. This highlights the need for further research on the interaction between
human genotype, diet, and microbiota development.
Altogether, the almost inﬁnite combinations of these environmental, family-
associated, and genetic factors are responsible for the unique bacterial population
harbored by the gut of each individual.
POTENTIAL MATERNAL-FETAL TRANSFER OF MICROBIOTA
Is There Actually a Maternal-Fetal Transfer of Microbiota?
The notion that the human fetal environment is sterile under physiological condi-
tions (the “sterile womb paradigm”) has been an accepted dogma for decades. Ac-
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cording to this concept, microbial colonization of the healthy newborn intestinal tract
starts during and after birth, by both vertical (from the mother’s microbiota) and
horizontal transmission. Most studies that established the sterile womb paradigm
employed traditional culture-based methods and microscopy, which, despite their
limitations (such as their failing to detect viable but noncultivable microbes), are still
considered valid today.
In contrast, many recent studies (most of them employing state-of-the-art,
cultivation-independent techniques) have challenged this traditional view and have
proposed that acquisition of the human microbiota begins in utero (see subsections
below). If certain, this notion would change our understanding of gut microbiota
acquisition and its role in human development. However, while it is possible that not
all healthy babies are born sterile as was previously assumed, it is also true that the data
that support the “in utero colonization hypothesis” must be taken with extreme caution,
since most of them were obtained with particular methodological limitations (136).
For example, the detected bacterial DNA may belong to dead organisms, rather than
viable microorganisms, which have been found in only very few studies in samples that
originated from the fetal environment (66). Furthermore, it has been pointed out that
the highly sensitive molecular techniques employed to study the low-abundance,
fetus-related microbiome tend to detect contaminating microbes, thereby generating
false-positive results. Avoiding contamination is nearly impossible when collecting
samples related to the in utero environment within a clinical setting. Furthermore, the
presence of contaminating DNA in PCR reagents, DNA extraction kits, and molecular
biology-grade water (137, 138) is a particularly relevant challenge when working with
samples that contain an extremely low (or no) microbial biomass, such as those
obtained from the placenta, amniotic ﬂuid, or meconium of healthy subjects. Therefore,
if contaminating DNA is present and ampliﬁed during the PCR step, this will cause
incorrect results and conclusions (139). A low level of (or no) bacterial target DNA in a
sample has been shown to correlate with a higher proportion of bacterial sequences
being attributable to contamination (64, 65). In this context, it has been reported that
only an estimated 0.002 mg of bacterial DNA can be extracted from each one-gram
placental tissue (63).
Contaminating DNA sequences typically correspond to water- and soil-associated bac-
terial genera, including Acinetobacter, Alcaligenes, Bacillus, Bradyrhizobium, Herbaspirillum,
Legionella, Leifsonia, Mesorhizobium, Methylobacterium, Microbacterium, Novosphingobium,
Pseudomonas, Ralstonia, Sphingomonas, Stenotrophomonas, and Xanthomonas. Interest-
ingly, a high proportion of the taxa considered “the placenta microbiome” (including
core members) in a highly cited publication overlaps with the microbial groups
indicated above (63). In a recent study, placental samples from healthy deliveries and
a matched set of controls (to check for the impact of contaminations) were subjected
to 16S rRNA gene sequencing and microbiota analysis, which indicated that the
microbiota data obtained from placental samples and controls could not be distin-
guished (64, 65, 140).
Although the presence of contaminating DNA has been acknowledged in the
literature, its possible impact on 16S rRNA gene-based proﬁling and shotgun metag-
enomic analyses of samples that typically contain low biomass has not properly been
taken into consideration in the currently available infant gut microbiomes (64, 65).
The presence of microorganisms in meconium and amniotic ﬂuid is frequently
considered evidence supporting the in utero colonization hypothesis. However, it has
been argued that only a relatively small subset of such samples contains detectable
microbes, which could be, at least partly, the result of postnatal colonization in the case
of meconium samples or of prelabor rupture of membranes in that of amniotic ﬂuid (66,
140, 141).
Finally, gnotobiology has been claimed as the strongest evidence against the
existence of microbiomes in the fetal environment because of the ability to derive
germfree animals via C-sections and subsequently raise the offspring in a sterile
environment (66). This fact has to be taken in account, although on the other hand, it
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may be challenging to transfer results obtained in a germfree system to those derived
from a conventional host (142).
In conclusion, concerns have been raised by the scientiﬁc community regarding the
“in utero colonization hypothesis” because most of the studies employed molecular
approaches that are unsuitable to study “low-biomass” microbial populations, lacked
appropriate controls to account for contamination, and/or did not show bacterial
viability (64, 66). However, the unambiguous presence of bacteria has occasionally been
found in fetus-related samples (143). Although “in utero colonization” skeptics argue
that this ﬁnding is due to subclinical conditions, it also indicates that fetal colonization
may, at least occasionally, occur and that this subject (and its relation to maternal, fetal,
and infant health) deserves further research. In addition, it is widely accepted that
exposure of the fetal environment to microbial metabolites and compounds (including
DNA) from the maternal microbiota may have a major impact on the pregnancy
outcome and infant development (144–146). However, research regarding the role of
viable bacterial cells or their DNA must be strictly controlled for DNA contamination
during sample collection and processing in order to determine which observations are
scientiﬁcally accurate. Recommendations to reduce the impact of contaminants in
sequence-based, low-biomass microbiota studies have already been made (64, 65). The
sections below should therefore be read with caution, keeping in mind that this is still
a highly controversial area.
The Reproductive Microbiota before Pregnancy
As we learn more about the human microbiota, it appears that its complex inter-
actions with the host occur on most epithelial and mucosal surfaces, even those
belonging to organs that in the past were considered sterile under physiological
conditions (Fig. 4). Until recently, the concept of a reproductive tract microbiota,
playing active roles in health and disease, was limited to the vaginal cavity (147, 148).
As an example, bacterial vaginosis, a condition that is characterized by a deviating or
so-called dysbiosis state, is the most prevalent vaginal disorder and is associated not
only with an increased incidence of intra-amniotic infection, a higher incidence of
preterm delivery, and spontaneous abortion (149–152) but also with a reduced ability
to conceive (153, 154).
FIG 4 Colonization routes of maternal microbiomes to the infant. The mother portrayal exhibits the
maternal microbiome locations and the related routes that result in the vertical transmission of the
microbiota to the infant.
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In contrast to the case for the vagina and cervix, the anatomical site of conception
and overall fetal environment, which encompass the fallopian tubes, endometrium,
placenta, and amniotic ﬂuid, were believed to be sterile (155). In fact, the notion that
fetuses are sterile in utero and that microbial colonization of the newborn starts during
and after birth had been widely accepted since the beginning of the 20th century. Thus,
the search for microorganisms in samples from such environments was pertinent only
when there were signs of infections related to adverse obstetric outcomes such as
preterm rupture of membranes, chorioamnionitis, miscarriage, and preterm deliveries
(62, 148, 156–163).
However, various publications have reported on the presence of a physiological
microbiota at every stage and in every location related to human reproduction body
compartments, including the reproductive tracts of both females (e.g., ovary,
follicle, oocyte, fallopian tube, uterus, cervix, and vagina) and males (e.g., testes,
semen/spermatozoa, prostate, and seminal glands), as well as fetal structures such as
the placenta and umbilical cord (155, 164, 165). The understanding that these bacteria
form their own bioﬁlms in the human reproductive tracts, allowing complex interac-
tions with the gametes, embryo, or fetus and with the maternal tissue interface, may
provide new insights in the ﬁeld of fertility and lead to advances in assisted reproduc-
tive technology (165).
The Endometrial Microbiome
As stated above, the uterus has traditionally been considered sterile in the absence
of infection (166). In 1989, Hemsell isolated up to 231 bacterial species from 49 out of
55 endometrial samples collected from asymptomatic women without a history of
previous uterine infection, providing the ﬁrst deviating view on this (until then)
uncontroversial subject (533). However, the number of subsequent studies dealing with
the uterine microbiota in healthy women has remained very small, even after the
availability of culture-independent techniques.
Recently, the microbiota composition of endometrial tissue and mucus samples
from 19 nonpregnant women scheduled for hysteroscopy, yet without uterine anom-
alies, has been analyzed by 16S rRNA gene microbial proﬁling (167). Notably, such
analyses highlighted the occurrence of bacteria in all samples, thus supporting the
notion of a natural microbiota in these body compartments (167).
Furthermore, the endometrial microbiota in women undergoing single-embryo
transfer was characterized (168) by 16S rRNA gene microbial proﬁling. Remarkably,
microbial taxonomy assignments were carried out in samples from 33 patients, of
whom 18 became pregnant and 15 did not. Several dominant bacterial genera, such as
Flavobacterium and Lactobacillus, were present in both patient groups (women with or
without ongoing pregnancy), while others appeared to vary by outcome. However, the
differences in the relative abundances of these taxa between the patient groups did not
reach statistical signiﬁcance.
Recently, data from another study have reinforced the hypothesis that the compo-
sition of the endometrial microbiota inﬂuences the rate of success of implantation
(169). Notably, the results of this work, involving patients undergoing in vitro fertiliza-
tion, showed that the bacterial communities identiﬁed in the collected endometrial
ﬂuid and vaginal aspirate samples are distinct. Interestingly, the microbiota composi-
tion in the endometrial ﬂuid could roughly be classiﬁed as “Lactobacillus dominated” or
“non-Lactobacillus dominated,” where the presence of a non-Lactobacillus-dominated
endometrial microbiota was associated with signiﬁcant decreases in implantation,
pregnancy, ongoing pregnancy, and live birth rates (169).
It is probable that the uterine microbiota inﬂuences the immune environment
during conception, since it has been reported that the cytokines involved in endome-
trial receptivity and embryo development are affected by infection (170). An altered
microbial consortia in endometrial ﬂuid may trigger an inﬂammatory response in the
endometrium compromising the success of embryo implantation, since a tight regu-
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lation of inﬂammatory mediators is required during the adhesion of the blastocyst to
the endometrial wall (171).
Other recently published studies using culture-dependent and -independent tech-
niques not only have reported the presence of live bacteria and bacterial DNA,
respectively, in endometrial samples (172) but also have indicated that dysbiosis in the
uterine microbiota may be related to a variety of adverse gynecological or obstetric
outcomes, including endometritis, endometriosis (173), endometrial polyps (174), and
endometrial cancer (175).
The process of conception and implantation is very complex, and recent ﬁndings
suggest that reproductive success is deﬁned not exclusively by endometrial histology
and eukaryotic gene expression but also by the contribution of the microbiota residing
in the reproductive tract (176).
Microbiotas of the Placenta and Meconium
Relatively few analyses have examined the uterine microbiota associated with
healthy, full-term pregnancies, partly because of the enduring inﬂuence of the sterile
womb paradigm but also because of technical and ethical issues that make it hard to
obtain representative samples from healthy pregnancies before birth (89). However, the
presence of bacteria in amniotic ﬂuid was ﬁrst reported in 1927 in samples collected
during C-sections (161). Later, a culture-based study was able to isolate bacteria from
21% of placentas after noninfected, full-term deliveries (177). During the last decade, a
more overt challenging of the in utero sterility dogma has led to an increasing number
of reports describing the presence of bacteria or bacterial DNA in a healthy placental
environment (161, 178, 179).
With the isolation of commensal bacteria in meconium samples from healthy
neonates born by either vaginal delivery or caesarean section, the presumption of
sterility of in utero fetuses has been challenged (180). Such ﬁndings suggest that
full-term fetuses are not completely sterile and that a mother-to-fetus efﬂux of com-
mensal bacteria mediated by the placenta may occur. Bacteria belonging to Enterococ-
cus faecium, Propionibacterium acnes, Staphylococcus epidermidis and Streptococcus
sanguinis were also isolated from umbilical cord blood of healthy neonates born by
caesarean section (61). Bacterial counts ranged from 30 to 300 CFU/ml after an
enrichment step, suggesting that the initial bacterial numbers in such samples must be
extremely low. The identiﬁed species associated with the umbilical cord are naturally
present in infants immediately after birth (181, 182), being generally regarded as
commensals in healthy infant hosts.
In situ hybridization using a ﬂuorescent probe targeting a highly conserved region
of the 16S rRNA gene allowed the detection of bacteria in most fetal membrane
samples (73%) after term delivery (183).
A careful microbiological investigation indicated the occurrence of intracellular
bacteria of diverse morphologies in the maternal basal plate in 27% of 195 sampled
placentas, although no results beyond Gram classiﬁcation and cell morphology were
obtained in that work (143). No differences were observed between placental basal
plates from preterm or term gestations, and intracellular bacteria were detected in
placentas without clinical or pathological chorioamnionitis. These results were corrob-
orated by a culture-based study, which identiﬁed bacteria in 16.4% of placentas from
noninfected pregnancies (184).
Recently, application of whole-genome shotgun metagenomics to placental speci-
mens collected under sterile conditions from 320 subjects suggested that the placenta
harbors a low-abundance yet metabolically rich site-speciﬁc microbiome, composed
largely of nonpathogenic commensals that belong to the Firmicutes, Tenericutes, Pro-
teobacteria, Bacteroidetes, and Fusobacteria phyla (63). At the species level, Escherichia
coli appears to dominate placental bacterial communities. Notably, the microbial
proﬁles that have been found in the placenta and their associated genomic composi-
tion revealed intriguing similarities with those identiﬁed in the oral environment (185).
Furthermore, the dominance of E. coli sequences suggests a direct or indirect connec-
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tion between the placental microbiota and that of the maternal gut, where this species
is a common and abundant microbial resident. Altogether, these data indicate that the
entire maternal digestive tract, i.e., from the oral cavity to distal colon, plays a key role
in placental colonization.
It has been found that the placental microbiota varies depending on the birth
weight of full-term neonates, where the relative abundance of Lactobacillus sequences
appears to be negatively associated with birth weight (186). Interestingly, the taxo-
nomic proﬁles that seem to be associated with either term or preterm pregnancies are
accompanied by changes in bacterium-encoded metabolic pathways, which are inde-
pendent of delivery mode (185). It is well known that metabolic syndrome and obesity
are linked with a state of inﬂammation and dysbiosis. In fact, obesity during pregnancy
has been associated with macrophage accumulation and inﬂammation in the placenta
(187–189) and also with preterm delivery (190–192). Recently, it has been shown that
the placental microbiota varied among 320 women with spontaneous preterm birth
depending on their excess gestational weight gain but not on obesity (193). Excess
gestational weight gain was shown to be associated not only with signiﬁcant changes
in the placental microbiota (including decreased species richness) but also with alter-
ations in the associated microbiome-encoded metabolic pathways (193).
Studies investigating nonbacterial components of the human reproductive micro-
biota are urgently required since they may play relevant, yet still unknown, roles in
supporting or preventing successful and healthy reproduction upon interaction with
bacteria and host cells. For example, it has been suggested that commensal bacteria
that are present in or on the mucus layer covering the uterine epithelium promote
induction of regulatory factors by trophoblast and decidual macrophages. In turn,
macrophages would secrete antimicrobial products to control commensal overgrowth
and prevent invasion by pathogenic bacteria. Recognition of bacterial products by
trophoblasts enhances expression of anti-inﬂammatory factors, expands T regulatory
cells, and promotes tolerance (194). However, viral infection at the implantation site
inhibits the capacity of macrophages to control bacterial growth, thereby disturbing
the symbiosis among microbiota, trophoblast, and immune cells at the implantation
site and leading to an inﬂammatory condition responsible for preterm birth (195). In a
murine model, infection of the placenta with murine herpesvirus 68 elicited a fetal
inﬂammatory response and sensitized the mother to bacterial endotoxin, which in turn
induced preterm labor (196). Consequently, it has recently been postulated that when
trophoblast cells interact normally with commensal bacteria (194), their durable ho-
meostatic relationship contributes to a ﬁne regulatory tuning of the maternal-fetal
interface. However, disturbances in this relationship may be the basis for an inﬂam-
matory state, which generally characterizes preterm birth and other adverse pregnancy
outcomes.
Microbiotas of Amniotic Fluid and Meconium
Amniotic ﬂuid surrounds and is continuously swallowed by fetuses. There are several
ﬁndings supporting the lack of microbiological sterility of umbilical cord blood, amni-
otic ﬂuid, or fetal membranes in human beings without any clinical or histological
evidence of infection or inﬂammation (61, 197). These data are further corroborated by
the isolation of viable bacteria in the ﬁrst meconium belonging to the same or similar
species previously isolated from umbilical cord blood (198). A recent 16S rRNA gene
microbial proﬁling study reported that within the same mother-infant pair, the bacterial
communities in meconium samples are very similar to those in the mother’s placenta,
regardless of the method of delivery, and that both differ from those found in the
maternal vagina (199). From these pioneering studies, it is now generally accepted that
the meconium harbors a complex microbial community and, similar to the case for the
placenta microbiota, various studies have investigated the microbial diversity of meco-
nium (141, 200–204).
Assessment of the microbiota composition of the ﬁrst-secreted meconium from 15
healthy term infants following vaginal delivery indicated that about 66% of the infants
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carried viable bacteria in their meconium (141). Each of the neonates enrolled in this
analysis contained between one and ﬁve microbial groups, with Biﬁdobacterium, En-
terobacteriaceae, Enterococcaceae, and Bacteroides-Prevotella being the most prevalent.
This analysis thus indicates that low numbers of bacteria are present in ﬁrst-pass
meconium samples from healthy, vaginally delivered, breastfed, term infants. Several
studies have also detected DNAs from different bacteria in the meconium of healthy
neonates (74, 200, 202, 204–206), further supporting the notion that gut microbial
colonization begins before birth.
So far, there is only fragmentary information available regarding the inﬂuence of
other maternal or infant health conditions on the bacterial communities in meconium.
In this context, there is experimental evidence indicating that the overall bacterial
content in meconium signiﬁcantly differs depending on maternal health status (202).
Speciﬁcally, the phylum Bacteroidetes and the genus Parabacteroides were enriched in
the meconium of infants from mothers affected by diabetes, while there was a higher
Proteobacteria abundance in the meconium of infants from nondiabetic mothers. It has
also been suggested that meconium microbiota types dominated by lactic acid or
enteric bacteria are differentially associated with maternal eczema and respiratory
problems in infants (200).
Overall, data from various independent laboratories indicate that the microbial taxa
found in meconium samples are uniquely distinct from those found in subsequent fecal
samples, irrespective of gestational age (201, 203, 207).
Origin of the Pregnancy-Related Microbiome
Several routes have been proposed to explain how bacteria are able to colonize the
uterine cavity during pregnancy, including a retrograde pathway through the abdom-
inal cavity or invasive procedures such as amniocentesis. Several possible routes have
been put forward in the context of intrauterine infections and adverse pregnancy
outcomes (159). In relation to healthy pregnancies, there are two main pathways that
are currently being considered (179): (i) vertical ascension from the vagina and/or
urinary tract and (ii) a hematogenous route through the placenta after translocation
from the digestive tract (oral cavity and gut). However, the fact that some bacterial
species (e.g., Lactobacillus salivarius, Streptococcus agalactiae, Streptococcus mitis, En-
terococcus faecalis, or E. coli) can be found in more than one ecological niche within the
same female has made it difﬁcult to elucidate the origin of the bacteria that colonize
the uterine environment.
Early investigations suggested that the vagina is the origin of pathogenic bacteria
that ultimately reach the placenta and fetus through translocation across the chorio-
decidual plate (159, 160). This process is believed to start during the second trimester
of pregnancy, although the actual timing is still unknown. The low frequency of
detection of lactobacillus DNA in samples of meconium from infants born by C-section
(204) suggests that the primary source of lactobacilli in the infant gut is mainly from the
maternal vaginal and rectal microbiota during vaginal delivery, and this may explain, at
least partly, the differences observed in the infant fecal microbiota depending on the
delivery mode (70). In contrast to the case for placental samples, the ﬁnding of (high
levels of) lactobacillus DNA in endometrial samples from nonpregnant women may
reﬂect the technical difﬁculty, or even impossibility, in retrieving samples free of vaginal
contamination when sampling devices are introduced through the vagina.
Although long-lasting paradigms in the context of preterm birth suggests that most
intrauterine bacteria originate in the lower genital tract and ascend into an otherwise
sterile intrauterine environment, many bacteria isolated or detected in the placenta
with culture-dependent or independent techniques are not found in the urogenital
tract but rather represent commensal species common to the digestive tract (179, 208).
The alternative mechanism that may explain early colonization of the fetus represents
hematogenously derived sources such as the maternal mouth (161, 209) and the
maternal intestinal tract due to higher intercellular junctional permeability and/or
dendritic cell transport (179).
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The mechanisms by which digestive bacteria may translocate and reach this human
niche are poorly understood. While the digestive epithelial barrier generally prevents
microbial entry into the circulatory system, dendritic cells can actively penetrate the
digestive tract epithelium, take up bacteria from the lumen, and transport live bacteria
throughout the body as they migrate to lymphoid organs (210). To test whether
maternal gut bacteria can be provisioned to fetuses in utero, two pioneering studies
investigated whether oral administration of genetically labeled Enterococcus faecium to
pregnant mice resulted in its presence in the amniotic ﬂuid and meconium of term
offspring after sterile C-section (61, 198). Remarkably, E. faecium with the genetic label
was cultured from the amniotic ﬂuid and meconium of pups from inoculated mothers
but not from pups of control mice. In addition, other murine studies have reported not
only signiﬁcant similarities between the oral and placental microbial communities but
also transmission of diverse oral bacteria to murine placenta, which further suggests
that the placental microbiome may be established, at least partly, by hematogenous
spread (211–215). In this context, a previous study carried out in pregnant women and
focusing on the impact of oral microbiota composition on pregnancy outcome showed
that certain bacteria, such as Actinomyces naeslundii, are associated with lower birth
weight and earlier delivery, while others, such as lactobacilli, are positively correlated
with a higher birth weight and later delivery date (216).
Many transient anatomical and physiological changes occur during pregnancy,
thereby providing a suitable framework for the development of the fetus ﬁrst and the
neonate later. These changes affect virtually all systems, including the cardiovascular,
respiratory, genitourinary, and digestive tracts. Interestingly, such adaptations may
favor an increased bacterial translocation during late pregnancy and lactation (210,
217). Globally, this offers the possibility that modulation of the oral and gut microbiome
during (pre)pregnancy may impact the pregnancy outcome and fetal and infant health.
HUMAN MILK OLIGOSACCHARIDES CONTRIBUTE TO SHAPING MICROBIAL
COMMUNITIES
General Features
Human milk is a rich source of components that contribute to shaping the infant gut
microbiota through a variety of mechanisms. After lactose and lipids, oligosaccharides
are the third most abundant component of human milk. One liter of mature human
milk contains 5 to 20 g of these complex sugars, which often exceeds the concentration
of all human milk proteins combined. Oligosaccharide concentrations in colostrum, an
early form of milk that is secreted in late pregnancy and shortly after delivery, are even
higher.
Human Milk Oligosaccharides Are a Diverse Group of Complex Glycans
Human milk oligosaccharides (HMOs) consist of the ﬁve monosaccharide building
blocks glucose (Glc), Galactose (Gal), N-acetylglucosamine (GlcNAc), fucose (Fuc), and
the sialic acid N-acetyl-neuraminic acid (Neu5Ac). The combination of these building
blocks in deﬁned glycosidic linkages yields several dozen (up to more than 100) structurally
distinct HMOs. All HMOs carry lactose (Gal1-4Glc) at the reducing end. Lactose can be
further elongated by the addition of 1-3- or 1-6-linked lacto-N-biose (Gal1-3GlcNAc-,
type 1 chain) or N-acetyllactosamine (Gal1-4GlcNAc-, type 2 chain). Elongation with
lacto-N-biose appears to terminate the chain, whereas N-acetyllactosamine can be further
extended by the addition of one of the two disaccharides. A 1-6 linkage between two
disaccharide units introduces chain branching. Lactose or the elongated and branched
oligosaccharide chain can be fucosylated (addition of Fuc) in 1-2, 1-3, or 1-4
linkages and/or sialylated (addition of sialic acid Neu5Ac) in 2-3 or 2-6 linkages. For
example, fucosylation of the terminal Gal in lactose in an 1-2 linkage yields 2=-
fucosyllactose (2=FL). Sialylation of the terminal Gal in lactose in an 2-6 linkage yields
6=-sialyllactose (6=SL). Addition of two sialic acids to the tetrasaccharide lacto-N-tetraose
(Gal1-3GlcNAc1-3Gal1-4Glc), one on the terminal Gal in an 2-3 linkage and one on
the subterminal GlcNAc in an 2-6 linkage, yields an HMO called disialyllacto-N-tetraose
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(DSLNT). HMOs can carry fucose, sialic acid, both, or neither. Thus, structural diversity
derives from both the complexity of the underlying backbone (chain elongation and
branching) as well as modiﬁcation (fucosylation and sialylation).
HMO Composition Varies between Women
The molecular structures of more than 100 different HMOs have been characterized,
but it is important to note that total amount and composition are highly variable
between different women. In other words, not every infant who receives human milk
is exposed to the same set of HMOs with respect to total amount and structural
composition. In fact, a recent cross-sectional, observational study revealed that the
HMO composition produced by healthy women varies geographically (218). However,
maternal genetic and environmental factors that determine HMO composition are
not well understood. HMO fucosylation corresponds to the mother’s secretor (Se)
and Lewis (Le) blood group characteristics, which are determined by two genetic
loci encoding the 1-2-fucosyltransferase FUT2 (encoded by the Se gene) and the
1-3/4-fucosyltransferase FUT3 (encoded by the Le gene) (219–225). Individuals with
an active Se locus are classiﬁed as secretors. Milk of secretor women is abundant in 2=FL,
lacto-N-fucopentaose 1 (LNFP I), and other 1-2-fucosylated HMOs. In contrast, nonse-
cretors lack a functional FUT2 enzyme, and their milk contains very low concentrations
of 1-2-fucosylated HMOs. Individuals with an active Le locus are classiﬁed as Le
positive. They express FUT3, which transfers Fuc in 1-4 linkage to subterminal GlcNAc
on type 1 chains (226). In contrast, the milk of Le-negative women contains very low
concentrations of these speciﬁc 1-4-fucosylated HMOs, e.g., LNFP II. Based on the
combination of active or inactive FUT2 and FUT3 enzymes, HMO proﬁles can be roughly
separated into four different groups: (i) Lewis-positive secretors (with active FUT2 and
active FUT3), (ii) Lewis-negative secretors (with active FUT2 and inactive FUT3), (iii)
Lewis-positive nonsecretors (with inactive FUT2 and active FUT3), and (iv) Lewis-
negative nonsecretors (with inactive FUT2 and inactive FUT3). While FUT2- and FUT3-
dependent fucosylation is almost an all-or-nothing phenomenon (the respective HMOs
are either present or absent), differential expression of genes that encode other
components of the cellular glycosylation machinery likely contributes to some of the
more subtle variations in HMO composition between women as well as slight changes
over the course of lactation. However, the inﬂuence of environmental exposures, such
as maternal diet, exercise, and medical or recreational drugs, on HMO composition is
currently unknown.
Once ingested, HMOs resist the low pH in the infant’s stomach as well as digestion
by pancreatic and brush border enzymes. HMOs are not degraded by the infant and
thus reach the distal small intestine and colon in an intact form, where they are
available to help shape microbial communities and host-microbe interactions.
HMOs Are Human Milk Prebiotics
HMOs are considered natural prebiotic compounds because they actively stimulate
the growth of speciﬁc members of the infant gut microbiota. In these terms, HMOs are
often considered “biﬁdogenic,” since they speciﬁcally enhance growth of biﬁdobacteria,
although it should be noted that only certain biﬁdobacterial taxa efﬁciently use HMOs
as a sole carbon source (227–230). HMO utilization is conserved within the Biﬁdobac-
terium longum subsp. infantis lineage (231). Biﬁdobacteria that are associated with an
adult microbiota, such as Biﬁdobacterium adolescentis, are unable to use the HMO core
structures (lacto-N-tetraose [LNT] or lacto-N-neo-tetraose [LNnT]). Thus, it is important
to note that the “biﬁdogenic” effect of HMOs is rather speciﬁc and favors B. longum
subsp infantis, and in part a few other infant-associated biﬁdobacteria, but not all
biﬁdobacteria alike (see below).
Other bacteria may also be able to utilize HMOs, in least in part, and thus HMO may
have not only speciﬁc “biﬁdogenic” effects but prebiotic effects in general. It is
important to note that the prebiotic effects of HMOs are likely structure speciﬁc, and
HMOs may not always be fully interchangeable. For example, bacterium A may have a
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fucosidase to cleave fucose from the underlying HMO backbone, while bacterium B
may not. Instead, bacterium B may produce sialidases that remove sialic acid. A diet rich
in fucosylated HMOs would favor growth of bacterium A, while sialylated HMOs favor
bacterium B. These fucosidases and sialidases are often structure speciﬁc in a way that
3=SL can be cleaved but 6=SL cannot or vice versa. The same is true for the underlying
HMO backbone. Some bacteria can metabolize type 1 structures (terminal Gal1-
3GlcNAc); other bacteria prefer type 2 structures (Gal1-4GlcNAc). Some bacteria may
be able to metabolize branched HMOs, while other bacteria cannot metabolically
access such structures.
Microbial Communities May Act in Concert To Fully Utilize HMOs
Only very few bacteria express the entire HMO-degrading machinery (e.g., B. longum
subsp. infantis ATCC 15697) (232), while other bacteria can only cleave and metabolize
speciﬁc elements of a complex HMO molecule (Fig. 5). However, microbial communities
might be able to act in concert, sequentially degrade, and metabolize complex HMO
structures in a team effort through cross-feeding activities (see below). A ﬁrst set of
bacteria may be able to cleave 1-2 linked fucose and expose an underlying HMO
structure to the breakdown activities of other bacteria. In turn, a different set of bacteria
that was unable to remove the terminal fucose now would be able to utilize the
remaining HMO backbone. It is important to emphasize the structure speciﬁcity of
prebiotics for several reasons. First, oligosaccharides that are structurally different from
HMOs, mostly galacto-oligosaccharides (GOS) and fructo-oligosaccharides (FOS), were
added to infant formula years ago in an attempt to introduce complex sugars that in
part mimic the prebiotic effects of HMOs. GOS represent galactose oligomers, and
FOS are fructose oligomers, not lacto-N-biose or N-acetyllactosamine oligomers like
HMOs, and neither GOS nor FOS are fucosylated or sialylated. In fact, fructose itself
is not part of human milk. It is easy to imagine that entirely different structures drive
the enrichment of different microbial communities. Second, feeding one or two differ-
ent speciﬁc HMOs such as 2=FL or LNnT instead of a mixture of dozens of structurally
distinct HMOs is also likely to enrich different microbial communities, namely, those
that can utilize 2=FL and LNnT. Other bacteria that specialize in sialic acid degradation
would not ﬁnd useful substrates in these speciﬁc HMOs. As a result, a balanced and
diverse microbial community may suffer from overgrowth of a limited number of
bacteria that thrive on these speciﬁc HMOs, while other bacteria are left at a disad-
vantage. Third and ﬁnally, since HMO composition varies between women, milk from
different women has different effects on infant microbial communities.
FIG 5 Chemical structures of human milk oligosaccharides and related enzymatic degradation. On the
left are listed the biﬁdobacterial species that encode enzymes for HMO breakdown retrieved into the
infant gut, while on the right are reported the products of the enzymatic reactions.
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HMOs and Antimicrobial Effects
As described above, HMOs may exploit prebiotic features toward certain bacterial
groups, while they may have opposite effects on others. For example, group B Strep-
tococcus (GBS) stops growing in the presence of HMOs (233). This bacteriostatic effect
seems to be linked to speciﬁc HMO structures that disrupt proper bacterial membrane
glycosylation (233). In contrast, HMOs do not directly impact growth of Candida
albicans yet alter hyphal morphology and length, which impacts the yeast’s attachment
to epithelial cells (234). Disseminated candidiasis is a frequent life-threatening infection
in premature infants, with rates as high as 23% in those born at extremely low birth
weights (1,000 g) (235).
HMOs and Antiadhesive Properties
In addition to their prebiotic and antimicrobial effects, HMOs contribute to shaping
the infant gut microbiota through various other mechanisms as well. Pathogens often
need to attach to epithelial surfaces to be able to colonize and in some cases invade
the host to cause disease. Pathogen attachment is often facilitated by protein-glycan
interactions either when pathogens are covered by glycans that bind to proteins on
epithelial cells or when pathogens express speciﬁc proteins that bind to glycans on the
host cell surface (glycocalyx). HMOs resemble some of these glycans and serve as
soluble analogs that can block pathogen attachment. For example, in vitro studies in
tissue culture models revealed that Campylobacter jejuni binds to 1-2-fucosylated
glycans and that 2=-fucosyllactose (2=FL) might be able to compete with cell surface
glycans to block C. jejuni attachment. Accordingly, feeding 1-2-fucosylated HMOs
reduces C. jejuni colonization in mice (236). Infants that receive human milk rich in
1-2-fucosylated HMOs are less likely to develop C. jejuni-associated diarrhea (237).
Similar antiadhesive effects have been shown for enteropathogenic E. coli (EPEC) both
in tissue culture and in mice (238). These effects are not limited to bacteria, as HMOs
also block adhesion of Entamoeba histolytica, a protozoan parasite that infects 50
million people worldwide and causes amebiasis, which is responsible for over 100,000
deaths annually (239).
HMOs May Affect Microbial Communities in Niches Other than the Infant Gut
As mentioned above, there are multiple different mechanisms by which HMOs help
to shape microbial communities in the infant gut: HMOs are prebiotics as well as
antimicrobials that directly affect growth of speciﬁc bacteria, while they also act as
antiadhesives that block the attachment of certain bacteria to epithelial cell surfaces,
with potential consequences for colonization and invasion. In addition to inﬂuencing
microbial communities and host-microbe interactions in the infant gut, HMOs may
already have an effect on microorganisms in the oral cavity and upper respiratory tract,
potentially even the skin, at least around the mouth. Furthermore, HMOs are absorbed
in the infant gut, reach the systemic circulation, and are eventually excreted in an intact
form with the infant’s urine. Although the concentrations of HMOs in the urinary tract
are much lower than those in the infant gut, it is possible that HMOs also impact
microbial communities in the infant’s urinary and genital tracts, with potential effects
on health outcomes, e.g., reducing urinary tract infections (240).
The microbiota-shaping effects of HMOs might occur even earlier, before they reach
the infant. Human milk itself is not sterile and contains bacterial communities that live
within the milk matrix while still in the mammary gland, waiting to be expressed (241).
Recent studies revealed that Firmicutes and Proteobacteria are the dominant bacterial phyla
found in human milk samples, with Lactobacillus, Streptococcus, Pseudomonas, and Staph-
ylococcus being the most abundant genera (242–245). In addition, the occurrence of
biﬁdobacteria has very recently been demonstrated in humanmilk samples as well as in the
milk of other mammalian species (246). Moreover, no statistically signiﬁcant difference
was observed between bacterial communities harbored by the milk of women who
delivered at term or preterm, delivered vaginally or by caesarean section (C-section), or
gave birth to boys or girls (242). Nevertheless, it must be underlined that the low
The Infant Gut Microbiota Microbiology and Molecular Biology Reviews
December 2017 Volume 81 Issue 4 e00036-17 mmbr.asm.org 23
 o
n
 August 20, 2018 by guest
http://m
m
br.asm
.org/
D
ow
nloaded from
 
bacterial abundance that is typical of human milk samples may lead to biases caused
by bacterial contaminants (65). Milk microbiota and HMOs colocalize in the mammary
gland between feeding or pumping episodes, potentially inﬂuencing each other
through mechanisms similar to those that have been described for the infant gut.
However, HMOs may act on microbial communities even earlier than that, potentially
even before the baby is born.
The Use of Individual HMOs Alone May Bear Risks
Individual HMOs such as 2=FL or LNnT are now available on large scales to be used
in a wide range of products with the goal to treat or even prevent diseases that are
associated with dysbiosis. Future research needs to investigate whether or not the use
of individual HMOs is harmful when they are used alone and not in concert with dozens
and potentially hundreds of other oligosaccharides as they naturally occur in human
milk.
It is important to emphasize that HMO composition varies between women. Thus,
infants receive a distinct set of HMOs with their mother’s milk, and the composition
changes over the course of lactation. In that sense, human milk can be regarded as
“personalized nutrition” and HMOs as “personalized prebiotics” that help shape a
distinct infant gut microbiome dependent on what HMOs are present in the mother’s
milk. Every mother provides a distinct HMO mix to her infant(s), shaping distinct infant
microbial communities with potential short- and long-term consequences.
Oligosaccharides in the Milk of Other Mammals
Oligosaccharides in the milk of many other mammals have been studied, but no
other animal matches the large amount and high structural diversity of HMOs (re-
viewed in reference 247). Oligosaccharide concentrations in milk of most farm animals,
including cows, goats, sheep, and pigs, are 100- to 1,000-fold lower than that in human
milk, with a lower number of different oligosaccharides and a higher abundance of
sialylated and a lower abundance of fucosylated oligosaccharides (248–252). Compar-
ative analyses have shown that oligosaccharides in the milk of primates, including
humans, are more complex and exhibit greater diversity than those in nonprimate milk
(253, 254). In humans, 50 to 80% of the oligosaccharides are fucosylated, depending on
the Se/Le group, which is followed by those in chimpanzees, at around 50%, and
gorillas, with only 15%. Most other species, including cows, show very low levels of
fucosylation (1%). In humans, 10 to 30% of the oligosaccharides are sialylated, and
similar values are found in chimpanzees, rhesus macaques, and gorillas. Interestingly,
primate milk oligosaccharide cluster analysis does not follow primate phylogeny,
suggesting an independent emergence of milk oligosaccharides, potentially driven by
distinct pathogen exposures (254).
TRANSFER OF BACTERIA FROM MOTHER TO CHILD
Maternal Inheritance of Bacteria
According to the holobiont concept when applied to reproduction, not only is the
eukaryotic body reproduced, but so is its symbiotic microorganisms, or at least part of
them. Thus, birth may be viewed as the passage from one set of symbiotic relationships
to another (255). According to this view, the two main partners are the mother and the
conceptus (fetus and then child), with a third player in this symbiotic arrangement
being represented by the mother’s microbiota. The mother is a holobiont, whose
associated microorganisms are actively metabolizing nutrients, while the maternal
blood which the fetus receives may also be substantially modiﬁed by metabolic
activities of the mother’s microbiota (256, 257). Indeed, it has been shown, for example,
that in mice almost all blood-derived serotonin is produced by symbiotic bacteria (256).
Consequently, we can argue that the fetus is not free of the mother’s symbiotic
associations, even assuming the concept of sterility of the fetus.
Upon birth, the infant is moving from one set of symbiotic assemblies to another,
transitioning from the mother’s microbiota to its own (255). According to the com-
Milani et al. Microbiology and Molecular Biology Reviews
December 2017 Volume 81 Issue 4 e00036-17 mmbr.asm.org 24
 o
n
 August 20, 2018 by guest
http://m
m
br.asm
.org/
D
ow
nloaded from
 
monly accepted scientiﬁc literature on this topic (although that is being challenged [see
above]), the fetus is developing under sterile conditions in the amnion, and the
microbial colonization occurs only when the amnion breaks and the conceptus moves
through the birth canal (258). Then, according to this assumption, the fetus passes
through the cervix and the vagina, and the microbiotas of these two body sites may
colonize the newborn. Interestingly, based on the hologenome concept, the micro-
biome can be viewed as an additional set of inherited genes, (some of) which, together
with the parental genes, are passed on from one generation to the following (259).
Such inheritance can be vertical in the case of a direct transmission of microbial
genes from mother to offspring or horizontal in the case of acquisition of microbial
genes from the environment. The mammalian newborn does not just leave the uterus
and passively acquire a new microbiota, but the mother seems to actively transfer
certain members of the microbiota to her offspring and may thus directly inﬂuence
(e.g., by the selective nourishment with prebiotic milk compounds certain microorgan-
isms such as biﬁdobacteria [see above]) the development of the new microbiota of her
child.
From a bacterial perspective, a newborn baby represents an essentially uninhabited
island, where the ﬁrst colonizers are provided with a choice of settling options, thereby
creating opportunities or restrictions for the next set of microbial colonizers (19). As
discussed in other sections of this review, elements of the gut and vaginal microbiotas
of the mother initiate new host-symbiont relationships, which are considered to be
pivotal for the health of the new holobiont (260).
Vertically Transmitted Microorganisms
Recently, investigators have tried to answer how the infant gut microbiota is
assembled soon after birth using metagenomic approaches. In this context, it has been
reported that Lactobacillus rhamnosus LGG, which had previously been supplemented
to their mothers, was detected by quantitative PCR (qPCR) in stool samples from infants
(261). Notably, half of the children with detected LGG shared the same strain with their
corresponding mothers and appeared to be heavily colonized by LGG at the very early
stages of life (before 3 months of age) (261). However, the observed colonization with
strain LGG seems to be transient, since no noticeable microbiota differences between
probiotic and placebo groups were identiﬁed at 1 year of age.
Recently, a comparative analysis of fecal microbiota data obtained by 16S rRNA gene
microbial proﬁling and involving 415 mothers and their children highlighted a highly
shared microbial population for each mother-newborn pair (67). Notably, the number
of phylotypes or OTUs that were shared between mothers and their children increased
with age. In this context, the OTUs that are shared between mother-baby pairs were
enriched in Bacteroidia and depleted of Clostridia, Gammaproteobacteria, and Erysip-
elotrichia (67). This indicates that the acquisition of the latter groups of bacteria, which
represent dominant members of the adult gut microbiota (262), occurs during the very
early phase of life (263). Furthermore, biﬁdobacteria appear to be subject to mother-
baby transfer (47, 67). Speciﬁcally, shared OTUs that correspond to Biﬁdobacterium
breve and Biﬁdobacterium biﬁdum were observed between mothers and their corre-
sponding children, which were shown to persist until 3 months and 1 year of life,
respectively (67). Similar ﬁndings were obtained in another recent study focusing on
the identiﬁcation of vertically acquired biﬁdobacterial strains (47) (Fig. 6). Such analyses
involved a combination of shotgun metagenomics, ITS biﬁdobacterial proﬁling analyses
(45), and culturomics and resulted in the isolation of two biﬁdobacterial strains, i.e., B.
breve BBRI4 and Biﬁdobacterium longum subsp. longum BLOI2, which were identiﬁed in
two mother-infant pairs and were also shown to persist in the infant gut until 6 months
of age (47) (Fig. 6). Recently, a detailed proﬁling of biﬁdobacterial communities in 25
mother-offspring pairs through ITS biﬁdobacterial proﬁling analyses followed by an
culturing approach revealed a large number of biﬁdobacterial strains that are com-
monly identiﬁed in mother and infant guts, as well as the corresponding human milk
sample (264). These data are further reinforced by the identiﬁcation of an identical
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scenario in other primate and nonprimate mammals, where biﬁdobacteria were shown
to be commonly transmitted from a mother to her offspring and where the mother’s
milk represents an important means to drive such events (265).
One may argue that biﬁdobacteria, despite their decline following weaning, persist
following their initial transfer to the infant gut and are then maintained at (very) low
levels in the adult gut, to be ultimately transferred to the next generation (47). Such a
transfer process may be the consequence of millennia of strict coevolution between
these bacteria and their mammalian host.
DYNAMICS OF THE MICROBIOTA COMPOSITION OF THE INFANT GUT
Dynamics of Colonization of the Infant Intestine
Immediately following birth, the neonatal intestine becomes rapidly colonized. As
stated above, during this early postnatal period, facultative and aerotolerant microor-
ganisms dominate the intestinal ecosystem. These microorganisms will reduce oxygen
levels in the intestine, thereby facilitating the subsequent proliferation of a complex
community dominated by anaerobic bacteria (74). In spite of this common pattern, the
FIG 6 Strain-speciﬁc tracing of biﬁdobacteria from mother to infant. Each panel displays the protocol for
shotgun sequencing of the high-abundance bacterial target and their corresponding tracing in mother
and infant gut microbiota samples.
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neonatal gut microbiota shows large interindividual differences, being more variable,
over time and between individuals, than that of adults (4, 113). However, the high initial
beta diversity is already reduced by 12 months of age (in contrast to alpha diversity,
which is increased as a function of time), indicating that the neonatal community
becomes more complex over time, while interindividual diversity progressively de-
creases to that typical of adults (73, 113). The exact age at which a stable adult-like gut
microbiota structure is formed is still unclear, but generally this happens at an age of
around 2.5 to 3 years (4, 113, 116). At this age, most bacterial groups have already
reached a state of adult microbiota stability, whereas other microbial groups may still
need more time to reach such a steady state (266). In fact, some differences seem to
persist up to preadolescent age (267). Bäckhed et al. (73) observed that 1-year-old
infants are more similar to their mothers in terms of microbiota composition and
function than when they are younger yet have differences awaiting further maturation.
The dynamics of the colonization process shows differences depending on the
perinatal factors present. While in full-term infants, delivery and feeding modes are
reported to represent the major drivers of microbiota development, in preterm infants,
the gestational age seems to have the biggest impact on the gut microbiota assembly
process (73, 96). The existence of a microbiota “core” of OTUs in full-term babies,
independently associated with delivery mode and lactation stage, has been reported,
providing support for the Savage theory, which predicts the creation of a conserved
stable microbiota, predicted to consist of approximately 30 OTUs, followed by a
variable microbiota (74).
Due to the high instability of early-life gut microbiota, the high interindividual
variability, and the multitude of factors (pre-, peri-, and postnatal) affecting the estab-
lishment of the microbiota, the deﬁnition of a “standard,” “normal,” or “healthy” infant
gut microbiota is still difﬁcult. Nevertheless, some general trends can be inferred from
the different studies available. While the adult gut microbiota is dominated by mem-
bers of the Firmicutes and Bacteroidetes phyla, the neonatal intestinal microbiota is
initially represented by microorganisms from Proteobacteria and Actinobacteria, becom-
ing more diverse later on with the rise of Firmicutes and Bacteroidetes (13, 268).
Biﬁdobacterium has been considered to represent the dominant bacterial genus in the
breastfed infant gut microbiota (41, 269), but recent studies have also shown a high
occurrence of enterobacteria in such an infant population. It has been observed that
Proteobacteria (mainly Enterobacteriaceae) dominate the infant intestinal microbiota
during the ﬁrst weeks, with biﬁdobacteria being the second microbial population,
which then increases over time with a concomitant decrease of enterobacteria (93).
These results were in concordance with observations in other cohorts, in which fecal
samples from the ﬁrst days of life were also characterized by high levels of Enterobac-
teriaceae, with samples from 6-month-old infants being dominated by Biﬁdobacterium,
Collinsella, or Bacteroides (2, 270). Similarly, Yassour et al. (3) reported that Enterobac-
teriaceae were present at higher levels than Biﬁdobacterium in fecal samples of infants
of up to 2 months of age, followed by replacement of the latter microbial group by
members of the Lachnospiraceae and Ruminococcaceae families by 12 months of life.
Members of the phylum Firmicutes were also detected in different studies, always
showing a low abundance during the ﬁrst weeks after birth (93, 270). Interestingly, it
has been shown that members of the Firmicutes phylum, such as the families Staphy-
lococcaceae, Clostridiaceae, Lachnospiraceae, and Veillonellaceae, are more numerous in
breastfed infants than in formula-fed, full-term infants, whose microbiota was found to
be dominated by enterobacteria up to 6 months after birth (271, 272). In contrast, a
recent study showed a high abundance of Biﬁdobacterium from the ﬁrst week following
birth and lasting until the age of 6 months (79). According to other recent studies,
another common intestinal bacterial phylum, Bacteroidetes, seems to be present,
although at low levels, from the early stages after birth (3, 79, 93). In contrast, Koenig
et al. (113) reported the absence of Bacteroides from the infant microbiota until the
introduction of solid food in a single baby. Other differences between these studies
may be due to the fact that the subjects originated from different countries and
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represented distinct populations, yet they may also be due to confounder factors, often
present in the neonatal population, which may not have been considered, or to
technical/methodological issues that signiﬁcantly inﬂuence the results (see also above)
(6). This variability observed for different studies calls for serious caution when inter-
preting and comparing published data, while it also illustrates the need for further
investigations in order to determine how to best characterize the infant gut microbiota.
The Infant Intestinal Colonization Process: the Foundation of Health
As indicated above, during the initial colonization steps, the microbiota remains
unstable and may suffer from sudden microbial succession phenomena that will
continue until the infant is 2 to 3 years old, at which point the microbiota reaches
a composition that resembles that of an adult microbiota (4). In spite of the
extended duration of this stepwise microbiota evolution, we now know that
microbiota-host cross talk is especially important during this period. These early
moments of microbiota-host communication constitute key events that underpin
appropriate maturation of the human host, with subsequent establishment and main-
tenance of the homeostasis of the host microbiota during early life, events that may
have immediate and long-term health consequences (Fig. 7).
The establishment of the early microbiota provides a massive antigenic stimulus
necessary for the adequate maturation of the gut and associated immune system
(273–275). This stimulus also affects the maturation of distal organs, affecting the host
at systemic level (276–278). Thus, it is likely that the basis for a healthy microbiota
throughout life is set up during its initial development, with the establishment and
development of the microbiota being critical for the maturation of the host and
long-term well-being (123, 260, 279). As an example of this, it was recently shown that
fecal levels of IgA, an important characteristic potentially related to the risk of disease,
may be determined by the presence of speciﬁc microbiota members (280). In this
context, it seems logical to assume that the neonatal microbial colonization process is
linked to the health of the infant and may represent a risk factor for disease later in life.
Indeed, evidence is accumulating in this respect, with different studies reporting early
microbiota alterations preceding disease development (281–284).
The key role of these early life microbiota events is demonstrated by in vivo trials
involving murine models in which conventional animals are compared with germfree
FIG 7 Infant health status and microbiota establishment. The schematic representation shows several
diseases related to the colonization of bacteria that are claimed to be pathogens.
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counterparts. These investigations have clearly demonstrated the serious health con-
sequences caused by the absence of any microbiota-host interaction (285). Moreover,
several authors have studied the effect of recolonizing germfree animals, at different
ages, on restoring the parameters altered by the lack of microbial exposure. Interest-
ingly, recolonizing animals in early life, as opposed to during adulthood, is needed to
restore the altered phenotypes found in germfree models. For example, animals lacking
a microbiota (germfree) were shown to exhibit increased levels of certain immune cells
in the mucosae, a phenomenon that is reverted (to normal levels) when these animals
are recolonized during early life, yet this reversion does not occur when recolonization
is facilitated at adulthood (286).
Therefore, an altered early colonization pattern may represent a risk with immediate
consequences for infant health and development yet may also present a risk for
long-term effects (as discussed below). Another corollary is that the use of germfree
mice colonized at some moment in time with human microbiota may be compromised
by an altered sequence of immune priming events.
Infant Intestinal Microbiota and the Risk of Neonatal Pathologies
During the neonatal period, due to immune immaturity, the risk of early- or
late-onset nosocomial infection is high (Fig. 7). Nosocomial sepsis in preterm infants is
often related to the use of catheters, with Gram-positive microorganisms from the
genus Staphylococcus being the main causative agent, followed by Gram-negative
bacteria, mostly enterobacteria such as E. coli or Klebsiella (92, 93, 287). Moreover,
especially in the case of premature neonates, this sepsis risk is exacerbated, as well as
the risk of developing necrotizing enterocolitis (NEC), which is a very serious and often
fatal condition (288). In a signiﬁcant number of cases, infants who develop NEC will also
develop sepsis, commonly caused by a dominant member of the gut microbiota of
preterm infants such as enterobacteria (92, 93).
Although particular microorganisms have been proposed as causative agents (289),
the etiology of NEC remains unclear. However, speciﬁc characteristics have been
observed in the microbiota of infants developing NEC. These infants typically exhibit a
reduced bacterial diversity in combination with increased levels of potentially patho-
genic microorganisms (290, 291). However, the trials that have been performed so far
have not identiﬁed a clear pattern of dysbiosis, though they have repeatedly identiﬁed
an increased abundance of Proteobacteria as well as Clostridium perfringens preceding
NEC development (291–295). Moreover, a potential protective role of high levels of
biﬁdobacteria has been suggested (296). Speciﬁc metabolic pathways associated with
NEC have been reported (288), and metabolome alterations have been observed in the
sera of these infants (296).
It has been postulated that an intensiﬁed immune response caused by high levels
of intestinal Proteobacteria may increase the risk of bacterial translocation and sepsis
(98). Various metagenome-based studies have shown lower bacterial diversity and
reduced levels of Biﬁdobacterium and Bacteroides, with a predominance of enterobac-
teria, in infants who develop late-onset sepsis compared with healthy counterparts
(100–102). However, available evidence is still limited, and additional investigations are
needed before drawing conclusions on the potential role that early microbiota altera-
tions play in determining the risk of infection and sepsis.
Infant Intestinal Microbiota and Growth
The early microbiota may also impact infant malnutrition/growth impairment. Dur-
ing the last few years an increasing number of studies have reported associations
between infant microbiota and neonatal growth (92, 297). Moreover, the microbiota of
malnourished children was found to be different from that of their healthy counter-
parts, and experiments with microbiota transplantation into germfree animals have
shown that receiving the microbiota from undernourished donors hampers weight gain
(298). The same researchers have also employed different animal models to demon-
strate a microbiota-dependent enhancement of growth after supplementation of the
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diet with certain (bovine) milk oligosaccharides (299). Several potential mechanisms
may explain this microbiota-growth association, among them the production of growth
hormones (300). Although more research is needed to fully understand the mechanis-
tics of this phenomenon, the potential relationship between infant malnutrition and
gut microbiota may constitute the basis for the development of microbiota modulation
strategies aimed at restoring normal infant growth and development (301).
ROLE OF EARLY-LIFE MICROBIOTA IN PROGRAMMING FUTURE HEALTH
Impact of Early-Life Microbiota on Long-Lasting Physiological Effects
Microbial colonization of the human gut is believed to be responsible for the
concurrent programming of our immune system and the simultaneous development of
the intestinal tract and associated metabolism. A continuous dialogue between the
microbiota and the host must occur in order to orchestrate these physiological pro-
cesses. Therefore, intestinal dysbiosis may disrupt or modify this dialogue, which may
in turn result in long-lasting physiological effects and health disorders (302). Among
these, extensive research has been carried out regarding the potential effects of
early-life microbiota on immune disorders. Some of the most convincing results come
from animal experiments and point to a very close relationship between early exposure
to microorganisms and development of immune pathologies. Although this relation-
ship has been known for decades, some recent ﬁndings are decisively contributing to
understand the mechanisms behind the long-term effects of our microbiota on (shap-
ing) the immune response. In this regard, it has been shown that microbial factors
regulate the activity of chemokine ligand CXCL16, which modulates the accumulation
of invariant natural killer T cells in the colon and lungs, and that neonatal colonization
of germfree mice with a conventional microbiota protects them from this accumulation
(286). In this context, it has been suggested that the early-life microbiota triggers
long-lasting effects, and the absence of such a microbial stimulus may induce later-life
inﬂammatory responses related to IBD and asthma (286). Recently, the importance of
a critical period in which disruption of the intestinal microbial balance can have
long-lasting consequences in immune pathologies has been suggested, and the or-
dered establishment of an adequate dialogue between commensals and the mucosal
surfaces of our body and its pivotal importance for the development of our immune
defenses have been highlighted. This cross talk is facilitated by host-microbial interac-
tions during the earliest days of life or even through microbial colonization during
pregnancy, suggesting that disease risk is programmed during early life, including the
prenatal period (273).
Allergy (Atopic Eczema and Asthma)
Among the immune pathologies related to a particular microbiota establishment,
allergy, mainly in the form of atopic eczema and later asthma, has been linked to
speciﬁc microbial features. Numerous epidemiological studies suggest that early de-
velopment of the infant gut microbiota inﬂuences the risk of allergic diseases later in
life (303). This has been attributed to an inappropriate development of gut microbiota
and associated disruption of immune homeostasis during the ﬁrst year of life (304).
Chronic recurring atopic eczema is the main symptom of atopic disease during the
ﬁrst years of life (305). Various research investigations involving infant cohorts have
provided valuable information on the potential role of gut microbiota in the develop-
ment of atopic eczema. More than a decade ago, pioneering analyses already reported
microbiota alterations at an early age in infants who subsequently developed atopic
diseases (283, 306). These investigations revealed differences, such as increased levels
of clostridia and reduced levels of biﬁdobacteria, in the early-life gut microbiota
composition of infants who did or did not develop atopic disease by the age of 2 years.
Similarly, in a recent study, a reduced abundance of biﬁdobacteria and other intestinal
anaerobes, such as Faecalibacterium, and an altered fecal metabolome were observed
in 3-month-old infants who later developed atopy (determined at 2 years of age) or
asthma (evaluated at 4 years) from a U.S. cohort (281). Another analysis using culture-
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independent PCR-based molecular techniques (quantitative real-time PCR) in a cohort
of 957 infants showed that differences in the gut microbiota composition at the age of
1 month precede the manifestation of atopic symptoms within the ﬁrst 2 years of life.
In particular, the presence of E. coli was associated with a higher risk of developing
eczema, and the presence of C. difﬁcile was associated with several atopic outcomes,
including eczema, wheeze, and allergic sensitization (307). Similarly, a nested case-
control study based on quantitative real-time PCR and PCR-denaturing gradient gel
electrophoresis (DGGE) analyses directed to explore the composition of the gut micro-
biota of a cohort of 646 infants revealed an association between the colonization by E.
coli in infants of 1 month and the development of IgE-associated eczema within the ﬁrst
year of life (308). Subsequent studies have indicated that a reduced microbial diversity
of early-life microbiota directly correlates with later development of atopic eczema. In
two of these analyses, a correlation between a low microbiota diversity at 1 week and
infants having atopic eczema at 12 and 18 months of age (309, 310). Next generation
sequencing methodologies and metagenomic approaches have shown that infants
with IgE-associated atopic eczema have a low microbiota diversity and a lower diversity
of the bacterial phylum Bacteroidetes during the ﬁrst month of life, compared with a
control group of infants without allergic manifestations until 2 years of age was
identiﬁed (311). Furthermore, a phylogenetic human intestinal tract chip (HITChip) was
used to analyze the intestinal microbiota signatures associated with eczema symptoms
in 6-month-old infants and the microbial changes associated with the physiology of this
disease during the following 3 months. Such analyses highlighted that a decrease in the
severity of eczema during the 3-month follow-up period was directly related to an
increase of the butyrate-producing bacterium Coprococcus eutactus (312). Although
these results do not correlate an early microbiota proﬁle with a decrease of atopic
eczema ailment, they indirectly point to the potential protective role of a butyrate-
producing bacterium in the development of atopic eczema. In fact, it has been shown
that a low relative abundance of butyrate producers precedes the development of
atopic eczema (284).
A direct association of speciﬁc microbial patterns early in life with the development
of asthma years later has not yet been unequivocally established, since genetic,
epigenetic, and other environmental factors also affect the development of the disease.
Nevertheless, it is becoming increasingly clear that the intestinal microbiota plays a
crucial role in the perinatal programming of asthma (313). Animal trials have repeatedly
reported the importance of the intestinal microbiota in determining the levels of
immune cells and their recruitment to various tissues (286, 314, 315) or in the devel-
opment of immune tolerance (316). As discussed below for metabolic diseases,
antibiotic-induced modiﬁcation of the early-life microbiota has been shown to increase
the risk of allergic asthma in laboratory animals (317). In addition, epidemiological data
sets have provided support for the notion that a link exists between perinatal antibiotic
exposure and the risk of subsequent allergic disease development (318–320). In this
regard, recent evidence suggests that the risk of suffering from asthma is higher in
infants who exhibited gut microbiota dysbiosis during the ﬁrst 100 days of life and that
this risk is associated with particular bacterial groups. Analysis of the gut microbiota
compositions of 319 subjects of a Canadian cohort showed that infants at risk of asthma
display signiﬁcantly decreased relative abundances of the genera Lachnospira, Veillo-
nella, Faecalibacterium, and Rothia. Furthermore, these differences in abundance of
bacterial taxa were linked to different levels of fecal bacterial metabolites. Inoculation
of these bacteria in germfree mice reduced airway inﬂammation in their progeny,
suggesting that some microbes play a causal role in the development of asthma (321).
Furthermore, a reduced gut microbiota diversity during the ﬁrst month of life is
associated with a higher prevalence of asthma in 7-year-old children (322), and lower
levels of Lachnospira and higher levels of Clostridium spp. at 3 months are positively
associated with asthma risk at 4 years of age. These ﬁndings suggest that the ratio
between these two genera can be used as a microbial biomarker to predict the risk of
asthma development (323). Notably, colonization by Clostridium difﬁcile detected at 1
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month was positively associated with asthma at age 6 to 7 years (324). In addition, early
IgA responses targeting the fecal microbiota during the ﬁrst year of life differed
between healthy children and children having asthma at up to 7 years of age (325).
Metabolic Disorders
The gut microbiota composition and function have been associated with obesity
and obesity-related disorders. By increasing energy harvest, the so-called obesogenic
microbiota regulates obesity behavior and peripheral metabolism. It has been sug-
gested that different factors that impact gut microbiota establishment during infancy
may contribute to the risk of obesity later in life (326). Microbiota-related obesity
studies in animal models, particularly in rodents, have broadened our understanding of
the role played by the gut microbiota in metabolic disorders. However, in recent years
it has become clear that one should be cautious in extrapolating the results of animal
studies to humans, thus highlighting the need for human clinical trials (327). In human
beings, it has been suggested that early microbial patterns may predict overweight in
children. In this context, it has been observed that the abundance of the biﬁdobacterial
population at 6 and 12 months inversely correlates with overweight in 7-year-old
children (282). Furthermore, in a large cohort study, quantitative PCR was used to
determine the levels of several bacterial groups in 909 1-month-old infants, and body
mass index (BMI) was reported from 1 to 10 years of age. That analysis showed that
Bacteroides fragilis levels at 1 month of age are signiﬁcantly associated with a higher
BMI in children (328).
The maintenance of a properly functioning intestinal barrier seems to be critical for
metabolic health, but different factors that disturb the microbial balance during early
life play a pivotal role in overweight, obesity development, and child adiposity in later
life. Among such factors, nutrition, maternal obesity, delivery mode, intestinal perme-
ability, pathogenic infections, and antibiotic use have been highlighted (270, 329–331).
In addition, recent literature also implicates microbiota-related epigenetic changes
during early development (332). Furthermore, the impact of gut microbiota on brain
developmental programming of obesity has also been suggested (333). Moreover,
considerable attention has been drawn to investigating the role of early-life antibiotic
therapy in being an important driver for subsequent development of metabolic dis-
eases. Several analyses involving murine models have shown that altering the gut
microbiota with antibiotics during early life will have long-lasting metabolic conse-
quences, including adiposity, weight gain, insulin resistance, type 2 diabetes, and liver
disease (334–336). In one of these studies, the authors observed that the effect on host
metabolism was sustained over time, even when the microbiota alterations had dis-
appeared following the discontinuation of the antibiotic treatment, which underlines
the importance of microbiota-host interactions during early life. Nevertheless, a recent
study encompassing a large cohort of more than 260,000 individuals proposed that
childhood obesity is positively correlated only with untreated infections and not with
antibiotic use during infancy (337). These above-mentioned analyses also demon-
strated a causal role of the microbiota as opposed to an antibiotic effect, since such an
antibiotic-modiﬁed microbiota, when transferred to germfree mice, was able to pro-
mote growth (335). Other murine trials have observed differences in the microbiota and
host physiology depending on the antibiotic used (96). Notably, these analyses suggest
that an association exists between early-life antibiotic-induced dysbiosis and alterations
of host metabolism in later life. Epidemiological studies in humans have also demon-
strated that antibiotic exposure is associated with long-term metabolic effects, includ-
ing weight gain and obesity in children and adults, and this antibiotic-microbiota-
obesity trinomial has attracted a substantial level of public interest (338). Investigations
involving a large infant cohort showed an association between early-life antibiotic
exposure and childhood obesity (339). In fact, it has been suggested that disturbances
of the intestinal microbiota caused by antibiotics, during either prenatal or postnatal
periods, increase the risk of becoming obese (340). However, more evidence from
human epidemiological studies is needed to deﬁnitively establish a causative link
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between early-life antibiotic-induced dysbiosis and subsequent metabolic conse-
quences in later life.
Other Long-Lasting Effects of the Infant Gut Microbiota
Early infant dysbiosis has also been associated with other chronic disorders that may
manifest later on in life; in particular, IBD, irritable bowel syndrome (IBS), and type 1
diabetes (T1D) have received a lot of interest from the scientiﬁc community in recent
years in this context.
T1D is an autoimmune disease characterized by the destruction of insulin-producing
beta cells. Several environmental factors may affect T1D, and accumulating evidence
supports the proposed role of intestinal microbiota in the development of this disease.
Longitudinal studies in patients with T1D have shown a lower diversity and signiﬁcant
differences in the ratios of the most abundant intestinal phyla, including Firmicutes and
Bacteroidetes, as well as a decreased abundance of the butyrate producer F. prausnitzii
in diabetic children (341). Indeed, butyrate-producing species are more abundant in
nondiabetic children, and it has been suggested that these bacteria play a key role in
reducing the risk of developing T1D (342). Furthermore, how early intestinal coloniza-
tion can inﬂuence the subsequent progression of T1D has also been investigated.
Experiments in rodents have shown that early-life microbiota modiﬁcations, notably by
low-dose or pulsed therapeutic antibiotic treatments, alter intestinal microbiota and
T cell populations, increase the risk of T1D, and accelerate T1D development in a
nonobese diabetic (NOD) murine model (343). Regarding human trials, recent ﬁndings
suggest a role of early dysbiosis in future development of T1D (344). It has been shown
that microbiota perturbations during early infancy may generate a proinﬂammatory
environment that facilitates the development of autoimmune disease. In this regard,
pioneering investigations by Kostic and coworkers reported different microbial patterns
in the fecal microbiota of infants who later developed T1D compared with those who
did not progress to diabetes (345). However, only a limited number of analyses have
tried to correlate infant microbiota and T1D development. Therefore, the monitoring of
human cohort studies, together with mechanistic studies, is needed to establish a
causal relationship between microbiota and T1D.
Diseases that involve intestinal inﬂammatory symptoms have also been related to
early-life microbiota colonization events. The notion that the human intestinal immune
system is “trained” during early microbial colonization presumes a link between pio-
neering microbial inhabitants of the gut and subsequent intestinal inﬂammatory
disease, notably IBD and IBS. A small number of trials have suggested that early-life
shifts in the populations of speciﬁc bacterial groups precede onset of intestinal
inﬂammatory diseases at later stages of life (346–349). However, convincing and
consistent data about the long-term effects of early-life dysbiosis in the development
of IBD and IBS in children and adults are scarce and do not allow the establishment of
causality. Thus, future work with animal models and human epidemiological studies
may shed light on microbiota-mediated immune and physiological responses that may
result in the onset of these diseases.
MICROBIAL BIOMARKERS ASSOCIATED WITH THE CORE INFANT GUT
MICROBIOTA
The Core Infant Gut Microbiota
Relative to the gut microbiota of adults or older children (age of1 year), the infant
gut microbiota exhibits low diversity, and the microbiota structure is generally unstable
and highly dynamic (see above) (123). In contrast, the gut microbiota of adults is
speciﬁc to an individual and is relatively stable (350). Nevertheless, biﬁdobacteria are
typically found in large amounts in infants, particularly breastfed infants, and thus are
considered a key member of the infant gut microbiota (41, 116, 123, 351).
Notably, despite the large variability at the intraindividual level during the period
from initial assemblage of the infant gut microbiota to the establishment of an adult
gut microbiota, the infant gut microbiota can be classiﬁed into six main types (Fig. 8)
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(114). Such infant gut microbiota types are determined according to the composition
of the gut microbiota and the occurrence of dominant bacterial groups. In detail, these
dominant groups encompass the following: group 1, consisting of Enterobacteriales;
group 2, formed by Bacteroidales and Verrucomicrobiales; group 3, encompassing
members of Selenomonadales as well as the Clostridiales genera Pseudoﬂavonifractor
and Subdoligranum and Deltaproteobacteria Desulfovibrio; group 4, including all Pas-
teurellales; group 5, comprising most of the Clostridiales; and group 6, involving the
Clostridiales genera Anaerostipes and Faecalibacterium and the Lactobacillales and
Biﬁdobacteriales (114) (Fig. 8). Nevertheless, additional investigations that involve large
data sets for infants from multiple geographic regions are needed to conﬁrm these
observations. Interestingly, the genera that dominate the infant gut microbiota in
different individuals are represented by Biﬁdobacterium, Veillonella, Streptococcus, Cit-
robacter, Escherichia, Bacteroides, and Clostridium, which are also abundant in the gut
microbiota of adults (114). Notably, further detailed analyses allowed the identiﬁcation
of an additional 10 genera that are shared between adults and infants, though at very
different abundancies: Bacillus, Bacteroides, Biﬁdobacterium, Clostridium, Enterococcus,
Escherichia, Eubacterium, Lactobacillus, Prevotella, Ruminococcus, and Streptococcus.
These core bacteria of the gut microbiota include members of four of the phylogenetic
groups described above (group 1, Escherichia; group 2, Bacteroides and Prevotella;
group 5, Clostridium and Eubacterium; and group 6, Biﬁdobacterium, Enterococcus,
Lactobacillus, Ruminococcus, and Streptococcus) (114).
FIG 8 The infant gut core microbiota. A 16S rRNA gene-based tree involving the infant bacterial core microbiota is displayed. The colors
of the branches indicate the six main phylogenetic groups of the infant gut microbiota. An electron microscopic image of the key infant
gut bacterial taxon is displayed for each branch of the tree.
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Biﬁdobacteria and the Gut Microbiota of Infants
As described above, biﬁdobacteria represent one of the dominant members of the
core infant gut microbiota, and several ecological studies based on culture-dependent
as well as culture-independent approaches have conﬁrmed such ﬁndings (3, 41, 42, 67,
80, 117, 351–354). Interestingly, biﬁdobacteria are presumed to be particularly abun-
dant in the colon, while they are identiﬁed at lower densities in the oral cavity (355).
Biﬁdobacteria were ﬁrst isolated from feces of a breastfed infant by Tissier in 1899 and
are classiﬁed as a distinct genus, i.e., Biﬁdobacterium, belonging to the Actinobacteria
phylum (356–358). The genus Biﬁdobacterium currently includes 59 different taxa, ﬁve
of which have been isolated from fecal samples from the human gut (265, 359, 360). An
ecological clustering of the currently described members of the Biﬁdobacterium genus
distinguishes seven different ecological niches encompassing the GITs of humans,
nonhuman mammals, birds, and social insects, wastewater, and human blood and oral
cavity (352). Notably, these apparently unrelated ecological origins may represent an
ecological niche that is common to all these habitats, represented by the fact that
biﬁdobacterial hosts are social animals whose offspring enjoy parental care. Therefore,
perhaps their ecological distribution is facilitated by direct transmission of biﬁdobac-
terial cells from mother/carer to newborn. Such a hypothesis has recently been
experimentally conﬁrmed by the identiﬁcation of biﬁdobacterial strains that are com-
mon between mothers and their corresponding children (see above) (67, 354). Further
detailed classiﬁcation of biﬁdobacteria based on the ecological origin suggests the
occurrence of (sub)species, such as Biﬁdobacterium animalis subsp. lactis/animalis,
Biﬁdobacterium adolescentis, Biﬁdobacterium dentium, and Biﬁdobacterium catenulatum,
that are found in different animals and which are therefore also known as cosmopolitan
biﬁdobacterial species (361). In contrast, other species, such as Biﬁdobacterium biﬁdum,
Biﬁdobacterium breve, and Biﬁdobacterium longum, appear to be less widely distributed
than the above-mentioned species, and thus it was not possible to identify a strict
host-speciﬁc adaptation of biﬁdobacterial species (265). Among those species identiﬁed
in primates (including humans) it is possible to distinguish biﬁdobacterial taxa that are
typically found in adults, e.g., B. adolescentis and B. catenulatum, while others are much
more commonly found in the guts of breastfed infants, such as B. biﬁdum, B. breve, and
B. longum subsp. infantis (41). Nevertheless, there does not seem to be a strict
infant-versus-adult subdivision of biﬁdobacterial taxa. This makes sense in the context
of vertical transfer of biﬁdobacterial species from mother to offspring, which also
includes adult-type members such as B. adolescentis (362, 363).
Contribution of biﬁdobacteria to the infant host. Due to their well-described
saccharolytic features, biﬁdobacteria make a major metabolic contribution to their host
through the degradation of diet-derived glycans and host-provided carbohydrates
(known as host glycans and including mucins and HMOs) (364). The glycan-based
metabolic activities exerted by biﬁdobacteria are pivotal in their establishment and
persistence in the gut at the early stages of life (365). In this context, genome analyses
of Biﬁdobacterium longum subsp. infantis ATCC 15697 and Biﬁdobacterium biﬁdum
PRL2010 have revealed how these two microorganisms are able to utilize host-derived
glycans (HMOs and mucin). In particular, the genome of B. longum subsp. infantis ATCC
15697, a strain that was originally isolated from a breastfed infant, contains genes that
encode enzymes predicted to be involved in the degradation (such as fucosidase,
sialidase, -hexosaminidase, and -galactosidase) and internalization (such as extracel-
lular solute binding proteins and permeases of ABC transporter systems) of HMOs (232).
Furthermore, the genome of this strain encompasses an operon involved in themetabolism
of urea, an important source of nitrogen in human milk (232). Notably, maternal geno-
types that determine fucosylation patterns of HMOs are implicated in the assemblage
of infants’ microbiota (366, 367). As mentioned above, speciﬁc infant-associated biﬁ-
dobacteria such as B. longum subsp. infantis efﬁciently metabolize HMO components,
e.g., lacto-N-tetraose (232, 368), although metabolic differences have been observed
with respect to HMO utilization proﬁles between biﬁdobacterial species.
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Mucin is another host-produced glycan that constitutes one of the main barriers
covering the GIT mucosa. The main glycan components of these glycoproteins are
N-acetylglucosamine, N-acetylgalactosamine, fucose, and galactose, and mucins are
frequently covered by sialic acid and/or sulfate groups (369). In order to metabolize
these glycoproteins, a number of speciﬁc glycosyl hydrolases are required, such as (i)
endo--N-acetylgalactosaminidase, catalyzing the hydrolysis of O-glycosidic -linkages
between galactosyl 1-3-N-acetylgalactosamine and serine or threonine residues (370),
and (ii) fucosidases, liberating the L-fucose from the oligosaccharide core of the mucin
structure (371). Additional enzymes responsible for the complete breakdown of mucin
encompass N-acetyl--hexosaminidases, -galactosidases, and sialidases (372). More-
over, the core oligosaccharide structure of mucin is formed by galacto-N-tetraose,
which is known to be metabolized by certain members of the human gut microbiota,
including speciﬁc biﬁdobacterial species, into galacto-N-biose (368) and then trans-
ported in the cytoplasm through a speciﬁc ABC-type transporter, phosphorylated by a
galacto-N-biose phosphorylase, and ﬁnally utilized in the glycolytic and glycoprotein
metabolic pathways (372).
Only a few members of the human gut microbiota can directly access mucin as
a C source, including Biﬁdobacterium biﬁdum and Akkermansia muciniphila (373–
376). Notably, in silico genome analyses of B. biﬁdum PRL2010, a strain isolated from infant
stool, revealed a gene set responsible for mucin metabolism, encoding extracellular en-
zymes that include sialidases, fucosidases, a putative cell wall-anchored endo--N-
acetylgalactosaminidase, N-acetyl--hexosaminidases, and -galactosidases (375). This
genetic repertoire is part of the unique core genome of members of the B. biﬁdum
species (377), providing an intriguing case of coevolution of a human gut commensal
to the (human) intestine, where glycans produced by the host act as a carbon and
energy source for the establishment and survival of certain biﬁdobacterial species
within the human gut (375).
Interestingly, among the biﬁdobacterial communities that reside in the gut of
human infants and adults, certain species are present, such as Biﬁdobacterium breve,
which possess carbohydrate breakdown capabilities toward both dietary and host-
derived glycans (378–382). Notably, while B. breve is not able to grow to any appre-
ciable density on mucin or HMOs, host-derived mono-/oligosaccharides may become
available through hydrolytic activities of other (biﬁdo)bacteria present in the human
gut microbiota through cross-feeding activities (364, 383–386).
Modulation of the infant gut microbiota by cross-feeding activities operated by
biﬁdobacteria. Within the human gut microbiota, biﬁdobacterial communities are
believed to establish several trophic interactions with each other and with other
members of the gut microbiota, leading to competition for or cooperative sharing of
nutrients. Commonly, microbe-microbe interactions can either positively or negatively
inﬂuence the ﬁtness of the affected organisms (387) by the release of molecules in the
environment (388, 389). Due to cross-feeding strategies, enteric microorganisms pro-
mote an expansion of their carbohydrate acquisition abilities, thereby positively inﬂu-
encing the ecological ﬁtness of a speciﬁc proportion or even the overall gut microbiota
(364). Cross-feeding actions in the gut are commonly exploited by primary microbial
degraders such as biﬁdobacteria, which, due to partial extracellular hydrolysis of
speciﬁc complex carbohydrates (e.g., host-produced glycans), provide monosaccha-
rides and oligosaccharides to other microbial gut inhabitants (390). In addition, their
fermentative metabolism of these carbohydrates generates end metabolites, such as
acetate, which in turn may act as a substrate for secondary microbial degraders such as
the butyrate-producing enteric bacteria (391–394).
Examples of cross-feeding activities in biﬁdobacterial communities have been ex-
perimentally demonstrated between two infant-type biﬁdobacteria (B. biﬁdum PRL2010
and B. breve UCC2003) when these bacteria were cultivated on sialyl lactose as the
unique carbon source (384, 385). Recently, the cross-feeding activities of various
biﬁdobacterial strains such as B. biﬁdum PRL2010, B. breve 12L, B. adolescentis 22L, and
B. thermophilum JCM7017, when grown on plant-derived glycans such as starch and
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xylan, have been evaluated (383). Notably, cocultivation trials coupled with transcrip-
tomic and metabolomic analyses revealed that the concurrent presence of the above-
mentioned biﬁdobacterial strains results in enhanced metabolic activity of B. biﬁdum
PRL2010, suggesting that PRL2010 cells beneﬁt from the presence of other biﬁdobac-
terial strains.
The existence of cross-feeding activities between various biﬁdobacterial strains
resembling the infant biﬁdobacterial communities, i.e., B. biﬁdum PRL2010, B. longum
subsp. infantis ATCC 15697, B. adolescentis 22L, and B. breve 12L, has been further
assessed under in vivo conditions in a conventional murine model (395). Remarkably, in
this study, transcriptomic experiments coupled with metagenomic analyses of single,
dual, or multiple associations of biﬁdobacterial strains uncovered cross-feeding behav-
ior that caused an apparent expansion of the murine gut glycobiome toward its
enzymatic potential related to the breakdown of plant-derived carbohydrates such as
xylo-oligosaccharides, arabinoxylan, starch, and host glycan substrates. Furthermore,
these analyses revealed distinct strategic responses by the different biﬁdobacterial
strains toward glycans; for example, a “selﬁsh” behavior was exhibited by B. longum
subsp. infantis ATCC 15697 as it internalizes HMOs prior to degradation, thereby
limiting opportunities for resource sharing by other enteric microorganisms. In contrast,
B. biﬁdum PRL2010 actively participates in extracellular breakdown of host glycans and
thus in the release of simple sugars that can in turn be utilized by other members of
the (biﬁdo)bacterial community (395).
How biﬁdobacteria interact with the human gut. The molecular mechanisms by
which biﬁdobacteria interact with the human host are still largely unexplored.
However, biﬁdobacterial colonization at the early stages of life seems to play an
important role in the host (see above). It has recently been demonstrated that many
biﬁdobacterial species encode cell surface-associated exopolysaccharides (EPSs),
cell surface-protruding proteinaceous appendages called ﬁmbriae or pili, and/or a
secreted serine protease inhibitor, all of which seem to be involved in host interactions
(352, 396–401) (Fig. 9).
EPSs are carbohydrate polymers present as an extracellular layer covering the
surfaces of various Gram-positive microorganisms (402). EPS can have two seemingly
opposing functions: bacterial EPS can act as a virulence factor in particular diseases but
may also elicit positive effects on human health by exploiting an immune modulatory
effect on the host (403, 404). The EPS synthetized by certain lactic acid bacteria (LAB)
can be classiﬁed in two groups: homopolysaccharides, consisting of just a single
repeated monosaccharide type, and heteropolysaccharides, which are composed of a
repeated oligosaccharide (405). Speciﬁcally, EPSs synthesized by biﬁdobacteria are
composed of various monosaccharides, such as D-glucose, D-galactose, and L-rhamnose,
and are thus classiﬁed as heteropolysaccharides (396). However, EPS gene clusters are
not conserved in different Biﬁdobacterium species or even between strains of the same
species. Several studies demonstrated that EPS production is linked with their ability to
modulate the host immune response (398, 406) and/or their ability to shape the
composition and activity of the gut microbiota (396). In this context, it has recently
been shown that the EPS produced by B. breve UCC2003 cells positively modulates the
small intestinal cell shedding response in IBD by reducing apoptotic signaling in the
epithelial compartment. Notably, such novel ﬁndings imply that capsular structures of
biﬁdobacteria play an important role in their host against pathological cell shedding
(407). Furthermore, it has been shown that EPS produced by B. longum 35624 exerts an
immune modulatory role by dampening proinﬂammatory host responses, while loss of
EPS production results in the induction of local TH17 responses (408, 409).
Another key cell surface structure considered to be crucial in biﬁdobacterial inter-
actions with its host, possibly with other members of the gut microbiota, is represented
by pili or ﬁmbriae (352). So far, in the various members of the genus Biﬁdobacterium
two different types of pili have been described, the tight-adherence (Tad) pili and the
sortase-dependent pili (353). Tad pili in biﬁdobacteria are encoded by a genetic locus
which was originally found in the genome of B. breve UCC2003 (399). The main tad
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locus of UCC2003 is similar to that of the type IVb pilus-encoding gene cluster of
Actinobacillus actinomycetemcomitans, though biﬁdobacteria harbor one tad gene
which is separated from the main tad locus (399). The main tad locus of B. breve
UCC2003 encodes proteins involved in pilus assembly and localization (TadB, TadA,
TadC, and TadZ), as well as the Flp prepilin and two pseudopilins (TadE and TadF), while
the second locus consists of a single gene, tadV, which is responsible for the processing
of pilin precursors to mature pilin proteins (399). The main tad locus was identiﬁed
through transcriptome analysis of B. breve UCC2003, which showed that upon murine
colonization, transcription of this gene cluster is induced, while it is not transcribed
under laboratory conditions. Thus, such extracellular structures may be produced only
when B. breve UCC2003 is found in its natural environment (399). Notably, a mutational
analysis of the tadA gene highlighted the crucial importance of the tad locus in the
colonization and persistence of UCC2003 cells in the mammalian gut. The tad locus is
highly conserved among sequenced biﬁdobacterial strains, which supports the hypoth-
esis that such extracellular structures mediate host colonization by biﬁdobacteria (353,
399). Further extracellular appendages that are believed to be pivotal for colonization
and/or the interaction of biﬁdobacterial cells with the mammalian host are represented
by sortase-dependent pili (401). Such structures were shown to promote adhesion of
biﬁdobacterial cells to human enterocytes through extracellular matrix (ECM) proteins
as well as the interaction with the immune system of the host by eliciting a local
proinﬂammatory response, which may be crucial in the ﬁrst stages of life of the human
host (401). In fact, the neonatal immune system is immature, and the presence of
FIG 9 Extracellular structures identiﬁed among members of the Biﬁdobacterium genus. The biﬁdobacterial phylogenetic tree is based on the core gene
sequences conserved in each biﬁdobacterial (sub)species. Colored dots show the presence of the different extracellular structures distributed among the
Biﬁdobacterium genus. The biﬁdobacterial colors are related to the ecological origin of each biﬁdobacterial (sub)species.
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proinﬂammatory stimuli such as those exerted by biﬁdobacterial pili may be essential
in developmental immunological programming. In this context, it is well known that
decreased antigenic exposure has adverse effects on the budding immune system and
increases the likelihood of developing atopic disorders (410).
Another protein that seems to be involved in biﬁdobacterium-host interaction is the
serine protease inhibitor (serpin), which is a member of the serpin superfamily (411).
Biﬁdobacterial serpins act as inhibitors of the human neutrophil and pancreatic elas-
tases (411). Serpin-encoding genes in biﬁdobacteria are present in the genomes of only
B. breve, B. longum, and B. dentium species (412). Functional analyses involving tran-
scriptomics and targeted gene inactivation revealed that transcription of the serpin-
encoding gene is enhanced when B. breve cultures are exposed to various host-derived
proteases, such as pancreatic elastase, human neutrophil elastase, thrombin, papain,
kallikrein, trypsin, -antitrypsin, chymotrypsin, and plasmin (412, 413). This ﬁnding is
highly relevant since many of these proteases are typically found within the human gut,
and thus the presence of a protease inhibitor may provide an ecological advantage to
biﬁdobacteria since serpin activity may protect them against these host proteases.
Biﬁdobacterial cells have also been characterized for the synthesis of an interspecies
signaling molecule known as the quorum sensing molecule AI-2 (414, 415). Synthesis of
AI-2 is modulated by an enzyme that forms an essential part of the activated methyl
cycle, i.e., LuxS, which is involved in recycling S-adenosylhomocysteine (416). The
LuxS-encoding gene belongs to the core genome of the genus Biﬁdobacterium (417)
and has been molecularly characterized in B. breve UCC2003 (415). Insertional inacti-
vation and complementation experiments indeed demonstrated that a functional luxS
gene is necessary for biﬁdobacterial AI-2 synthesis. Furthermore, these analyses showed
that the UCC2003 luxS mutant, compared to the UCC2003 wild-type strain, is less
effective in iron sequestering and unable to colonize the murine gastrointestinal tract,
while this mutant was also shown to confer less protection against Salmonella infection
in a nematode model (415).
Other Members of the Core Infant Gut Microbiota
The Clostridia class. Members of the genus Clostridium have recently been reclas-
siﬁed into several genera that all fall within the Clostridia class (418). These species are
commonly found among microbial taxa present in the infant gut microbiota. So far, 72
different species of the Clostridia class have been isolated from the human gut (32).
Among the infant gut microbiota-associated members of the Clostridium sensu stricto
(cluster I) group, we should mention C. perfringens, while also worth mentioning is a
member of the Peptostreptococcaceae family, Clostridiodes difﬁcile, the recently reclas-
siﬁed Clostridium difﬁcile (418, 419). Both of these species are known as pathogenic
microorganisms that may cause bacteremia and pseudomembranous colitis, and their
presence at high densities is interpreted as an indicator of an unhealthy microbiota
(420). Historically, cultivation-based analyses have revealed that C. perfringens and other
Clostridium sensu strictomembers can be present in infants at densities of up to 107 CFU
g1 fecal content (421).
The Clostridia class also includes certain common human gut commensals such as
species belonging to the Ruminococcaceae and Lachnospiraceae families, formerly
known as Clostridium clusters IV and XIVa (422). Notably, the Ruminococcaceae and
Lachnospiraceae families encompass highly diverse species, many of which produce
SCFAs (423–425). Thus, a depletion of Ruminococcaceae and Lachnospiraceae is corre-
lated with reduced production of SCFAs, e.g., butyrate, and the onset of IBD.
The genus Bacteroides. Members of the Bacteroides genus are dominant compo-
nents of the adult gut microbiota (262), although they may also be present in the infant
gut microbiota, where their presence seems to be modulated by HMOs in a fashion
similar to that for biﬁdobacteria (365). Notably, in mouse experiments, it has been
shown that gut colonization by Bacteroides spp. is a result of the recognition and
selection by the immune system of the host (426), mediated through Toll-like receptors
(TLRs) (404) and other speciﬁc microbe-host interactions (427). Members of this genus
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are classiﬁed as saccharoclastic bacteria that are able to metabolize host-produced
glycans, such as HMOs and mucins, but also complex plant polysaccharides such as
starch, cellulose, xylans, and pectins (428, 429). Bacteroides species commonly possess
proteolytic activity due to the action of extracellular proteases (430). Other key meta-
bolic functions exploited by members of the Bacteroides genus encompass deconju-
gation of bile acids (431).
(i) How Bacteroides cells interact with the host. Among the Bacteroides genus, B.
fragilis has been described as a member that can produce multiple capsular polysac-
charides (432), known as polysaccharide A (PSA), which act as important mediators of
gut microbiota colonization, host-microbe cross talk, and/or immune modulation (433).
In various Bacteroides species, capsular polysaccharides are predicted to alter the
physical properties of cell surfaces and to play a key role in host-bacterial commen-
salism (434). Cells of B. fragilis are able to produce multiple capsular polysaccharides,
and any experimental attempts to eliminate capsule-mediated protection against the
host immune system lead to competitive defects of noncapsular mutants with subse-
quent spontaneous phenotypic reversion (432, 434–436). This reversion is explained by
the ﬁnding that B. fragilis acapsular mutants are capable of reestablishing capsule
production. The establishment of the production of other capsular polysaccharides
restores the reduced ﬁtness of acapsular mutants in the gut.
The genera Veillonella and Streptococcus. A minor component of the core infant
gut microbiota is represented by bacterial taxa belonging to the Veillonella genus.
These bacteria are saccharolytic and utilize end products of carbohydrate fermentation
(e.g., lactate) of other infant gut bacteria, such as Streptococcus spp. and Biﬁdobacterium
spp., to produce propionate, forming an important trophic chain. This short-chain fatty
acid is considered a beneﬁcial product of the gut microbiota as it displays anti-
inﬂammatory features, and inﬂuences glucose and energy homeostasis and increases
insulin sensitivity (437).
Speciﬁc members of the genus Streptococcus also form part of the core infant gut
microbiota and are among the ﬁrst established bacteria in the infant gut, where they
can be identiﬁed within the ﬁrst 24 h following birth (200, 438).
The genus Collinsella. Members of the genus Collinsella have recently been shown
to reach high numbers when they are associated with an infant gut microbiota
dominated by biﬁdobacteria (270). The Collinsella genus was identiﬁed from the
reclassiﬁcation of Eubacterium aerofaciens based on a 16S rRNA gene sequence diver-
gence and the presence of a unique peptidoglycan type compared to other members
of the genus Eubacterium (439). So far, the Collinsella genus includes ﬁve species,
Collinsella aerofaciens, Collinsella intestinalis, Collinsella stercoris, Collinsella ihuae, and
Collinsella tanakaei, which were all isolated from the human gastrointestinal tract
(439–441). However, the biology of these bacteria is still largely ignored, and only
recently a genome sequence of a member of this genus has been published (442).
The genus Lactobacillus. Lactobacilli are known to be present in the infant gut
microbiota, although they are present at lower numbers in the large intestine than the
above-mentioned bacterial genera yet are present soon after delivery (438). In this
context, lactobacilli belonging to the Lactobacillus gasseri, Lactobacillus ruminis, Lacto-
bacillus casei, Lactobacillus reuteri, Lactobacillus sakei, Lactobacillus plantarum, and
Lactobacillus brevis species were detected in the meconium, where their abundance is
higher in vaginally delivered (VG) neonates than in caesarian section-delivered (CS)
newborns (204). Follow-up studies of lactobacilli revealed that compared to that in VG
infants, the rate of detection of the Lactobacillus genus remained signiﬁcantly lower in
CS infants at different time points during the ﬁrst 6 months of life (204). It may be
argued that vertical transmission of Lactobacillus species present in the maternal
vaginal tract represents the origin of this early infant Lactobacillus microbiota compo-
nent. In this context, preliminary genetic insights supporting the occurrence of the
enzymatic arsenal for HMO metabolism have recently been discovered in the genomes
of L. casei (443).
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The genus Akkermansia. A. muciniphila is the sole intestinal representative of the
Verrucomicrobia that is present, though at very low levels, in the human gut since early
life (444, 445). The presence of A. muciniphila has been correlated with intestinal
integrity, and its relative abundance and absolute numbers are known to increase
rapidly with age and speciﬁcally after weaning (446). Mouse experiments conﬁrmed the
effect of A. muciniphila on intestinal barrier function and demonstrated that its admin-
istration protects against diet-induced obesity (447). Recently, a mechanistic explana-
tion involving TLR signaling via a speciﬁc pilus-associated protein has been provided
(448, 449). These ﬁndings and the indications that A. muciniphila may ferment HMOs
(450) make this species a relevant inhabitant in the early-life gut, even at low abun-
dance, and a potential target for therapeutic developments aimed at increasing barrier
function (451, 452).
MICROBIAL BIOMARKERS ASSOCIATED WITH INFANT HEALTH
General Features of Microbial Biomarkers
Alterations in the infant gut microbiota composition have been linked to multiple
diseases and disorders (see above). Although the precise mechanisms and causalities of
these associations still have to be uncovered, microbiota changes across various stages
of disease/disorder might be utilized for novel diagnostic and prognostic tests, also
known as microbial biomarkers. We categorize microbial markers in the following
groups, which will be discussed further below: (i) microbiota maturation, (ii) microbial
diversity, (iii) presence and abundance of biﬁdobacteria, (iv) presence and abundance
of butyrogenic bacteria belonging to the Lachnospiraceae and Ruminococcaceae fam-
ilies, (v) concentration of SCFAs and pH, and (vi) microbial cell wall products.
Microbiota Maturation as a Marker for Health
Different aspects of the microbiota can be indicative of differences between healthy
and disease states (453). Single microbial taxa or microbial products are preferable as
health markers, since these make strategies for nutritional interventions or therapy
most feasible. However, in many cases, if differences are found between a healthy
microbiota and that of an ill person, the microbial biomarkers are not particularly
speciﬁc. They are described as differences in community structure or differences in
transition of the complete microbiota. Microbiota maturation has been deﬁned as the
rate at which the infant gut microbiota develops, as measured by age-dependent
succession stages (2). A “mature” microbiota contains certain taxa that are biomarkers
for the particular age group of the child/infant, while an “immature” or delayed
microbiota resembles that of a younger child/infant (2). Delayed microbiota maturation
is associated with physiological disturbances in the host. Typical factors that can
hamper the process of microbiota maturation are premature birth as well as formula
feeding, undernutrition, and antibiotic use (2, 73, 83, 454).
Microbial Diversity as a Biomarker for Health
In adults, microbial diversity is considered to represent a biomarker that can be
associated with either health or disease. A decrease in microbial diversity, calculated as
either Chao1, Simpson, Shannon, or phylogenetic diversity, is reported in states of
disease. Notably, a decrease in metagenomic richness of the microbiota is described as
a biomarker for metabolic syndrome, despite the fact that the sole evaluation of
changes in biodiversity is not considered to be sufﬁcient to reliably identify and conﬁrm
the presence of an ongoing pathological condition (455). In contrast, a healthy intes-
tinal microbiota in early life is associated with a low microbial diversity (4, 269). Infants
born preterm or by caesarean section show an even further reduced diversity com-
pared to infants born vaginally at term. Milk typically makes up the complete nutrition
of infants in the ﬁrst months following birth. Depending on the milk source, either
breast milk or formula, the microbiota is less or more diverse, respectively (456). HMOs
in human breast milk render the microbiota low in diversity and richness and high in
biﬁdobacteria (456). In this context, compared to that of a breastfed infant (of the same
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age), the microbiota of a formula-fed infant is usually higher in diversity and richness
yet with lower abundance of biﬁdobacteria (73). During and after weaning, the changes
that occur in microbial diversity are more pronounced in breastfed than in formula-fed
infants (2). This is due to a rapid decrease of biﬁdobacteria, being replaced in relative
abundance by Bacteroides spp. and members of the Lachnospiraceae and Ruminococ-
caceae families.
When the infant microbiota is exposed to antibiotics the diversity can drop to an
even lower value compared to that of a reference non-antibiotic-treated, breastfed
infant (2, 457). In this case, the low diversity and decrease of biﬁdobacteria are
considered a biomarker for hampered microbiota development and risk for later-life
health. The decline of biﬁdobacterial and Bacteroides sp. counts leads to higher relative
abundances of enterobacteria and enterococci. The latter groups contain opportunistic
pathogens and increase the risk of infections and disease (456). In prematurely born
infants, microbial colonization is hampered, and low microbial richness and the abun-
dance of facultative anaerobic species from the enterobacteria and enterococci are
directly linked to an increased risk of NEC development (458).
In early life, low microbial diversity has been described to be correlated with colic
and atopic dermatitis (456, 459). In infants suffering from colic, the increase of microbial
diversity in the ﬁrst weeks of life was less marked than that observed in healthy control
subjects. This lower microbial diversity in colic infants continued across the ﬁrst 2 years
following birth and was accompanied by a signiﬁcantly lower abundance of biﬁdobac-
teria and lactobacilli in such colic infants compared to healthy controls. The manifes-
tation of colic symptoms is most pronounced in the ﬁrst 6 weeks after birth; therefore,
the reduced diversity and speciﬁc microbiota signature observed in infants with colic in
the ﬁrst weeks of life suggest a potential role of microbiota development in the etiology
of colic (459).
Microbial diversity is a nonstable factor in early life as it gradually increases toward
adulthood. Deviations in this transition, such as lower diversity at certain stages in this
transition, might be a measure for risk of certain early-life disease. Speciﬁc microbial
signatures accompanied with this diversity measure are important and are further
discussed below.
Presence and Abundance of Biﬁdobacteria as a Biomarker for Health
Biﬁdobacteria colonize the intestine early in life, and biﬁdobacterial levels become
lower yet remain relatively stable in adulthood, tending to decrease as a result of
senescence. As discussed above, infants typically possess a microbiota dominated by
biﬁdobacteria. When considering a vaginally delivered, breastfed infant as a healthy
reference, formula-fed infants have a more diverse microbiota and infants born preterm
or by caesarean section show a delayed colonization by biﬁdobacteria (83, 123).
Biﬁdobacterial presence and abundance are described to be associated with a positive
health status and can therefore be considered a potential microbial biomarker.
There are examples of early-life disease, such as colic and NEC, as well as later-life
development of obesity, celiac disease, and autoimmune diseases, that are correlated
with diminished levels of biﬁdobacteria in the infant intestine (460, 461). Malnutrition
in children is typically characterized by lower abundances of B. longum and puts these
children at increased risk for impaired learning ability and physical stunting in later life
(454).
The use of antibiotics shifts the composition of the gut microbiota toward an
increased abundance of Proteobacteria by further reducing Biﬁdobacterium populations.
Antibiotic use in the ﬁrst days of life delays colonization by biﬁdobacteria in the gut.
Antibiotics are routinely administered perinatally during caesarean sections, which is a
confounder in analyses where biﬁdobacteria have been shown to be transmitted
vertically with vaginal but not caesarean delivery. The decreased amounts of biﬁdo-
bacteria and increased amounts of speciﬁc Firmicutes, including different Clostridia class
groups such as members of the families Ruminococcaceae and Lachnospiraceae, have
been associated with the development and onset of allergic diseases (456). Further-
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more, in celiac disease and childhood constipation, there is a reduced proportion of
Biﬁdobacterium spp. (279, 462). At the same time, biﬁdobacteria have been suggested
to alleviate gastrointestinal symptoms of adult celiac patients and have been associated
with reduced abdominal pain and discomfort in healthy adults, thus opening novel
opportunities for nutritional intervention to treat disease with low abundance of
biﬁdobacteria.
The protective ability of biﬁdobacteria against early-life disease is suggested to work
through speciﬁc immune stimulation and acidiﬁcation of the intestinal environment
through the production of SCFAs and lactate. It is unclear whether speciﬁc strains of
biﬁdobacteria or even a diverse community of different biﬁdobacteria elicits different
effects. The colonization of B. longum subsp. infantis has been associated with normal
development of immune tolerance, and the species has been shown to be capable of
normalizing the permeability of the intestinal mucosa (463, 464). B. animalis subsp.
lactis has been shown to protect against infections in infants (465).
The presence of aberrant biﬁdobacterial numbers is one of the most frequently
observed intestinal microbiota alterations (461) in early-life-associated diseases. This
fact suggests an important role for the biﬁdobacterial population in establishing
intestinal homeostasis. Biﬁdobacteria may therefore be used as a biomarker to assess
the intestinal status with regard to a putative dysbiosis. In addition, increasing biﬁdo-
bacterial levels in the gastrointestinal tract may be considered a target to prevent
and/or alleviate microbiota-associated diseases.
The Lachnospiraceae and Ruminococcaceae Families as a Marker for Health
The commonly described microbial fermentation product butyrate is not typically
the most abundant SCFA in the early-life intestine, where biﬁdobacteria dominate.
Butyrate-producing bacteria that are present in the adult human gut have been
proposed to reduce pain sensation, as pointed out by studies relying on butyrate
enemas (466). Butyrate serves as a primary energy source for colonic epithelial cells, and
it is also described as beneﬁcial for gut health by causing, for example, decreased
intestinal permeability. Signatures of butyrate-producing bacteria are, however, detect-
able in the infant microbiota and described as markers for health. Colonization by low num-
bers of butyrogenic microorganisms early in life is thought to help the fast transition of
microbes during the process of weaning, which rapidly changes the biﬁdobacterium-
dominated microbiota to a microbiota rich in Bacteroides spp. and Clostridium spp. In this
context, it should be noted that a negative association between crying and butyrate-
producing bacteria in infants with colic symptoms has been reported (459).
Acidity as a Result of Biﬁdobacteria and LAB in the Early-Life Intestine
Acetate is the most abundantly produced SCFA in the colons of adults, and its
production is a common feature of most gut microbiota members (453). Compared to
those in adults, the levels of fecal SCFAs in breastfed infants are characterized by higher
relative proportions of acetate, lower proportions of propionate, and an almost com-
plete absence of butyrate. Furthermore, lactate is more commonly detected in the feces
of infants, while it is usually found at low levels (5 mM) in healthy adults. Acetate and
lactate are the precursors for butyrate production by certain microbiota members, and
these organic acids are therefore rapidly converted in the adult intestine. The high
levels of acetate and lactate in breastfed infants reﬂect the dominance of biﬁdobacteria
and lactobacilli. As such, breastfed infants have a lower fecal pH (average of 5.8) than
formula-fed infants (average of 7.1) (467). It has been suggested that the higher
relative abundance of lactic acid in breastfed infants drives this pH difference. The low
acidity in the early-life intestine is thought to play a beneﬁcial role, as it is prohibitive
to the colonization of pathogens (468).
Microbial Lipids and Proteins as Modulators of Gut Health
As described above, aspects of microbiota maturation, microbial diversity, and
abundance of microbial taxa can be indicative of health status in early life. Such
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characteristics may be used for future diagnostic methods to identify predisease states
and states of disease. Apart from the use of the microbiota as a tool, it can be exploited
as a target. Stimulation of the right microbes and combinations of microorganisms in
the early-life intestine can modulate infant health. The exact mechanisms by which
microbiota maturation, diversity, or taxon abundance are able to modulate the onset
and severity of various disease states are still lacking. Mechanistic insights into micro-
bial functionality in host-microbe interaction processes are scarce. The role of SCFAs in
the intestinal tract and their effects on intestinal health and physiology represent nice
examples of the direct effects of the microbiota toward host-microbe interactions.
Microbially produced lipids and proteins represent two other major biological com-
pounds that are directly encountered by the host epithelial cells.
Clinicians commonly use the differences in the outer membrane compositions of
Gram-negative microorganisms as a ﬁrst tool to identify pathogenic isolates. The
categorization of Gram-positive and Gram-negative bacteria is based on the expression
of lipids on the cell surface of bacteria. Gram-positive microorganisms have a thicker
peptidoglycan layer and a lower lipid content, whereas in Gram-negative bacteria the
outer membrane contains a high lipopolysaccharide (LPS) content and only a thin layer
peptidoglycan below it. In the host gut, epithelial cells have evolved separate mech-
anisms dedicated to sense the presence of these different components. Toll-like
receptor 4 (TLR4) is specialized in monitoring LPS from microbiota members, while TLR2
is responsive toward peptidoglycan. LPS is a precursor for host inﬂammatory responses.
This might be related to the fact that Gram-negative bacteria induce a more severe
inﬂammatory response than Gram-positive bacteria (469). A higher relative abundance
of Gram-negative bacteria is associated with several inﬂammatory and metabolic
disease states in adults, despite the fact that certain Gram-negative taxa, such as
members of the genus Bacteroides, have been shown to exert anti-inﬂammatory
activities. In infants, a higher abundance of Gram-negative bacteria, such as those from
the phylum Proteobacteria, is associated with colic symptoms, constipation, and atopic
dermatitis (456, 459, 462).
Biﬁdobacterium spp. and Bacteroides spp. are typically the most abundant microor-
ganisms in the infant microbiota. Both Biﬁdobacterium spp. and Bacteroides spp. have
been reported to have anti-inﬂammatory properties. They are, for example, rich in TLR9
ligands; TLR9-mediated stimulation is known to both enhance epithelial integrity and
direct immune responses, with the ability to direct the cellular and physical maturation
of the developing immune system (470). Furthermore, polysaccharide A produced by
Bacteroides has been shown to promote immunological tolerance through induction of
regulatory T cells, causing suppression of an interleukin-17 (IL-17)-mediated response in
mice (404). Bioactive factors secreted by B. longum subsp. infantis have been shown to
induce the expression of tight-junction proteins, thus increasing gut barrier function. As
described above, the exopolysaccharide of B. breve masks other surface antigens and
allows such bacteria to remain immunologically “invisible” (398). The beneﬁcial effects
of Biﬁdobacterium spp. and Bacteroides spp. may be diminished in allergic subjects, who
tend to carry reduced numbers of these microorganisms in their gut (456).
There is evidence, however, that species belonging to the Biﬁdobacterium or Bac-
teroides genus do matter in terms of immune regulation when present as part of the
microbiota. In this context, B. longum subsp. infantis, for example, does not induce
production of IL-10 by dendritic cells, while B. biﬁdum, B. longum subsp. longum, and B.
pseudocatenulatum do activate dendritic cells to produce IL-10 (471).
As another example, recent ﬁndings indicate that LPS from Bacteroides dorei harbors
tetra- and penta-acylated lipid A structures, as opposed to the hexa-acylated lipid A
observed in E. coli (472). Children in countries with high susceptibility to autoimmunity
more often harbor Bacteroides species in the microbiota that produce the immune-
inhibitory LPS. It has been argued that the immune-inhibitory properties of Bacteroides
LPS may prevent early education of the mucosal immune system and contribute to
development of type 1 diabetes (472).
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Altogether, these publications suggest that the host has established many processes
to detect and respond to both commensal bacteria and pathogens by differentiating
the responses toward the different microbial cell structures on their cell walls. Early in
life, the developing immune system is trained to develop immunological tolerance.
Examples of both immune stimulation and immune inhibition are reported as beneﬁcial
in this process during early life and in the potential effects on autoimmune diseases
that may occur in later life. Before microbial cell wall products can be used reliably as
biomarkers, more insights are needed to understand the differences between different
members of the same genus within the microbiota.
ROLE OF THE INFANT GUT VIROME IN MODULATING THE INFANT GUT
HOMEOSTASIS
General Features of the Gut Virome
The gut virome is deﬁned as the portion of the intestinal microbiome representing
viruses that target either eukaryotic host cells (eukaryotic virome), bacteria (bacterial
virome), or archaea (archaeal virome). It also includes all virus-derived genetic elements
which are found integrated in host chromosomes (prophages or endogenous viral
elements) (473). It is estimated that the human gut is host to more than 1012 bacterial
cells, which in turn are outnumbered by their infecting or associated viral counterparts
(bacteriophages or phages) by an estimated ratio of 10:1. The predation of bacterial
populations by these phages is believed to play an important role in shaping the
bacterial community structure of the gut (Fig. 10) (474).
An aberrant gut microbiota in early life may cause an imbalance between resident
gut bacteria, which in turn may result in incorrect immune system maturation with
consequences in later life (60). In this regard, a better understanding of the interactions
between the bacterial gut community and its associated virome is necessary in order to
devise strategies to positively inﬂuence gut microbiota development in a newborn
and/or restore an anomalous gut microbiota to a “normal” one.
Compared to bacterial microbiome investigations, the study of the virome is still
in its infancy (27). Virome analysis has greatly beneﬁted from modern culture-
independent approaches, using next-generation sequencing technologies (e.g.,
shotgun metagenomics) combined with advanced bioinformatic tools (475). Detec-
FIG 10 Contribution of phages to gut microbiota development through human aging. Putative factors
inﬂuencing the virome biodiversity from infant to adult are schematically represented as factors of the
curve’s formula. Phage and bacterial loads are schematically represented to express the concept that
while the phage load decreases during aging, the gut microbial population increases in complexity and
abundance. The number of bacterial or phage particles schematically represents the number of species
and complexity of the population.
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tion of virus-associated sequences in metagenomic data sets has to overcome the
challenge of detecting relationships between extremely divergent sequences, where
the majority of genes (up to 90%) identiﬁed in viral metagenomic data sets have no
known function (476, 477). However, as viral DNA represents only 2 to 5% of the total
gut community DNA (478), metagenomic sequencing may not provide the desired
depth of data for downstream analysis. Therefore, speciﬁc enrichment approaches have
been developed to obtain data sets representing deep DNA sequencing (479).
A recent study has established that viruses targeting bacteria are found in abun-
dance in the infant gut (Fig. 10) (480). A hypothesis of transkingdom interactions
occurring between viruses and bacteria has been proposed, in which both parties are
responsible for modulating their relative composition and impacting the health status
of the host (27). This dynamic relationship is exempliﬁed by their progression from early
infancy to adulthood (Fig. 10). Immediately following birth and up to 2 to 3 years of age,
the infant gut microbiota appears to be extremely dynamic, undergoing a process of
rapid expansion and diversiﬁcation to result in an adult-like microbiota. Very little is
known about the factors that drive this early gut microbiota development; however,
recent studies have indicated that the gut virome plays a role in this dynamic microbial
(re)shaping process (480).
Similar to the bacterial microbiota, the virome appears to be highly dynamic during
infant microbiota development, with the highest diversity of bacteriophages, especially
Caudovirales (i.e., tailed phages), observed during the ﬁrst months after birth (27, 480,
481). Subsequently, the bacteriophage virome (or phageome) undergoes a mechanism
of contraction and loss of diversity, shifting toward a Microviridae-dominated compo-
sition (480, 481). The development and diversiﬁcation of the gut microbiota appear to
occur at the expense of the phage community (27). Interestingly, the aforementioned
virome contraction occurs during the same period when the infant microbiota adopts
an adult-like composition, which indicates that the resultant reduction in predator
numbers facilitates the establishment of a diverse bacterial community in the gastro-
intestinal tract (27).
In contrast, the eukaryotic virome is observed to be low in diversity during the ﬁrst
days of life (average, 2.6 days), with an increase in richness over a period of 24 months
in a study involving four sets of twins. This suggests that eukaryotic viruses are
obtained primarily from environmental sources (480). Anelloviridae have repeatedly
been identiﬁed as the most prevalent eukaryotic DNA virus in infant fecal samples (482).
In a longitudinal study, an increase in prevalence of such viruses was observed in fecal
samples from infants at 6 and 12 months, yet they were rarely detected before the age
of 3 months. It was suggested that the expansion of the annellovirus complement is
linked to the immunocompromised state of the infant following reduction of maternal
antibodies (480). The virome composition in the gut can be inﬂuenced by several
factors, among which geography and diet appear to have strongest inﬂuence. Inter-
estingly, it has been shown that individuals who follow the same dietary habits have a
tendency to harbor a similar virome, likely reﬂecting a diet-dependent microbiota,
allowing the proliferation of phages infecting the more dominant members of this
microbiota (483). This becomes even more relevant in the context of early infancy, a
crucial period when host immune maturation and various metabolic developments
take place.
Particularly relevant information on the virome community has been derived from
the study of twins. Comparative analysis of twin-derived viromes has shown that the
fecal viromes of corresponding twins are more similar to each other than to those of
unrelated individuals, a phenomenon that appears to persist throughout life (477, 480,
481). A longitudinal study following monozygotic and dizygotic twins for 30 months
reafﬁrmed that the viromes of twin pairs (regardless of zygosity) are more similar to
each other than to any other group and are distinguishable from those of their mothers
or nontwin siblings. Moreover, the viromes of unrelated twins of the same age were
found to be more similar to each other than to those of any relative, suggesting that
the age of the infant represents a relevant factor in virome composition (481).
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Phage-associated sequences of the gut virome may also be detected as integrated
genetic elements or prophages within the bacterial chromosome, and as such they
constitute part of the bacterial mobilome. Furthermore, their persistence in the host
chromosome and subsequent acquisition by lateral transfer between members of a
bacterial community make them an important source and catalyst of intraspecies
diversity (484).
Integration of temperate phage genomes into the chromosome of their bacterial
host(s) may act as a modulating factor of the gut microbiota through lysogenic
conversion. Such lysogenic conversion may impart phenotypic alterations on the host
cells that provide a competitive advantage (e.g., in the form of phage resistance). For
this reason, the carriage of prophages by bacteria may promote their dominance
among other competing strains cohabiting the same niche. This phenomenon may
explain the apparent lack of “kill-the-winner” phage-host dynamics in the human gut,
as phage-resistant lysogenic hosts are allowed to persist (485). Through the analysis of
18 infant fecal samples collected over a time frame of 14 months, an inverse trend was
observed between the abundance of a speciﬁc taxon (e.g., Biﬁdobacterium scardovii or
B. longum) and biﬁdobacterium-associated phage (or biﬁdophage) DNA. This observa-
tion indicates that phages impact biﬁdobacterial establishment and prevalence in the
gut and suggests that these phages may enter the lytic cycle, thereby modulating
biﬁdobacterial colonization of the gut and their relative abundance in the gut (486).
These ﬁndings therefore support the notion that the virome plays a role in inﬂu-
encing the bacterial microbiome composition and establishment, necessitating the
introduction of community-scale genetic approaches for further analyses (487). There-
fore, future microbiota engineering methodologies may be aimed at restoring micro-
biota imbalances by in situ manipulation of bacterial communities using (selected)
phages.
PROBIOTIC/PREBIOTIC THERAPIES AS EXTERNAL MODULATORS OF THE INFANT
GUT MICROBIOTA
General Features
The recent identiﬁcation of differences in gut microbiota composition between
healthy and diseased individuals makes it a valuable tool that can be exploited as a
support for diagnostics and treatment. Disruption of natural development of the infant
microbiota may increase the neonate’s risk of gastric, metabolic, and immune diseases.
The best-known risk factors for differential development of the infant microbiota are
caesarean section delivery, pre-/perinatal antibiotic use, and formula feeding. Different
strategies are available, and those involving the use of orally supplied pre- and
probiotics to inﬂuence and direct the microbiota development in these early stage of
life are the most common. Another strategy is the transfer of the mother’s vaginal and
fecal microbiota immediately following birth.
While the literature on probiotic applications is promising, it is unclear how strain
speciﬁc the beneﬁcial effects are and if combinations of strains might be more efﬁcient.
It is also of great importance that safety is taken into account when probiotic trials are
performed in infants, especially those infants who are at increased risk for infections,
such as prematurely delivered and antibiotic-treated infants. A literature review of
studies addressing the safety of probiotics concluded that “there is a lack of assessment
and systematic reporting of adverse events in probiotic intervention studies, and
interventions are poorly documented” (488). Future research should therefore focus on
the different strains and combinations of strains, the timing of administration, safety,
and whether or not these probiotics are more efﬁcacious in conjunction with prebiotics.
Probiotic Therapy during Pregnancy or for Infant Nutrition
The fact that infants encounter their ﬁrst microbiota during the birthing process has
led to the development of strategies to modulate the maternal fecal and vaginal
microbiota during pregnancy. Treatment of women during the second and third
trimesters of pregnancy with L. rhamnosus resulted in maintenance of a vaginal
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microbiota free of pathogenic microorganisms and helped to maintain a low vaginal pH
(489). Probiotic supplementation of the mother during and after pregnancy has also
been shown to alter the infant’s microbiota. In this context, L. rhamnosus, supplied to
women during and after pregnancy, was shown to colonize the intestines of their
infants and was correlated with an increase in the abundance of biﬁdobacteria in the
infant gut (490, 491). Noticeably, treatment of mothers before delivery and subse-
quent supplementation of the infants after delivery with L. rhamnosus GG also
positively correlated with the abundance of biﬁdobacteria and lactobacilli in the
infant microbiota.
A culture-based study evaluated a synbiotic treatment of newborns with Lactoba-
cillus plantarum and FOS and found that the synbiotic resulted in rapid microbial
colonization of the infant gut. Infants even remained colonized several months after
therapy was terminated (492). However, probiotic gut colonization has also been
shown to result in lower levels of colonization or in transient colonization (109). The
efﬁcacy with which different probiotic microbes are capable of colonizing the gut may
underlie this variability.
Preterm-delivered infants are at high risk for the development of gastric infections
due to immune immaturity, antibiotic treatments, and delayed microbial colonization.
Several publications show that oral probiotics, using either biﬁdobacteria, lactobacilli,
Saccharomyces boulardii, or a combination of different biﬁdobacteria with Streptococcus
thermophilus, reduce the risk of or prevent NEC in preterm-delivered infants (493–495).
Furthermore, the effects of probiotics on pediatric diseases/disorders include effects
on allergies, obesity, gastrointestinal infections, or colic (496–498). As such, L. reuteri
DSM 17938 has been evaluated for its effects on infantile colic. Average crying and
fussing were signiﬁcantly less in infants from the probiotic group than in infants in the
placebo group (499–501). The potential of L. rhamnosus GG in alleviation of colic
symptoms has also been reported (502, 503). In contrast, it was recently also shown that
L. reuteri DSM 17938 or Lactobacillus salivarius CEC5713 is not effective in protecting
newborns from colic (504, 505). While the impacts of these and other data are discussed
elsewhere (505), these ﬁndings should help to design future clinical approaches for the
development of speciﬁc therapies for colic prevention and alleviation.
In infants at risk for allergic diseases, the administration of B. longum BB536 and L.
rhamnosus GG during the ﬁrst 6 months of life was not shown to inﬂuence the overall
composition of the gut microbiota, and the probiotic bacteria did not persist once
administration was stopped (506). Based on a systematic literature review, there is
evidence suggesting that probiotics can in some cases alleviate allergic symptoms but
are usually not effective in modulating microbiota composition and overall are not
sufﬁcient for the treatment of allergic diseases in early life (507). However, combina-
tions of biﬁdobacteria with Streptococcus thermophilus have been shown to be effective
in the prevention and treatment of antibiotic-associated diarrhea in children (508).
Proposed mechanisms of probiotic action include enhanced epithelial barrier func-
tion, enhanced mucosal IgA responses, direct antagonism against pathogens, compet-
itive exclusion of pathogens, prevention of apoptosis, production of anti-inﬂammatory
cytokines, and downregulation of proinﬂammatory pathways (109). The exact mecha-
nism of probiotics is probably strain dependent. The overall complexity of the micro-
biota and its interaction with the immune system make it rather hard to assess. It has
been reported, however, that lactobacilli and biﬁdobacteria exert direct effects on
intestinal epithelial barrier function by decreasing intestinal permeability and improv-
ing intestinal epithelial resistance (109).
Microbiota Modulation through Prebiotics
The knowledge that biﬁdobacteria are the main microbes beneﬁtting from the
prebiotic HMOs in breast milk has led to the administration of prebiotic biﬁdogenic
ﬁbers to pregnant women and infants. Nondigestible oligosaccharides that are added
to formula have shown results similar to those of breastfeeding in reducing the colonic
pH and increasing the production of SCFAs and lactate. Prebiotics were also shown to
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be effective in selectively increasing the abundance of biﬁdobacteria and lactobacilli in
both pregnant women and formula-fed infants (509, 510). The consumption of infant
formula containing prebiotics promotes the development of a neonatal gut microbiota
similar to that of breastfed infants (108). Nevertheless, such studies evaluated the
microbiota composition at the genus level, and thus species-speciﬁc effects of probi-
otics with respect to HMOs still need to be fully elucidated. The main prebiotics that are
used in infant formula are GOS, FOS, and polydextrose (PDX). For both GOS and
inulin-type fructans, there is strong clinical support that they are beneﬁcial for digestive
and immune health (511, 512).
In pregnant women, GOS/long-chain FOS (lcFOS) was shown to signiﬁcantly in-
crease fecal biﬁdobacterial levels, with potential beneﬁts for the transmission of
microbes to their infant host during birth (513). Feeding with infant formula containing
either oligofructose/FOS, GOS/FOS, or standard formula indicated that the bacterial
composition in the ﬁrst two formulas better resembles that of breastfed infants (509,
514). Addition of GOS or a GOS/FOS mixture to infant formula has a positive effect on
biﬁdobacterial abundance (509, 515–517). GOS alone was shown to increase lactobacilli
(509, 516, 517). The proportion of biﬁdobacteria was reported to be higher in a
prebiotic group treated with GOS/FOS. Notably, B. breve numbers were higher and
those of C. difﬁcile were lower in infants that were fed GOS than in those fed control
formula (518). Even though prebiotic administration may cause the microbiota com-
position to be more similar to that of breastfed infants, this does not mean that these
probiotics are also effective for host immune response regulation. In a recent study, the
feeding of GOS-containing infant formula did not lead to changes in the incidence of
infection or allergic manifestation even though the formula produced a deﬁnite
prebiotic effect as evident from changes in microbiota composition, stool consistency,
and stool frequency (518).
Supplementation of infants with the prebiotic PDX also caused an increased abun-
dance of biﬁdobacteria (519). It is worth mentioning that the metabolic activity of the
prebiotic-stimulated biﬁdobacteria is probably similar to that exerted by breast milk: a
semisynthetic medium containing GOS showed a transcriptional effect similar to that of
human milk for B. longum subsp. longum under in vitro conditions (520).
Finally, high-risk, prematurely born infants given FOS-supplemented formula were
shown to have a positive response in terms of the (increased) numbers of biﬁdobacteria
present in fecal samples and a corresponding signiﬁcant reduction of E. coli and
enterococci (521). Furthermore, results from a randomized controlled trial showed that
oral synbiotics given to preterm babies alter the composition of their gut microbiota
and decrease their risk of developing atopic diseases (522), while also reducing the
levels of fussing and crying (502).
The use of prebiotics in infant formula is already a common practice in infant
feeding systems. There is no clarity about functional differences between the effects of
different types of prebiotics, the combination of different prebiotics, or even synbiotics.
Usually, the effect of prebiotics is measured as an increase of biﬁdobacteria in the infant
gut. However, information on the type of stimulated biﬁdobacteria and the direct
effects on immune stimulation is still lacking. It is hoped that future research will
provide more insights into the mechanisms of pro/prebiotics and their further use in
infants.
Mode of Delivery Impacts Microbiota Transfer from Mother to Infant
As described above, the mode of delivery has a major impact on the composition of
the microbiota of newborns. In particular, early-colonizing bacteria may commonly be
acquired from the infant’s mother, while late-colonizing bacteria may be the result of
environmental contamination. In order to trace vertical transmission events, several in
silico pipelines have recently been developed (45, 523). Vaginally delivered infants
harbor bacterial communities resembling those of the maternal vagina, whereas cae-
sarean section-delivered infants are enriched in skin microbiota (70). The deviation of
microbiota development is associated with long-term effects on host metabolism and
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impaired immune development. Restoration of the microbiota development of infants
born via caesarean section could be achieved by exposure of the neonate to maternal
vaginal and fecal contents. Recent results suggest that the fecal, skin, and oral micro-
biotas of the exposed neonates more closely resemble those from vaginally born than
from caesarean section-born babies (524). Although the long-term health conse-
quences of restoring the microbiota of caesarean section-delivered infants remain
unclear, these results demonstrate that vaginal microbes can be partially restored at
birth in caesarean section-delivered neonates.
While the risks involved in this procedure should be similar to those during vaginal
delivery, research is warranted to optimize the safety and mechanism of such exposure.
Given the rapid development of the infant microbiome, early introduction of key
founder populations may be crucial in facilitating a more natural microbial ecological
succession and host immune and metabolic responses.
CONCLUSIONS
The gut microbiota represents a prime example of how an environment which is
considered sterile, or at least poorly colonized, at birth is rapidly occupied by a plethora
of microbial communities. Notably, this colonization appears to follow typical trajec-
tories that are governed by stochastic processes and microbe-host coevolution forces.
In this context, only speciﬁc microorganisms that are maternally inherited are, under
natural circumstances, driving the establishment of the infant gut microbiota. The
subsequent development of this early gut microbiota is then modulated by speciﬁc
dietary compounds present in human milk that support selective colonization. It has
been shown that the genomes of infant gut commensals, in particular biﬁdobacteria,
are genetically adapted to utilize speciﬁc glycan components of this human secretory
ﬂuid (232). This represents a very intriguing example of host-microbe coevolution,
where both partners are believed to beneﬁt. There is growing evidence that such a
mechanism, by which host products act as key agents for the modulation of the gut
microbiota, thus acting as natural prebiotics, is a common scheme not limited to
humans or other primates but extending to all species across the mammalian tree of
life. Notably, other maternally linked forces responsible for the establishment of the
very early infant gut microbiota include the mode of delivery, host genetics, gestational
age, and maternal diet. There are intriguing indications that the infant gut is not always
sterile at delivery and that fetal colonization might sometimes occur, with a concurrent
transfer of maternal microbiota to the fetus during pregnancy. In this context, the early
stages of life represent a more opportunistic period of human life where the gut
microbiota may be more prone to changes by interventions involving probiotics,
prebiotics, phages, or combinations of these.
In recent years, a substantial number of publications in the ﬁeld of microbiology
have focused on dissecting microbial (infant) gut communities and their interaction
with their human host, being a determining factor in host physiology and metabolic
activities. Such studies have highlighted a reduction of microbial diversity and/or an
aberrant microbiota composition, also known as dysbiosis, both of which have been
causally linked to a number of intestinal diseases in infants, such as NEC, or diseases
that manifest themselves at later stages of life, including chronic diseases such as IBD
as well as metabolic disorders such as obesity or IBS. Thus, there is preliminary data that
suggest that the early human gut microbiota inﬂuences risk factors related to both
childhood and adult health conditions. However, clinical data about the long-term
effects of early dysbiosis in the development of IBD in children and adults are very
scarce, most likely because such analyses will require clinical data collected during very
long periods of time and ideally during the entire human life span. Thus, future
or-already ongoing works (525) involving both animal models and human epidemio-
logical studies must shed light on microbiota-mediated immune and physiological
responses that may cause the onset of IBD.
We are only beginning to understand this early-life interaction, which may already
be initiated during gestation (206, 526), and its long-term effects on health. Therefore,
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it may be time to put forward alternatives for favoring the correct development of the
microbiota in those cases in which, for various reasons, this process is challenged.
This concept has fueled the development of various strategies based on various
nutraceutical products (e.g., probiotics and/or prebiotics) to shape the infant microbi-
ota. This intervention theory is linked to an appropriate evaluation of the composition
of the infant gut microbiota and the identiﬁcation of shifts in the abundance of those
microorganisms considered to have a crucial role in the establishment of diseases, i.e.,
the microbial biomarkers. The identiﬁcation of microbial biomarkers is very challenging
for future prophylactic approaches as well as for early diagnosis of diseases. Currently,
substantial efforts have been made to investigate the dominant members of the infant
gut microbiota, e.g., biﬁdobacteria, and to understand their impact on the physiology
of the infant gut as well as in the priming of the immune system and the metabolism
of the host. Nevertheless, the level of understanding of their interactive behavior with
the host as well as with other members of the gut microbiota is still very preliminary
and largely restricted to a few species and strains. However, in contrast to the case for
other infant gut commensals, in the case of biﬁdobacteria, some effort is being made
beyond the cataloguing of OTUs in order to understand the individuality of strains and
species and their impact on the microbiota and their associated host. Notably, the
contribution of biﬁdobacteria to the overall gut microbiota composition displays
regional differences much more than other microorganisms typically found in the
infant gut. In this context, the presence of biﬁdobacteria is markedly reduced in the
offspring ecosystem of industrialized areas (2). In contrast, surveys of the infant gut
microbiota composition from babies born in Africa, as well as Asia, showed a higher
occurrence of biﬁdobacteria (125, 527, 528).
Such ﬁndings are also complemented by early studies performed in industrialized
countries of Northern Europe, displaying higher a abundance of biﬁdobacteria in the
infant gut (529–531). Thus, comparing data related to biﬁdobacterial occurrence in
infants described in older literature with those in recent publications, one may argue
that biﬁdobacteria represent one of the “missing microbes,” i.e., bacterial taxa that have
been lost or are now present in low abundance. This apparent process of extinction of
biﬁdobacteria may have been due to modiﬁcations of the human diet, including the
widespread use of formula milk instead of breast milk, yet may also be due to or
compounded by other factors, such as the use of antibiotics, increased hygiene, and
C-sections.
As described in this review, biﬁdobacteria represent the dominant norm for the
infant gut microbiota, and their use as health-promoting microorganisms for infants is
already exploited by the food industry. However, most of the probiotic biﬁdobacterial
strains do not fulﬁll any scientiﬁc criteria in terms of ecological origin, i.e., autochtho-
nous origin, as well as knowledge of the molecular basis of their health-promoting
effects (532).
Future probiotic interventions directed to prevent and/or counteract gut microbiota
dysbiosis may necessarily involve “next-generation” probiotic bacteria, which may
include “classical” probiotic bacteria belonging to the Biﬁdobacterium or the Lactoba-
cillus genus yet may also consist of other microbial groups of the infant core gut
microbiota.
It is expected that investigations of the infant gut microbiota will be central to
understand human health and disease. Novel experimental approaches available in the
coming years will no doubt lead to pivotal discoveries that can be applied in functional
food and nutraceutical industries or in medical settings.
ACKNOWLEDGMENTS
This work was funded by the EU Joint Programming Initiative “A Healthy Diet for a
Healthy Life” (JPI HDHL, http://www.healthydietforhealthylife.eu/) and MIUR to M.V. and
by the Spanish MINECO to M.G. (project PCIN-2015-233). A.M. and S.D.P. are partially
funded by grants from the Instituto Danone and by the Spanish Plan Estatal de IDI
(reference AGL2016-78311-R). D.V.S. is a member of the APC Microbiome Institute
The Infant Gut Microbiota Microbiology and Molecular Biology Reviews
December 2017 Volume 81 Issue 4 e00036-17 mmbr.asm.org 51
 o
n
 August 20, 2018 by guest
http://m
m
br.asm
.org/
D
ow
nloaded from
 
funded by Science Foundation Ireland (SFI) through the Irish Government’s National
Development Plan (grant number SFI/12/RC/2273). J.M.R. is in receipt of AGL2016-
75476-R (Ministerio de Economía y Competitividad (Spain). J.M. is in receipt of a Starting
Investigator Research Grant (SIRG) (no. 15/SIRG/3430) funded by Science Foundation
Ireland (SFI).
Part of this research was conducted using the High Performance Computing (HPC)
facility of the University of Parma.
We declare that we have no competing interests.
REFERENCES
1. Lozupone CA, Stombaugh JI, Gordon JI, Jansson JK, Knight R. 2012.
Diversity, stability and resilience of the human gut microbiota. Nature
489:220–230. https://doi.org/10.1038/nature11550.
2. Bokulich NA, Chung J, Battaglia T, Henderson N, Jay M, Li H, Lieber AD,
Wu F, Perez-Perez GI, Chen Y, Schweizer W, Zheng X, Contreras M,
Dominguez-Bello MG, Blaser MJ. 2016. Antibiotics, birth mode, and diet
shape microbiome maturation during early life. Sci Transl Med 8:
343ra82. https://doi.org/10.1126/scitranslmed.aad7121.
3. Yassour M, Vatanen T, Siljander H, Hamalainen AM, Harkonen T, Ry-
hanen SJ, Franzosa EA, Vlamakis H, Huttenhower C, Gevers D, Lander
ES, Knip M, DABIMMUNE Study Group, Xavier RJ. 2016. Natural history
of the infant gut microbiome and impact of antibiotic treatment on
bacterial strain diversity and stability. Sci Transl Med 8: 343ra81. https://
doi.org/10.1126/scitranslmed.aad0917.
4. Yatsunenko T, Rey FE, Manary MJ, Trehan I, Dominguez-Bello MG,
Contreras M, Magris M, Hidalgo G, Baldassano RN, Anokhin AP, Heath
AC, Warner B, Reeder J, Kuczynski J, Caporaso JG, Lozupone CA, Lauber
C, Clemente JC, Knights D, Knight R, Gordon JI. 2012. Human gut
microbiome viewed across age and geography. Nature 486:222–227.
5. Ventura M, O’Flaherty S, Claesson MJ, Turroni F, Klaenhammer TR, van
Sinderen D, O’Toole PW. 2009. Genome-scale analyses of health-
promoting bacteria: probiogenomics. Nat Rev Microbiol 7:61–71.
https://doi.org/10.1038/nrmicro2047.
6. Ventura M, Turroni F, Canchaya C, Vaughan EE, O’Toole PW, van
Sinderen D. 2009. Microbial diversity in the human intestine and novel
insights from metagenomics. Front Biosci 14:3214–3221. https://doi
.org/10.2741/3445.
7. Ursell LK, Clemente JC, Rideout JR, Gevers D, Caporaso JG, Knight R.
2012. The interpersonal and intrapersonal diversity of human-
associated microbiota in key body sites. J Allergy Clin Immunol 129:
1204–1208. https://doi.org/10.1016/j.jaci.2012.03.010.
8. Sevelsted A, Stokholm J, Bonnelykke K, Bisgaard H. 2015. Cesarean
section and chronic immune disorders. Obstet Gynecol Surv 70:
303–305. https://doi.org/10.1097/01.ogx.0000466336.81671.9f.
9. Huh SY, Rifas-Shiman SL, Zera CA, Edwards JWR, Oken E, Weiss ST,
Gillman MW. 2012. Delivery by caesarean section and risk of obesity in
preschool age children: a prospective cohort study. Arch Dis Child
97:610–616. https://doi.org/10.1136/archdischild-2011-301141.
10. Eggesbo M, Botten G, Stigum H, Nafstad P, Magnus P. 2003. Is delivery
by cesarean section a risk factor for food allergy? J Allergy Clin Immunol
112:420–426. https://doi.org/10.1067/mai.2003.1610.
11. Relman DA. 2012. The human microbiome: ecosystem resilience and
health. Nutr Rev 70(Suppl 1):S2–S9. https://doi.org/10.1111/j.1753-4887
.2012.00489.x.
12. Tamboli CP, Neut C, Desreumaux P, Colombel JF. 2004. Dysbiosis in
inﬂammatory bowel disease. Gut 53:1–4. https://doi.org/10.1136/gut
.53.1.1.
13. Spor A, Koren O, Ley R. 2011. Unravelling the effects of the environ-
ment and host genotype on the gut microbiome. Nat Rev Microbiol
9:279–290. https://doi.org/10.1038/nrmicro2540.
14. Kim A. 2015. Dysbiosis: a review highlighting obesity and inﬂammatory
bowel disease. J Clin Gastroenterol 49(Suppl 1):S20–S4. https://doi.org/
10.1097/MCG.0000000000000356.
15. Baothman OA, Zamzami MA, Taher I, Abubaker J, Abu-Farha M. 2016.
The role of Gut microbiota in the development of obesity and diabetes.
Lipids Health Dis 15:108. https://doi.org/10.1186/s12944-016-0278-4.
16. Matsuoka K, Kanai T. 2015. The gut microbiota and inﬂammatory bowel
disease. Semin Immunopathol 37:47–55. https://doi.org/10.1007/s00281
-014-0454-4.
17. Mancabelli L, Milani C, Lugli GA, Turroni F, Mangifesta M, Viappiani A,
Ticinesi A, Nouvenne A, Meschi T, van Sinderen D, Ventura M. 2017.
Unveiling the gut microbiota composition and functionality associated
with constipation through metagenomic analyses. Sci Rep 7:9879.
https://doi.org/10.1038/s41598-017-10663-w.
18. Vellend M. 2010. Conceptual synthesis in community ecology. Q Rev
Biol 85:183–206. https://doi.org/10.1086/652373.
19. Costello EK, Stagaman K, Dethlefsen L, Bohannan BJ, Relman DA. 2012.
The application of ecological theory toward an understanding of the
human microbiome. Science 336:1255–1262. https://doi.org/10.1126/
science.1224203.
20. Smillie CS, Smith MB, Friedman J, Cordero OX, David LA, Alm EJ. 2011.
Ecology drives a global network of gene exchange connecting the
human microbiome. Nature 480:241–244. https://doi.org/10.1038/
nature10571.
21. Kerr B, Riley MA, Feldman MW, Bohannan BJ. 2002. Local dispersal
promotes biodiversity in a real-life game of rock-paper-scissors. Nature
418:171–174. https://doi.org/10.1038/nature00823.
22. Bordenstein SR, Theis KR. 2015. Host biology in light of the microbiome:
ten principles of holobionts and hologenomes. PLoS Biol 13:e1002226.
https://doi.org/10.1371/journal.pbio.1002226.
23. Bosch TCG, McFall-Ngai MJ. 2011. Metaorganisms as the new frontier.
Zoology 114:185–190. https://doi.org/10.1016/j.zool.2011.04.001.
24. Gilbert SF, Sapp J, Tauber AI. 2012. A symbiotic view of life: we have
never been individuals. Q Rev Biol 87:325–341. https://doi.org/10.1086/
668166.
25. Zilber-Rosenberg I, Rosenberg E. 2008. Role of microorganisms in the
evolution of animals and plants: the hologenome theory of evolution.
FEMS Microbiol Rev 32:723–735. https://doi.org/10.1111/j.1574-6976
.2008.00123.x.
26. Rosenberg E, Sharon G, Atad I, Zilber-Rosenberg I. 2010. The evolution
of animals and plants via symbiosis with microorganisms. Environ
Microbiol Rep 2:500–506. https://doi.org/10.1111/j.1758-2229.2010
.00177.x.
27. Lim ES, Wang D, Holtz LR. 2016. The bacterial microbiome and virome
milestones of infant development. Trends Microbiol 24:801–810.
https://doi.org/10.1016/j.tim.2016.06.001.
28. Clemente JC, Ursell LK, Parfrey LW, Knight R. 2012. The impact of the
gut microbiota on human health: an integrative view. Cell 148:
1258–1270. https://doi.org/10.1016/j.cell.2012.01.035.
29. Rautava S, Luoto R, Salminen S, Isolauri E. 2012. Microbial contact
during pregnancy, intestinal colonization and human disease. Nat Rev
Gastroenterol Hepatol 9:565–576. https://doi.org/10.1038/nrgastro
.2012.144.
30. Biteen JS, Blainey PC, Cardon ZG, Chun MY, Church GM, Dorrestein PC,
Fraser SE, Gilbert JA, Jansson JK, Knight R, Miller JF, Ozcan A, Prather
KA, Quake SR, Ruby EG, Silver PA, Taha S, van den Engh G, Weiss PS,
Wong GCL, Wright AT, Young TD. 2016. Tools for the microbiome: nano
and beyond. ACS Nano 10:6–37. https://doi.org/10.1021/acsnano
.5b07826.
31. Browne HP, Forster SC, Anonye BO, Kumar N, Neville BA, Stares MD,
Goulding D, Lawley TD. 2016. Culturing of ‘unculturable’ human mi-
crobiota reveals novel taxa and extensive sporulation. Nature 533:
543–546. https://doi.org/10.1038/nature17645.
32. Rajilic-Stojanovic M, de Vos WM. 2014. The ﬁrst 1000 cultured species
of the human gastrointestinal microbiota. FEMS Microbiol Rev 38:
996–1047. https://doi.org/10.1111/1574-6976.12075.
33. Hamady M, Knight R. 2009. Microbial community proﬁling for human
Milani et al. Microbiology and Molecular Biology Reviews
December 2017 Volume 81 Issue 4 e00036-17 mmbr.asm.org 52
 o
n
 August 20, 2018 by guest
http://m
m
br.asm
.org/
D
ow
nloaded from
 
microbiome projects: tools, techniques, and challenges. Genome Res
19:1141–1152. https://doi.org/10.1101/gr.085464.108.
34. Caporaso JG, Kuczynski J, Stombaugh J, Bittinger K, Bushman FD,
Costello EK, Fierer N, Pena AG, Goodrich JK, Gordon JI, Huttley GA,
Kelley ST, Knights D, Koenig JE, Ley RE, Lozupone CA, McDonald D,
Muegge BD, Pirrung M, Reeder J, Sevinsky JR, Turnbaugh PJ, Walters
WA, Widmann J, Yatsunenko T, Zaneveld J, Knight R. 2010. QIIME allows
analysis of high-throughput community sequencing data. Nat Methods
7:335–336. https://doi.org/10.1038/nmeth.f.303.
35. Schloss PD, Westcott SL, Ryabin T, Hall JR, Hartmann M, Hollister EB,
Lesniewski RA, Oakley BB, Parks DH, Robinson CJ, Sahl JW, Stres B,
Thallinger GG, Van Horn DJ, Weber CF. 2009. Introducing mothur:
open-source, platform-independent, community-supported software
for describing and comparing microbial communities. Appl Environ
Microbiol 75:7537–7541. https://doi.org/10.1128/AEM.01541-09.
36. Clarridge JE. 2004. Impact of 16S rRNA gene sequence analysis for
identiﬁcation of bacteria on clinical microbiology and infectious dis-
eases. Clin Microbiol Rev 17:840-. https://doi.org/10.1128/CMR.17.4
.840-862.2004.
37. Gilbert JA, Dupont CL. 2011. Microbial metagenomics: beyond the
genome. Annu Rev Mar Sci 3:347–371. https://doi.org/10.1146/annurev
-marine-120709-142811.
38. Neefs JM, Vandepeer Y, Derijk P, Chapelle S, Dewachter R. 1993.
Compilation of small ribosomal-subunit RNA structures. Nucleic Acids
Res 21:3025–3049. https://doi.org/10.1093/nar/21.13.3025.
39. Sundquist A, Bigdeli S, Jalili R, Druzin ML, Waller S, Pullen KM, El-Sayed
YY, Taslimi MM, Batzoglou S, Ronaghi M. 2007. Bacterial ﬂora-typing
with targeted, chip-based pyrosequencing. BMC Microbiol 7:108.
https://doi.org/10.1186/1471-2180-7-108.
40. Claesson MJ, Wang QO, O’Sullivan O, Greene-Diniz R, Cole JR, Ross RP,
O’Toole PW. 2010. Comparison of two next-generation sequencing
technologies for resolving highly complex microbiota composition
using tandem variable 16S rRNA gene regions. Nucleic Acids Res
38:e200. https://doi.org/10.1093/nar/gkq873.
41. Turroni F, Peano C, Pass DA, Foroni E, Severgnini M, Claesson MJ, Kerr
C, Hourihane J, Murray D, Fuligni F, Gueimonde M, Margolles A, De
Bellis G, O’Toole PW, van Sinderen D, Marchesi JR, Ventura M. 2012.
Diversity of biﬁdobacteria within the infant gut microbiota. PLoS One
7:e36957. https://doi.org/10.1371/journal.pone.0036957.
42. Milani C, Hevia A, Foroni E, Duranti S, Turroni F, Lugli GA, Sanchez B,
Martin R, Gueimonde M, van Sinderen D, Margolles A, Ventura M. 2013.
Assessing the fecal microbiota: an optimized ion torrent 16S rRNA
gene-based analysis protocol. PLoS One 8:e68739. https://doi.org/10
.1371/journal.pone.0068739.
43. Rinke C, Schwientek P, Sczyrba A, Ivanova NN, Anderson IJ, Cheng JF,
Darling A, Malfatti S, Swan BK, Gies EA, Dodsworth JA, Hedlund BP,
Tsiamis G, Sievert SM, Liu WT, Eisen JA, Hallam SJ, Kyrpides NC, Step-
anauskas R, Rubin EM, Hugenholtz P, Woyke T. 2013. Insights into the
phylogeny and coding potential of microbial dark matter. Nature 499:
431–437. https://doi.org/10.1038/nature12352.
44. Chakravorty S, Helb D, Burday M, Connell N, Alland D. 2007. A detailed
analysis of 16S ribosomal RNA gene segments for the diagnosis of
pathogenic bacteria. J Microbiol Methods 69:330–339. https://doi.org/
10.1016/j.mimet.2007.02.005.
45. Milani C, Lugli GA, Turroni F, Mancabelli L, Duranti S, Viappiani A,
Mangifesta M, Segata N, van Sinderen D, Ventura M. 2014. Evaluation
of biﬁdobacterial community composition in the human gut by means
of a targeted amplicon sequencing (ITS) protocol. FEMS Microbiol Ecol
90:493–503. https://doi.org/10.1111/1574-6941.12410.
46. Milani C, Turroni F, Duranti S, Lugli GA, Mancabelli L, Ferrario C, van
Sinderen D, Ventura M. 2015. Genomics of the genus Biﬁdobacterium
reveals species-speciﬁc adaptation to the glycan-rich gut environ-
ment. Appl Environ Microbiol 82:980–991. https://doi.org/10.1128/AEM
.03500-15.
47. Milani C, Mancabelli L, Lugli GA, Duranti S, Turroni F, Ferrario C,
Mangifesta M, Viappiani A, Ferretti P, Gorfer V, Tett A, Segata N, van
Sinderen D, Ventura M. 2015. Exploring vertical transmission of biﬁdo-
bacteria from mother to child. Appl Environ Microbiol 81:7078–7087.
https://doi.org/10.1128/AEM.02037-15.
48. Dean FB, Nelson JR, Giesler TL, Lasken RS. 2001. Rapid ampliﬁcation of
plasmid and phage DNA using Phi 29 DNA polymerase and multiply-
primed rolling circle ampliﬁcation. Genome Res 11:1095–1099. https://
doi.org/10.1101/gr.180501.
49. McLean JS, Lombardo MJ, Badger JH, Edlund A, Novotny M, Yee-
Greenbaum J, Vyahhi N, Hall AP, Yang Y, Dupont CL, Ziegler MG,
Chitsaz H, Allen AE, Yooseph S, Tesler G, Pevzner PA, Friedman RM,
Nealson KH, Venter JC, Lasken RS. 2013. Candidate phylum TM6 ge-
nome recovered from a hospital sink bioﬁlm provides genomic insights
into this uncultivated phylum. Proc Natl Acad Sci U S A 110:E2390-9.
https://doi.org/10.1073/pnas.1219809110.
50. Fodor AA, DeSantis TZ, Wylie KM, Badger JH, Ye Y, Hepburn T, Hu P,
Sodergren E, Liolios K, Huot-Creasy H, Birren BW, Earl AM. 2012. The
“most wanted” taxa from the human microbiome for whole genome
sequencing. PLoS One 7:e41294. https://doi.org/10.1371/journal.pone
.0041294.
51. Marcy Y, Ouverney C, Bik EM, Losekann T, Ivanova N, Martin HG, Szeto
E, Platt D, Hugenholtz P, Relman DA, Quake SR. 2007. Dissecting
biological “dark matter” with single-cell genetic analysis of rare and
uncultivated TM7 microbes from the human mouth. Proc Natl Acad Sci
U S A 104:11889–11894. https://doi.org/10.1073/pnas.0704662104.
52. Lugli GA, Milani C, Mancabelli L, Turroni F, Ferrario C, Duranti S, van
Sinderen D, Ventura M. 2017. Ancient bacteria of the Otzi’s microbiome: a
genomic tale from the Copper Age. Microbiome 5:5. https://doi.org/10
.1186/s40168-016-0221-y.
53. Segata N, Waldron L, Ballarini A, Narasimhan V, Jousson O, Hutten-
hower C. 2012. Metagenomic microbial community proﬁling using
unique clade-speciﬁc marker genes. Nat Methods 9:811–814. https://
doi.org/10.1038/nmeth.2066.
54. Hugon P, Dufour JC, Colson P, Fournier PE, Sallah K, Raoult D. 2015. A
comprehensive repertoire of prokaryotic species identiﬁed in human
beings. Lancet Infect Dis 15:1211–1219. https://doi.org/10.1016/S1473
-3099(15)00293-5.
55. Goodman AL, Kallstrom G, Faith JJ, Reyes A, Moore A, Dantas G, Gordon
JI. 2011. Extensive personal human gut microbiota culture collections
characterized and manipulated in gnotobiotic mice. Proc Natl Acad Sci
U S A 108:6252–6257. https://doi.org/10.1073/pnas.1102938108.
56. Walker AW, Duncan SH, Louis P, Flint HJ. 2014. Phylogeny, culturing,
and metagenomics of the human gut microbiota. Trends Microbiol
22:267–274. https://doi.org/10.1016/j.tim.2014.03.001.
57. Lagier JC, Khelaiﬁa S, Alou MT, Ndongo S, Dione N, Hugon P, Caputo A,
Cadoret F, Traore SI, Seck EH, Dubourg G, Durand G, Mourembou G,
Guilhot E, Togo A, Bellali S, Bachar D, Cassir N, Bittar F, Delerce J, Mailhe
M, Ricaboni D, Bilen M, Dangui Nieko NP, Dia Badiane NM, Valles C,
Mouelhi D, Diop K, Million M, Musso D, Abrahao J, Azhar EI, Bibi F, Yasir
M, Diallo A, Sokhna C, Djossou F, Vitton V, Robert C, Rolain JM, La Scola
B, Fournier PE, Levasseur A, Raoult D. 2016. Culture of previously
uncultured members of the human gut microbiota by culturomics. Nat
Microbiol 1:16203. https://doi.org/10.1038/nmicrobiol.2016.203.
58. Lagier JC, Armougom F, Million M, Hugon P, Pagnier I, Robert C, Bittar
F, Fournous G, Gimenez G, Maraninchi M, Trape JF, Koonin EV, La Scola
B, Raoult D. 2012. Microbial culturomics: paradigm shift in the human
gut microbiome study. Clin Microbiol Infect 18:1185–1193. https://doi
.org/10.1111/1469-0691.12023.
59. Browne HP, Forster SC, Anonye BO, Kumar N, Neville BA, Stares MD,
Goulding D, Lawley TD. 2016. Culturing of ‘unculturable’ human mi-
crobiota reveals novel taxa and extensive sporulation. Nature 533:543.
https://doi.org/10.1038/nature17645.
60. Rodriguez JM, Murphy K, Stanton C, Ross RP, Kober OI, Juge N, Aver-
shina E, Rudi K, Narbad A, Jenmalm MC, Marchesi JR, Collado MC. 2015.
The composition of the gut microbiota throughout life, with an em-
phasis on early life. Microb Ecol Health Dis 26:26050.
61. Jimenez E, Fernandez L, Marin ML, Martin R, Odriozola JM, Nueno-Palop
C, Narbad A, Olivares M, Xaus J, Rodriguez JM. 2005. Isolation of
commensal bacteria from umbilical cord blood of healthy neonates
born by cesarean section. Curr Microbiol 51:270–274. https://doi.org/
10.1007/s00284-005-0020-3.
62. DiGiulio DB, Romero R, Amogan HP, Kusanovic JP, Bik EM, Gotsch F, Kim
CJ, Erez O, Edwin S, Relman DA. 2008. Microbial prevalence, diversity
and abundance in amniotic ﬂuid during preterm labor: a molecular
and culture-based investigation. PLoS One 3:e3056. https://doi.org/10
.1371/journal.pone.0003056.
63. Aagaard K, Ma J, Antony KM, Ganu R, Petrosino J, Versalovic J. 2014. The
placenta harbors a unique microbiome. Sci Transl Med 6: 237ra65.
https://doi.org/10.1126/scitranslmed.3008599.
64. Lauder AP, Roche AM, Sherrill-Mix S, Bailey A, Laughlin AL, Bittinger K,
Leite R, Elovitz MA, Parry S, Bushman FD. 2016. Comparison of placenta
samples with contamination controls does not provide evidence for a
The Infant Gut Microbiota Microbiology and Molecular Biology Reviews
December 2017 Volume 81 Issue 4 e00036-17 mmbr.asm.org 53
 o
n
 August 20, 2018 by guest
http://m
m
br.asm
.org/
D
ow
nloaded from
 
distinct placenta microbiota. Microbiome 4:29. https://doi.org/10.1186/
s40168-016-0172-3.
65. Salter SJ, Cox MJ, Turek EM, Calus ST, Cookson WO, Moffatt MF, Turner
P, Parkhill J, Loman NJ, Walker AW. 2014. Reagent and laboratory
contamination can critically impact sequence-based microbiome anal-
yses. BMC Biol 12:87. https://doi.org/10.1186/s12915-014-0087-z.
66. Perez-Munoz ME, Arrieta MC, Ramer-Tait AE, Walter J. 2017. A critical
assessment of the “sterile womb” and “in utero colonization”
hypotheses: implications for research on the pioneer infant micro-
biome. Microbiome 5:48. https://doi.org/10.1186/s40168-017-0268-4.
67. Avershina E, Lundgard K, Sekelja M, Dotterud C, Storro O, Oien T,
Johnsen R, Rudi K. 2016. Transition from infant- to adult-like gut
microbiota. Environ Microbiol 18:2226–2236. https://doi.org/10.1111/
1462-2920.13248.
68. Avershina E, Storro O, Oien T, Johnsen R, Wilson R, Egeland T, Rudi K.
2013. Biﬁdobacterial succession and correlation networks in a large
unselected cohort of mothers and their children. Appl Environ Micro-
biol 79:497–507. https://doi.org/10.1128/AEM.02359-12.
69. Munyaka PM, Khaﬁpour E, Ghia JE. 2014. External inﬂuence of early
childhood establishment of gut microbiota and subsequent health
implications. Front Pediatr 2:109. https://doi.org/10.3389/fped.2014
.00109.
70. Dominguez-Bello MG, Costello EK, Contreras M, Magris M, Hidalgo G,
Fierer N, Knight R. 2010. Delivery mode shapes the acquisition and
structure of the initial microbiota across multiple body habitats in
newborns. Proc Natl Acad Sci U S A 107:11971–11975. https://doi.org/
10.1073/pnas.1002601107.
71. Biasucci G, Rubini M, Riboni S, Morelli L, Bessi E, Retetangos C. 2010.
Mode of delivery affects the bacterial community in the newborn
gut. Early Hum Dev 86(Suppl 1):S13–S15. https://doi.org/10.1016/j
.earlhumdev.2010.01.004.
72. Fouhy F, Ross RP, Fitzgerald GF, Stanton C, Cotter PD. 2012. Composi-
tion of the early intestinal microbiota: knowledge, knowledge gaps and
the use of high-throughput sequencing to address these gaps. Gut
Microbes 3:203–220. https://doi.org/10.4161/gmic.20169.
73. Backhed F, Roswall J, Peng Y, Feng Q, Jia H, Kovatcheva-Datchary P, Li
Y, Xia Y, Xie H, Zhong H, Khan MT, Zhang J, Li J, Xiao L, Al-Aama J,
Zhang D, Lee YS, Kotowska D, Colding C, Tremaroli V, Yin Y, Bergman
S, Xu X, Madsen L, Kristiansen K, Dahlgren J, Wang J. 2015. Dynamics
and stabilization of the human gut microbiome during the ﬁrst year of
life. Cell Host Microbe 17:690–703. https://doi.org/10.1016/j.chom.2015
.04.004.
74. Del Chierico F, Vernocchi P, Petrucca A, Paci P, Fuentes S, Pratico G,
Capuani G, Masotti A, Reddel S, Russo A, Vallone C, Salvatori G, Buffone
E, Signore F, Rigon G, Dotta A, Miccheli A, de Vos WM, Dallapiccola B,
Putignani L. 2015. Phylogenetic and metabolic tracking of gut micro-
biota during perinatal development. PLoS One 10:e0137347. https://
doi.org/10.1371/journal.pone.0137347.
75. Adlerberth I, Strachan DP, Matricardi PM, Ahrne S, Orfei L, Aberg N,
Perkin MR, Tripodi S, Hesselmar B, Saalman R, Coates AR, Bonanno CL,
Panetta V, Wold AE. 2007. Gut microbiota and development of atopic
eczema in 3 European birth cohorts. J Allergy Clin Immunol 120:
343–350. https://doi.org/10.1016/j.jaci.2007.05.018.
76. Jakobsson HE, Abrahamsson TR, Jenmalm MC, Harris K, Quince C,
Jernberg C, Bjorksten B, Engstrand L, Andersson AF. 2014. Decreased
gut microbiota diversity, delayed Bacteroidetes colonisation and re-
duced Th1 responses in infants delivered by caesarean section. Gut
63:559–566. https://doi.org/10.1136/gutjnl-2012-303249.
77. Neu J, Rushing J. 2011. Cesarean versus vaginal delivery: long-term
infant outcomes and the hygiene hypothesis. Clin Perinatol 38:
321–331. https://doi.org/10.1016/j.clp.2011.03.008.
78. Penders J, Thijs C, Vink C, Stelma FF, Snijders B, Kummeling I, van den
Brandt PA, Stobberingh EE. 2006. Factors inﬂuencing the composition
of the intestinal microbiota in early infancy. Pediatrics 118:511–521.
https://doi.org/10.1542/peds.2005-2824.
79. Hill CJ, Lynch DB, Murphy K, Ulaszewska M, Jeffery IB, O’Shea CA,
Watkins C, Dempsey E, Mattivi F, Touhy K, Ross RP, Ryan CA, O’Toole
PW, Stanton C. 2017. Evolution of gut microbiota composition from
birth to 24 weeks in the INFANTMET cohort. Microbiome 5:4. https://
doi.org/10.1186/s40168-016-0213-y.
80. Martin R, Makino H, Cetinyurek Yavuz A, Ben-Amor K, Roelofs M,
Ishikawa E, Kubota H, Swinkels S, Sakai T, Oishi K, Kushiro A, Knol J.
2016. Early-life events, including mode of delivery and type of feeding,
siblings and gender, shape the developing gut microbiota. PLoS One
11:e0158498. https://doi.org/10.1371/journal.pone.0158498.
81. Salminen S, Gibson GR, McCartney AL, Isolauri E. 2004. Inﬂuence of
mode of delivery on gut microbiota composition in seven year old
children. Gut 53:1388–1389. https://doi.org/10.1136/gut.2004.041640.
82. Falony G, Joossens M, Vieira-Silva S, Wang J, Darzi Y, Faust K, Kurilshikov
A, Bonder MJ, Valles-Colomer M, Vandeputte D, Tito RY, Chaffron S,
Rymenans L, Verspecht C, De Sutter L, Lima-Mendez G, D’Hoe K,
Jonckheere K, Homola D, Garcia R, Tigchelaar EF, Eeckhaudt L, Fu J,
Henckaerts L, Zhernakova A, Wijmenga C, Raes J. 2016. Population-level
analysis of gut microbiome variation. Science 352:560–564. https://doi
.org/10.1126/science.aad3503.
83. Chu DM, Ma J, Prince AL, Antony KM, Seferovic MD, Aagaard KM. 23
January 2017. Maturation of the infant microbiome community struc-
ture and function across multiple body sites and in relation to mode of
delivery. Nat Med https://doi.org/10.1038/nm.4272.
84. Malamitsi-Puchner A, Protonotariou E, Boutsikou T, Makrakis E, Saran-
dakou A, Creatsas G. 2005. The inﬂuence of the mode of delivery on
circulating cytokine concentrations in the perinatal period. Early Hum
Dev 81:387–392. https://doi.org/10.1016/j.earlhumdev.2004.10.017.
85. Thavagnanam S, Fleming J, Bromley A, Shields MD, Cardwell CR. 2008. A
meta-analysis of the association between Caesarean section and child-
hood asthma. Clin Exp Allergy 38:629–633. https://doi.org/10.1111/j.1365
-2222.2007.02780.x.
86. Bager P, Wohlfahrt J, Westergaard T. 2008. Caesarean delivery and risk
of atopy and allergic disease: meta-analyses. Clin Exp Allergy 38:
634–642. https://doi.org/10.1111/j.1365-2222.2008.02939.x.
87. Cardwell CR, Stene LC, Joner G, Cinek O, Svensson J, Goldacre MJ,
Parslow RC, Pozzilli P, Brigis G, Stoyanov D, Urbonaite B, Sipetic S,
Schober E, Ionescu-Tirgoviste C, Devoti G, de Beaufort CE, Buschard K,
Patterson CC. 2008. Caesarean section is associated with an increased risk
of childhood-onset type 1 diabetes mellitus: a meta-analysis of observa-
tional studies. Diabetologia 51:726–735. https://doi.org/10.1007/s00125
-008-0941-z.
88. Pei Z, Heinrich J, Fuertes E, Flexeder C, Hoffmann B, Lehmann I, Schaaf
B, von Berg A, Koletzko S, Inﬂuences of Lifestyle-Related Factors on the
Immune System and the Development of Allergies in Childhood plus
Air Pollution and Genetics (LISAplus) Study Group. 2014. Cesarean
delivery and risk of childhood obesity. J Pediatr 164:1068–1073.e2.
https://doi.org/10.1016/j.jpeds.2013.12.044.
89. Ruiz L, Moles L, Gueimonde M, Rodriguez JM. 2016. Perinatal micro-
biomes’ inﬂuence on preterm birth and preterms’ health: inﬂuencing
factors and modulation strategies. J Pediatr Gastroenterol Nutr 63:
e193–e203. https://doi.org/10.1097/MPG.0000000000001196.
90. Rouge C, Goldenberg O, Ferraris L, Berger B, Rochat F, Legrand A, Gobel
UB, Vodovar M, Voyer M, Roze JC, Darmaun D, Piloquet H, Butel MJ, de
La Cochetiere MF. 2010. Investigation of the intestinal microbiota in
preterm infants using different methods. Anaerobe 16:362–370.
https://doi.org/10.1016/j.anaerobe.2010.06.002.
91. Jacquot A, Neveu D, Aujoulat F, Mercier G, Marchandin H, Jumas-Bilak
E, Picaud JC. 2011. Dynamics and clinical evolution of bacterial gut
microﬂora in extremely premature patients. J Pediatr 158:390–396.
https://doi.org/10.1016/j.jpeds.2010.09.007.
92. Arboleya S, Binetti A, Salazar N, Fernandez N, Solis G, Hernandez-
Barranco A, Margolles A, de los Reyes-Gavilan CG, Gueimonde M. 2012.
Establishment and development of intestinal microbiota in preterm
neonates. FEMS Microbiology Ecology 79:763–772. https://doi.org/10
.1111/j.1574-6941.2011.01261.x.
93. Arboleya S, Sanchez B, Milani C, Duranti S, Solis G, Fernandez N, de los
Reyes-Gavilan CG, Ventura M, Margolles A, Gueimonde M. 2015. Intes-
tinal microbiota development in preterm neonates and effect of peri-
natal antibiotics. J Pediatr 166:538–544. https://doi.org/10.1016/j.jpeds
.2014.09.041.
94. Cong X, Xu W, Janton S, Henderson WA, Matson A, McGrath JM, Maas
K, Graf J. 2016. Gut microbiome developmental patterns in early life of
preterm infants: impacts of feeding and gender. PLoS One 11:
e0152751. https://doi.org/10.1371/journal.pone.0152751.
95. Aujoulat F, Roudiere L, Picaud JC, Jacquot A, Filleron A, Neveu D, Baum
TP, Marchandin H, Jumas-Bilak E. 2014. Temporal dynamics of the very
premature infant gut dominant microbiota. BMC Microbiol 14:325.
https://doi.org/10.1186/s12866-014-0325-0.
96. La Rosa PS, Warner BB, Zhou Y, Weinstock GM, Sodergren E, Hall-Moore
CM, Stevens HJ, Bennett WE, Jr, Shaikh N, Linneman LA, Hoffmann JA,
Hamvas A, Deych E, Shands BA, Shannon WD, Tarr PI. 2014. Patterned
Milani et al. Microbiology and Molecular Biology Reviews
December 2017 Volume 81 Issue 4 e00036-17 mmbr.asm.org 54
 o
n
 August 20, 2018 by guest
http://m
m
br.asm
.org/
D
ow
nloaded from
 
progression of bacterial populations in the premature infant gut. Proc
Natl Acad Sci U S A 111:12522–12527. https://doi.org/10.1073/pnas
.1409497111.
97. Groer MW, Gregory KE, Louis-Jacques A, Thibeau S, Walker WA. 2015.
The very low birth weight infant microbiome and childhood health.
Birth Defects Res C Embryo Today 105:252–264. https://doi.org/10
.1002/bdrc.21115.
98. Collado MC, Cernada M, Neu J, Perez-Martinez G, Gormaz M, Vento M.
2015. Factors inﬂuencing gastrointestinal tract and microbiota immune
interaction in preterm infants. Pediatr Res 77:726–731. https://doi.org/
10.1038/pr.2015.54.
99. Torrazza RM, Neu J. 2013. The altered gut microbiome and necrotizing
enterocolitis. Clin Perinatol 40:93–108. https://doi.org/10.1016/j.clp.2012
.12.009.
100. Madan JC, Salari RC, Saxena D, Davidson L, O’Toole GA, Moore JH, Sogin
ML, Foster JA, Edwards WH, Palumbo P, Hibberd PL. 2012. Gut micro-
bial colonisation in premature neonates predicts neonatal sepsis.
Arch Dis Child Fetal Neonatal Ed 97:F456–F462. https://doi.org/10
.1136/fetalneonatal-2011-301373.
101. Mai V, Torrazza RM, Ukhanova M, Wang X, Sun Y, Li N, Shuster J, Sharma
R, Hudak ML, Neu J. 2013. Distortions in development of intestinal
microbiota associated with late onset sepsis in preterm infants. PLoS
One 8:e52876. https://doi.org/10.1371/journal.pone.0052876.
102. Cernada M, Bauerl C, Serna E, Collado MC, Martinez GP, Vento M. 2016.
Sepsis in preterm infants causes alterations in mucosal gene expression
and microbiota proﬁles compared to non-septic twins. Sci Rep 6:25497.
https://doi.org/10.1038/srep25497.
103. Arboleya S, Sanchez B, Solis G, Fernandez N, Suarez M, Hernandez-
Barranco AM, Milani C, Margolles A, de Los Reyes-Gavilan CG, Ventura
M, Gueimonde M. 2016. Impact of prematurity and perinatal antibiotics
on the developing intestinal microbiota: a functional inference study.
Int J Mol Sci 17:649. https://doi.org/10.3390/ijms17050649.
104. O’Sullivan A, Farver M, Smilowitz JT. 2015. The inﬂuence of early
infant-feeding practices on the intestinal microbiome and body com-
position in infants. Nutr Metab Insights 8:1–9. https://doi.org/10.4137/
NMI.S29530.
105. Maynard CL, Elson CO, Hatton RD, Weaver CT. 2012. Reciprocal inter-
actions of the intestinal microbiota and immune system. Nature 489:
231–241. https://doi.org/10.1038/nature11551.
106. Bezirtzoglou E, Tsiotsias A, Welling GW. 2011. Microbiota proﬁle in feces
of breast- and formula-fed newborns by using ﬂuorescence in situ
hybridization (FISH). Anaerobe 17:478–482. https://doi.org/10.1016/j
.anaerobe.2011.03.009.
107. Praveen P, Jordan F, Priami C, Morine MJ. 2015. The role of breast-
feeding in infant immune system: a systems perspective on the intes-
tinal microbiome. Microbiome 3:41. https://doi.org/10.1186/s40168
-015-0104-7.
108. Guaraldi F, Salvatori G. 2012. Effect of breast and formula feeding on
gut microbiota shaping in newborns. Front Cell Infect Microbiol 2:94.
https://doi.org/10.3389/fcimb.2012.00094.
109. Gritz EC, Bhandari V. 2015. The human neonatal gut microbiome: a
brief review. Front Pediatr 3:17. https://doi.org/10.3389/fped.2015
.00017.
110. Harmsen HJ, Wildeboer-Veloo AC, Raangs GC, Wagendorp AA, Klijn N,
Bindels JG, Welling GW. 2000. Analysis of intestinal ﬂora development
in breast-fed and formula-fed infants by using molecular identiﬁcation
and detection methods. J Pediatr Gastroenterol Nutr 30:61–67. https://
doi.org/10.1097/00005176-200001000-00019.
111. Le Huerou-Luron I, Blat S, Boudry G. 2010. Breast- v. formula-
feeding: impacts on the digestive tract and immediate and long-
term health effects. Nutr Res Rev 23:23–36. https://doi.org/10.1017/
S0954422410000065.
112. Fallani M, Amarri S, Uusijarvi A, Adam R, Khanna S, Aguilera M, Gil A,
Vieites JM, Norin E, Young D, Scott JA, Dore J, Edwards CA, INFABIO
Team. 2011. Determinants of the human infant intestinal microbiota
after the introduction of ﬁrst complementary foods in infant samples
from ﬁve European centres. Microbiology 157:1385–1392. https://doi
.org/10.1099/mic.0.042143-0.
113. Koenig JE, Spor A, Scalfone N, Fricker AD, Stombaugh J, Knight R,
Angenent LT, Ley RE. 2011. Succession of microbial consortia in the
developing infant gut microbiome. Proc Natl Acad Sci U S A 108(Suppl
1):S4578–S4585. https://doi.org/10.1073/pnas.1000081107.
114. Valles Y, Artacho A, Pascual-Garcia A, Ferrus ML, Gosalbes MJ, Abellan
JJ, Francino MP. 2014. Microbial succession in the gut: directional
trends of taxonomic and functional change in a birth cohort of Spanish
infants. PLoS Genet 10:e1004406. https://doi.org/10.1371/journal.pgen
.1004406.
115. Laursen MF, Andersen LB, Michaelsen KF, Molgaard C, Trolle E, Bahl MI,
Licht TR. 2016. Infant gut microbiota development is driven by transi-
tion to family foods independent of maternal obesity. mSphere
1:e00069-15. https://doi.org/10.1128/mSphere.00069-15.
116. Bergstrom A, Skov TH, Bahl MI, Roager HM, Christensen LB, Ejlerskov KT,
Molgaard C, Michaelsen KF, Licht TR. 2014. Establishment of intestinal
microbiota during early life: a longitudinal, explorative study of a large
cohort of Danish infants. Appl Environ Microbiol 80:2889–2900. https://
doi.org/10.1128/AEM.00342-14.
117. Nuriel-Ohayon M, Neuman H, Koren O. 2016. Microbial changes during
pregnancy, birth, and infancy. Front Microbiol 7:1031. https://doi.org/
10.3389/fmicb.2016.01031.
118. Levin AM, Sitarik AR, Havstad SL, Fujimura KE, Wegienka G, Cassidy-
Bushrow AE, Kim H, Zoratti EM, Lukacs NW, Boushey HA, Ownby DR,
Lynch SV, Johnson CC. 2016. Joint effects of pregnancy, sociocultural,
and environmental factors on early life gut microbiome structure and
diversity. Sci Rep 6:31775. https://doi.org/10.1038/srep31775.
119. Davis MY, Zhang H, Brannan LE, Carman RJ, Boone JH. 2016. Rapid
change of fecal microbiome and disappearance of Clostridium difﬁcile
in a colonized infant after transition from breast milk to cow milk.
Microbiome 4:53. https://doi.org/10.1186/s40168-016-0198-6.
120. Collado MC, Isolauri E, Laitinen K, Salminen S. 2010. Effect of mother’s
weight on infant’s microbiota acquisition, composition, and activity
during early infancy: a prospective follow-up study initiated in early
pregnancy. Am J Clin Nutr 92:1023–1030. https://doi.org/10.3945/ajcn
.2010.29877.
121. Chu DM, Antony KM, Ma J, Prince AL, Showalter L, Moller M, Aagaard
KM. 2016. The early infant gut microbiome varies in association with a
maternal high-fat diet. Genome Med 8:77. https://doi.org/10.1186/
s13073-016-0330-z.
122. Laursen MF, Zachariassen G, Bahl MI, Bergstrom A, Host A, Michaelsen
KF, Licht TR. 2015. Having older siblings is associated with gut micro-
biota development during early childhood. BMC Microbiol 15:154.
https://doi.org/10.1186/s12866-015-0477-6.
123. Arrieta MC, Stiemsma LT, Amenyogbe N, Brown EM, Finlay B. 2014. The
intestinal microbiome in early life: health and disease. Front Immunol
5:427. https://doi.org/10.3389/ﬁmmu.2014.00427.
124. De Filippo C, Cavalieri D, Di Paola M, Ramazzotti M, Poullet JB, Massart
S, Collini S, Pieraccini G, Lionetti P. 2010. Impact of diet in shaping gut
microbiota revealed by a comparative study in children from Europe
and rural Africa. Proc Natl Acad Sci U S A 107:14691–14696. https://doi
.org/10.1073/pnas.1005963107.
125. Grzeskowiak L, Collado MC, Mangani C, Maleta K, Laitinen K, Ashorn P,
Isolauri E, Salminen S. 2012. Distinct gut microbiota in southeastern
African and northern European infants. J Pediatr Gastroenterol Nutr
54:812–816. https://doi.org/10.1097/MPG.0b013e318249039c.
126. Lin A, Bik EM, Costello EK, Dethlefsen L, Haque R, Relman DA, Singh U.
2013. Distinct distal gut microbiome diversity and composition in
healthy children from Bangladesh and the United States. PLoS One
8:e53838. https://doi.org/10.1371/journal.pone.0053838.
127. Echarri PP, Gracia CM, Berruezo GR, Vives I, Ballesta M, Solis G, Morillas
IV, Reyes-Gavilan CG, Margolles A, Gueimonde M. 2011. Assessment of
intestinal microbiota of full-term breast-fed infants from two different
geographical locations. Early Hum Dev 87:511–513. https://doi.org/10
.1016/j.earlhumdev.2011.03.013.
128. Stearns JC, Zulyniak MA, de Souza RJ, Campbell NC, Fontes M, Shaikh
M, Sears MR, Becker AB, Mandhane PJ, Subbarao P, Turvey SE, Gupta M,
Beyene J, Surette MG, Anand SS. 2017. Ethnic and diet-related differ-
ences in the healthy infant microbiome. Genome Med 9:32. https://doi
.org/10.1186/s13073-017-0421-5.
129. Benson AK, Kelly SA, Legge R, Ma F, Low SJ, Kim J, Zhang M, Oh PL,
Nehrenberg D, Hua K, Kachman SD, Moriyama EN, Walter J, Peterson
DA, Pomp D. 2010. Individuality in gut microbiota composition is a
complex polygenic trait shaped by multiple environmental and host
genetic factors. Proc Natl Acad Sci U S A 107:18933–18938. https://doi
.org/10.1073/pnas.1007028107.
130. Leamy LJ, Kelly SA, Nietfeldt J, Legge RM, Ma F, Hua K, Sinha R, Peterson
DA, Walter J, Benson AK, Pomp D. 2014. Host genetics and diet, but not
immunoglobulin A expression, converge to shape compositional fea-
tures of the gut microbiome in an advanced intercross population of
mice. Genome Biol 15:552. https://doi.org/10.1186/s13059-014-0552-6.
The Infant Gut Microbiota Microbiology and Molecular Biology Reviews
December 2017 Volume 81 Issue 4 e00036-17 mmbr.asm.org 55
 o
n
 August 20, 2018 by guest
http://m
m
br.asm
.org/
D
ow
nloaded from
 
131. Turpin W, Espin-Garcia O, Xu W, Silverberg MS, Kevans D, Smith MI,
Guttman DS, Grifﬁths A, Panaccione R, Otley A, Xu L, Shestopaloff K,
Moreno-Hagelsieb G, Paterson AD, Croitoru K. 2016. Association of host
genome with intestinal microbial composition in a large healthy co-
hort. Nat Genet 48:1413–1417. https://doi.org/10.1038/ng.3693.
132. Stewart JA, Chadwick VS, Murray A. 2005. Investigations into the inﬂu-
ence of host genetics on the predominant eubacteria in the faecal
microﬂora of children. J Med Microbiol 54:1239–1242. https://doi.org/
10.1099/jmm.0.46189-0.
133. Turnbaugh PJ, Hamady M, Yatsunenko T, Cantarel BL, Duncan A, Ley
RE, Sogin ML, Jones WJ, Roe BA, Affourtit JP, Egholm M, Henrissat B,
Heath AC, Knight R, Gordon JI. 2009. A core gut microbiome in
obese and lean twins. Nature 457:480–484. https://doi.org/10.1038/
nature07540.
134. Turnbaugh PJ, Quince C, Faith JJ, McHardy AC, Yatsunenko T, Niazi F,
Affourtit J, Egholm M, Henrissat B, Knight R, Gordon JI. 2010. Organis-
mal, genetic, and transcriptional variation in the deeply sequenced gut
microbiomes of identical twins. Proc Natl Acad Sci U S A 107:
7503–7508. https://doi.org/10.1073/pnas.1002355107.
135. Bonder MJ, Kurilshikov A, Tigchelaar EF, Mujagic Z, Imhann F, Vila AV,
Deelen P, Vatanen T, Schirmer M, Smeekens SP, Zhernakova DV, Jankip-
ersadsing SA, Jaeger M, Oosting M, Cenit MC, Masclee AA, Swertz MA,
Li Y, Kumar V, Joosten L, Harmsen H, Weersma RK, Franke L, Hofker MH,
Xavier RJ, Jonkers D, Netea MG, Wijmenga C, Fu J, Zhernakova A. 2016.
The effect of host genetics on the gut microbiome. Nat Genet 48:
1407–1412. https://doi.org/10.1038/ng.3663.
136. Walker RW, Clemente JC, Peter I, Loos RJF. 2017. The prenatal gut
microbiome: are we colonized with bacteria in utero? Pediatr Obes
12(Suppl 1):S3–S17. https://doi.org/10.1111/ijpo.12217.
137. Grahn N, Olofsson M, Ellnebo-Svedlund K, Monstein HJ, Jonasson J.
2003. Identiﬁcation of mixed bacterial DNA contamination in broad-
range PCR ampliﬁcation of 16S rDNA V1 and V3 variable regions by
pyrosequencing of cloned amplicons. FEMS Microbiol Lett 219:87–91.
https://doi.org/10.1016/S0378-1097(02)01190-4.
138. Muhl H, Kochem AJ, Disque C, Sakka SG. 2010. Activity and DNA
contamination of commercial polymerase chain reaction reagents for
the universal 16S rDNA real-time polymerase chain reaction detection
of bacterial pathogens in blood. Diagn Microbiol Infect Dis 66:41–49.
https://doi.org/10.1016/j.diagmicrobio.2008.07.011.
139. Laurence M, Hatzis C, Brash DE. 2014. Common contaminants in
next-generation sequencing that hinder discovery of low-
abundance microbes. PLoS One 9:e97876. https://doi.org/10.1371/
journal.pone.0097876.
140. Parnell LA, Briggs CM, Cao B, Delannoy-Bruno O, Schrieffer AE, My-
sorekar IU. 2017. Microbial communities in placentas from term normal
pregnancy exhibit spatially variable proﬁles. Sci Rep 7:11200. https://
doi.org/10.1038/s41598-017-11514-4.
141. Hansen R, Scott KP, Khan S, Martin JC, Berry SH, Stevenson M, Okpapi
A, Munro MJ, Hold GL. 2015. First-pass meconium samples from healthy
term vaginally-delivered neonates: an analysis of the microbiota. PLoS
One 10:e0133320. https://doi.org/10.1371/journal.pone.0133320.
142. Sekirov I, Russell SL, Antunes LC, Finlay BB. 2010. Gut microbiota in
health and disease. Physiol Rev 90:859–904. https://doi.org/10.1152/
physrev.00045.2009.
143. Stout MJ, Conlon B, Landeau M, Lee I, Bower C, Zhao Q, Roehl KA,
Nelson DM, Macones GA, Mysorekar IU. 2013. Identiﬁcation of intracel-
lular bacteria in the basal plate of the human placenta in term and
preterm gestations. Am J Obstet Gynecol 208:226.e1–7. https://doi.org/
10.1016/j.ajog.2013.01.018.
144. Gray J, Oehrle K, Worthen G, Alenghat T, Whitsett J, Deshmukh H. 2017.
Intestinal commensal bacteria mediate lung mucosal immunity and
promote resistance of newborn mice to infection. Sci Transl Med
9:eaaf9412. https://doi.org/10.1126/scitranslmed.aaf9412.
145. Romano-Keeler J, Weitkamp JH. 2015. Maternal inﬂuences on fetal
microbial colonization and immune development. Pediatr Res 77:
189–195. https://doi.org/10.1038/pr.2014.163.
146. Macpherson AJ, de Aguero MG, Ganal-Vonarburg SC. 2017. How nutri-
tion and the maternal microbiota shape the neonatal immune system.
Nat Rev Immunol 17:508–517. https://doi.org/10.1038/nri.2017.58.
147. Green KA, Zarek SM, Catherino WH. 2015. Gynecologic health and
disease in relation to the microbiome of the female reproductive tract.
Fertil Steril 104:1351–1357. https://doi.org/10.1016/j.fertnstert.2015.10
.010.
148. Solt I. 2015. The human microbiome and the great obstetrical
syndromes: a new frontier in maternal-fetal medicine. Best Pract Res
Clin Obstet Gynaecol 29:165–175. https://doi.org/10.1016/j.bpobgyn
.2014.04.024.
149. Krohn MA, Hillier SL, Nugent RP, Cotch MF, Carey JC, Gibbs RS, Eschen-
bach DA. 1995. The genital ﬂora of women with intraamniotic infection.
Vaginal Infection and Prematurity Study Group. J Infect Dis 171:
1475–1480.
150. Newton ER, Piper J, Peairs W. 1997. Bacterial vaginosis and intraamni-
otic infection. Am J Obstet Gynecol 176:672–677. https://doi.org/10
.1016/S0002-9378(97)70568-4.
151. Leitich H, Bodner-Adler B, Brunbauer M, Kaider A, Egarter C, Husslein P.
2003. Bacterial vaginosis as a risk factor for preterm delivery: a meta-
analysis. Am J Obstet Gynecol 189:139–147. https://doi.org/10.1067/
mob.2003.339.
152. Yudin MH. 2005. Bacterial vaginosis in pregnancy: diagnosis, screening,
and management. Clin Perinatol 32:617–627. https://doi.org/10.1016/
j.clp.2005.05.007.
153. Eckert LO, Moore DE, Patton DL, Agnew KJ, Eschenbach DA. 2003.
Relationship of vaginal bacteria and inﬂammation with conception and
early pregnancy loss following in-vitro fertilization. Infect Dis Obstet
Gynecol 11:11–17. https://doi.org/10.1155/S1064744903000024.
154. van Oostrum N, De Sutter P, Meys J, Verstraelen H. 2013. Risks associ-
ated with bacterial vaginosis in infertility patients: a systematic review
and meta-analysis. Hum Reprod 28:1809–1815. https://doi.org/10
.1093/humrep/det096.
155. Reid G, Brigidi P, Burton JP, Contractor N, Duncan S, Fargier E, Hill C,
Lebeer S, Martin R, McBain AJ, Mor G, O’Neill C, Rodriguez JM, Swann
J, van Hemert S, Ansell J. 2015. Microbes central to human reproduc-
tion. Am J Reprod Immunol 73:1–11. https://doi.org/10.1111/aji.12319.
156. Roos PJ, Malan AF, Woods DL, Botha P, Hyland J, Heese Hde V. 1980.
The bacteriological environment of preterm infants. S Afr Med J 57:
347–350.
157. Naeye RL, Peters EC. 1980. Causes and consequences of premature
rupture of fetal membranes. Lancet i:192–194.
158. Dong Y, St Clair PJ, Ramzy I, Kagan-Hallet KS, Gibbs RS. 1987. A
microbiologic and clinical study of placental inﬂammation at term.
Obstet Gynecol 70:175–182.
159. Goldenberg RL, Culhane JF, Iams JD, Romero R. 2008. Epidemiology
and causes of preterm birth. Lancet 371:75–84. https://doi.org/10
.1016/S0140-6736(08)60074-4.
160. Onderdonk AB, Hecht JL, McElrath TF, Delaney ML, Allred EN, Leviton A.
2008. Colonization of second-trimester placenta parenchyma. Am J
Obstet Gynecol 199:52.e1–52.e10. https://doi.org/10.1016/j.ajog.2007
.11.068.
161. Payne MS, Bayatibojakhi S. 2014. Exploring preterm birth as a polymi-
crobial disease: an overview of the uterine microbiome. Front Immunol
5:595. https://doi.org/10.3389/ﬁmmu.2014.00595.
162. Romero R, Miranda J, Kusanovic JP, Chaiworapongsa T, Chaemsaithong
P, Martinez A, Gotsch F, Dong Z, Ahmed AI, Shaman M, Lannaman K,
Yoon BH, Hassan SS, Kim CJ, Korzeniewski SJ, Yeo L, Kim YM. 2015.
Clinical chorioamnionitis at term I: microbiology of the amniotic cavity
using cultivation and molecular techniques. J Perinat Med 43:19–36.
https://doi.org/10.1515/jpm-2014-0249.
163. Vinturache AE, Gyamﬁ-Bannerman C, Hwang J, Mysorekar IU, Jacob-
sson B. 2016. Maternal microbiome—a pathway to preterm birth.
Semin Fetal Neonatal Med 21:94–99. https://doi.org/10.1016/j.siny
.2016.02.004.
164. Mandar R. 2013. Microbiota of male genital tract: impact on the health
of man and his partner. Pharmacol Res 69:32–41. https://doi.org/10
.1016/j.phrs.2012.10.019.
165. Franasiak JM, Scott RT, Jr. 2015. Reproductive tract microbiome in
assisted reproductive technologies. Fertil Steril 104:1364–1371. https://
doi.org/10.1016/j.fertnstert.2015.10.012.
166. Ansbacher R, Boyson WA, Morris JA. 1967. Sterility of the uterine cavity.
Am J Obstet Gynecol 99:394–396. https://doi.org/10.1016/S0002
-9378(16)34549-5.
167. Verstraelen H, Vilchez-Vargas R, Desimpel F, Jauregui R, Vankeirsbilck N,
Weyers S, Verhelst R, De Sutter P, Pieper DH, Van De Wiele T. 2016.
Characterisation of the human uterine microbiome in non-pregnant
women through deep sequencing of the V1-2 region of the 16S rRNA
gene. PeerJ 4:e1602. https://doi.org/10.7717/peerj.1602.
168. Franasiak JM, Werner MD, Juneau CR, Tao X, Landis J, Zhan Y, Treff NR,
Scott RT. 2016. Endometrial microbiome at the time of embryo transfer:
Milani et al. Microbiology and Molecular Biology Reviews
December 2017 Volume 81 Issue 4 e00036-17 mmbr.asm.org 56
 o
n
 August 20, 2018 by guest
http://m
m
br.asm
.org/
D
ow
nloaded from
 
next-generation sequencing of the 16S ribosomal subunit. J Assist
Reprod Genet 33:129–136. https://doi.org/10.1007/s10815-015-0614-z.
169. Moreno I, Codoner FM, Vilella F, Valbuena D, Martinez-Blanch JF,
Jimenez-Almazan J, Alonso R, Alama P, Remohi J, Pellicer A, Ramon D,
Simon C. 2016. Evidence that the endometrial microbiota has an effect
on implantation success or failure. Am J Obstet Gynecol 215:684–703.
https://doi.org/10.1016/j.ajog.2016.09.075.
170. Robertson SA, Chin PY, Glynn DJ, Thompson JG. 2011. Peri-conceptual
cytokines—setting the trajectory for embryo implantation, pregnancy
and beyond. Am J Reprod Immunol 66(Suppl 1):S2–S10. https://doi
.org/10.1111/j.1600-0897.2011.01039.x.
171. Dominguez F, Gadea B, Mercader A, Esteban FJ, Pellicer A, Simon C.
2010. Embryologic outcome and secretome proﬁle of implanted blas-
tocysts obtained after coculture in human endometrial epithelial cells
versus the sequential system. Fertil Steril 93:774–782.e1. https://doi
.org/10.1016/j.fertnstert.2008.10.019.
172. Pelzer E, Willner D, Huygens F, Buttini M. 2015. Is diversiﬁcation of the
endometrial microbiome signiﬁcant for reproductive success? Placenta
36:A23–A23. https://doi.org/10.1016/j.placenta.2015.07.253.
173. Khan KN, Fujishita A, Kitajima M, Hiraki K, Nakashima M, Masuzaki H.
2014. Intra-uterine microbial colonization and occurrence of endome-
tritis in women with endometriosis. Hum Reprod 29:2446–2456.
https://doi.org/10.1093/humrep/deu222.
174. Fang RL, Chen LX, Shu WS, Yao SZ, Wang SW, Chen YQ. 2016. Barcoded
sequencing reveals diverse intrauterine microbiomes in patients suf-
fering with endometrial polyps. Am J Transl Res 8:1581–1592.
175. Walther-Antonio MR, Chen J, Multinu F, Hokenstad A, Distad TJ, Cheek
EH, Keeney GL, Creedon DJ, Nelson H, Mariani A, Chia N. 2016. Potential
contribution of the uterine microbiome in the development of endo-
metrial cancer. Genome Med 8:122. https://doi.org/10.1186/s13073
-016-0368-y.
176. Giudice LC. 2016. Challenging dogma: the endometrium has a micro-
biome with functional consequences! Am J Obstet Gynecol 215:
682–683.
177. Hillier SL, Martius J, Krohn M, Kiviat N, Holmes KK, Eschenbach DA.
1988. A case-control study of chorioamnionic infection and histologic
chorioamnionitis in prematurity. N Engl J Med 319:972–978. https://doi
.org/10.1056/NEJM198810133191503.
178. Diaz Heijtz R. 2016. Fetal, neonatal, and infant microbiome: perturba-
tions and subsequent effects on brain development and behavior.
Semin Fetal Neonatal Med 21:410–417. https://doi.org/10.1016/j.siny
.2016.04.012.
179. Neu J. 2016. The microbiome during pregnancy and early postnatal life.
Semin Fetal Neonatal Med 21:373–379. https://doi.org/10.1016/j.siny
.2016.05.001.
180. Martin R, Langa S, Reviriego C, Jimenez E, Marin ML, Olivares M, Boza
J, Jimenez J, Fernandez L, Xaus J, Rodriguez JM. 2004. The commensal
microﬂora of human milk: new perspectives for food bacteriotherapy
and probiotics. Trends Food Sci Technol 15:121–127. https://doi.org/
10.1016/j.tifs.2003.09.010.
181. Favier CF, Vaughan EE, De Vos WM, Akkermans AD. 2002. Molecular
monitoring of succession of bacterial communities in human neonates.
Appl Environ Microbiol 68:219–226. https://doi.org/10.1128/AEM.68.1
.219-226.2002.
182. Martin R, Langa S, Reviriego C, Jiminez E, Marin ML, Xaus J, Fernandez
L, Rodriguez JM. 2003. Human milk is a source of lactic acid bacteria for
the infant gut. J Pediatr 143:754–758. https://doi.org/10.1016/j.jpeds
.2003.09.028.
183. Steel JH, Malatos S, Kennea N, Edwards AD, Miles L, Duggan P, Reynolds
PR, Feldman RG, Sullivan MH. 2005. Bacteria and inﬂammatory cells in
fetal membranes do not always cause preterm labor. Pediatr Res
57:404–411. https://doi.org/10.1203/01.PDR.0000153869.96337.90.
184. Queiros da Mota V, Prodhom G, Yan P, Hohlfheld P, Greub G, Rouleau
C. 2013. Correlation between placental bacterial culture results and
histological chorioamnionitis: a prospective study on 376 placentas. J
Clin Pathol 66:243–248. https://doi.org/10.1136/jclinpath-2012-201124.
185. Aagaard K, Petrosino J, Keitel W, Watson M, Katancik J, Garcia N, Patel
S, Cutting M, Madden T, Hamilton H, Harris E, Gevers D, Simone G,
McInnes P, Versalovic J. 2013. The Human Microbiome Project strategy
for comprehensive sampling of the human microbiome and why it
matters. FASEB J 27:1012–1022. https://doi.org/10.1096/fj.12-220806.
186. Zheng J, Xiao X, Zhang Q, Mao L, Yu M, Xu J. 2015. The placental
microbiome varies in association with low birth weight in full-term
neonates. Nutrients 7:6924–6937. https://doi.org/10.3390/nu7085315.
187. Hauguel-de Mouzon S, Guerre-Millo M. 2006. The placenta cytokine
network and inﬂammatory signals. Placenta 27:794–798. https://doi
.org/10.1016/j.placenta.2005.08.009.
188. Stewart FM, Freeman DJ, Ramsay JE, Greer IA, Caslake M, Ferrell WR.
2007. Longitudinal assessment of maternal endothelial function and
markers of inﬂammation and placental function throughout pregnancy
in lean and obese mothers. J Clin Endocrinol Metab 92:969–975.
https://doi.org/10.1210/jc.2006-2083.
189. Challier JC, Basu S, Bintein T, Minium J, Hotmire K, Catalano PM,
Hauguel-de Mouzon S. 2008. Obesity in pregnancy stimulates macro-
phage accumulation and inﬂammation in the placenta. Placenta 29:
274–281. https://doi.org/10.1016/j.placenta.2007.12.010.
190. Baeten JM, Bukusi EA, Lambe M. 2001. Pregnancy complications and
outcomes among overweight and obese nulliparous women. Am J
Public Health 91:436–440. https://doi.org/10.2105/AJPH.91.3.436.
191. McDonald SD, Han Z, Mulla S, Beyene J. 2010. Overweight and obesity
in mothers and risk of preterm birth and low birth weight infants:
systematic review and meta-analyses. BMJ 341:c3428. https://doi.org/
10.1136/bmj.c3428.
192. Azevedo FA, Andrade-Moraes CH, Curado MR, Oliveira-Pinto AV,
Guimaraes DM, Szczupak D, Gomes BV, Alho AT, Polichiso L, Tampellini
E, Lima L, de Lima DO, da Silva HA, Lent R. 2013. Automatic isotropic
fractionation for large-scale quantitative cell analysis of nervous tissue.
J Neurosci Methods 212:72–78. https://doi.org/10.1016/j.jneumeth
.2012.09.015.
193. Antony KM, Ma J, Mitchell KB, Racusin DA, Versalovic J, Aagaard K. 2015.
The preterm placental microbiome varies in association with excess
maternal gestational weight gain. Am J Obstet Gynecol 212:
653.e1–e16. https://doi.org/10.1016/j.ajog.2014.12.041.
194. Racicot K, Kwon JY, Aldo P, Silasi M, Mor G. 2014. Understanding the
complexity of the immune system during pregnancy. Am J Reprod
Immunol 72:107–116. https://doi.org/10.1111/aji.12289.
195. Mira-Pascual L, Cabrera-Rubio R, Ocon S, Costales P, Parra A, Suarez A,
Moris F, Rodrigo L, Mira A, Collado MC. 2015. Microbial mucosal colonic
shifts associated with the development of colorectal cancer reveal the
presence of different bacterial and archaeal biomarkers. J Gastroenterol
50:167–179. https://doi.org/10.1007/s00535-014-0963-x.
196. Cardenas I, Means RE, Aldo P, Koga K, Lang SM, Booth CJ, Manzur A,
Oyarzun E, Romero R, Mor G. 2010. Viral infection of the placenta leads
to fetal inﬂammation and sensitization to bacterial products predispos-
ing to preterm labor. J Immunol 185:1248–1257. https://doi.org/10
.4049/jimmunol.1000289.
197. Hitti J, Riley DE, Krohn MA, Hillier SL, Agnew KJ, Krieger JN, Eschenbach
DA. 1997. Broad-spectrum bacterial rDNA polymerase chain reaction
assay for detecting amniotic ﬂuid infection among women in prema-
ture labor. Clin Infect Dis 24:1228–1232. https://doi.org/10.1086/
513669.
198. Jimenez E, Marin ML, Martin R, Odriozola JM, Olivares M, Xaus J,
Fernandez L, Rodriguez JM. 2008. Is meconium from healthy newborns
actually sterile? Res Microbiol 159:187–193. https://doi.org/10.1016/j
.resmic.2007.12.007.
199. Dong XD, Li XR, Luan JJ, Liu XF, Peng J, Luo YY, Liu CJ. 2015. Bacterial
communities in neonatal feces are similar to mothers’ placentae. Can J
Infect Dis Med Microbiol 26:90–94.
200. Gosalbes MJ, Llop S, Valles Y, Moya A, Ballester F, Francino MP. 2013.
Meconium microbiota types dominated by lactic acid or enteric bac-
teria are differentially associated with maternal eczema and respiratory
problems in infants. Clin Exp Allergy 43:198–211. https://doi.org/10
.1111/cea.12063.
201. Moles L, Gomez M, Heilig H, Bustos G, Fuentes S, de Vos W, Fernandez
L, Rodriguez JM, Jimenez E. 2013. Bacterial diversity in meconium of
preterm neonates and evolution of their fecal microbiota during the
ﬁrst month of life. PLoS One 8:e66986. https://doi.org/10.1371/journal
.pone.0066986.
202. Hu J, Nomura Y, Bashir A, Fernandez-Hernandez H, Itzkowitz S, Pei Z,
Stone J, Loudon H, Peter I. 2013. Diversiﬁed microbiota of meconium is
affected by maternal diabetes status. PLoS One 8:e78257. https://doi
.org/10.1371/journal.pone.0078257.
203. Ardissone AN, de la Cruz DM, Davis-Richardson AG, Rechcigl KT, Li N,
Drew JC, Murgas-Torrazza R, Sharma R, Hudak ML, Triplett EW, Neu J.
2014. Meconium microbiome analysis identiﬁes bacteria correlated with
premature birth. PLoS One 9:e90784. https://doi.org/10.1371/journal.pone
.0090784.
204. Nagpal R, Tsuji H, Takahashi T, Kawashima K, Nagata S, Nomoto K,
The Infant Gut Microbiota Microbiology and Molecular Biology Reviews
December 2017 Volume 81 Issue 4 e00036-17 mmbr.asm.org 57
 o
n
 August 20, 2018 by guest
http://m
m
br.asm
.org/
D
ow
nloaded from
 
Yamashiro Y. 2016. Sensitive quantitative analysis of the meconium
bacterial microbiota in healthy term infants born vaginally or by ce-
sarean section. Front Microbiol 7:1997. https://doi.org/10.3389/fmicb
.2016.01997.
205. Makino H, Kushiro A, Ishikawa E, Kubota H, Gawad A, Sakai T, Oishi K,
Martin R, Ben-Amor K, Knol J, Tanaka R. 2013. Mother-to-infant trans-
mission of intestinal biﬁdobacterial strains has an impact on the early
development of vaginally delivered infant’s microbiota. PLoS One
8:e78331. https://doi.org/10.1371/journal.pone.0078331.
206. Collado MC, Rautava S, Aakko J, Isolauri E, Salminen S. 2016. Human gut
colonisation may be initiated in utero by distinct microbial communi-
ties in the placenta and amniotic ﬂuid. Sci Rep 6:23129. https://doi.org/
10.1038/srep23129.
207. Mshvildadze M, Neu J, Shuster J, Theriaque D, Li N, Mai V. 2010.
Intestinal microbial ecology in premature infants assessed with non-
culture-based techniques. J Pediatr 156:20–25. https://doi.org/10.1016/
j.jpeds.2009.06.063.
208. Satokari R, Gronroos T, Laitinen K, Salminen S, Isolauri E. 2009. Biﬁdo-
bacterium and Lactobacillus DNA in the human placenta. Lett Appl
Microbiol 48:8–12. https://doi.org/10.1111/j.1472-765X.2008.02475.x.
209. Vanterpool SF, Been JV, Houben ML, Nikkels PG, De Krijger RR, Zim-
mermann LJ, Kramer BW, Progulske-Fox A, Reyes L. 2016. Porphyromo-
nas gingivalis within placental villous mesenchyme and umbilical cord
stroma is associated with adverse pregnancy outcome. PLoS One
11:e0146157. https://doi.org/10.1371/journal.pone.0146157.
210. Rodriguez JM. 2014. The origin of human milk bacteria: is there a
bacterial entero-mammary pathway during late pregnancy and lacta-
tion? Adv Nutr 5:779–784. https://doi.org/10.3945/an.114.007229.
211. Han YW, Shen T, Chung P, Buhimschi IA, Buhimschi CS. 2009. Unculti-
vated bacteria as etiologic agents of intra-amniotic inﬂammation lead-
ing to preterm birth. J Clin Microbiol 47:38–47. https://doi.org/10
.1128/JCM.01206-08.
212. Han YW, Redline RW, Li M, Yin L, Hill GB, McCormick TS. 2004. Fuso-
bacterium nucleatum induces premature and term stillbirths in preg-
nant mice: implication of oral bacteria in preterm birth. Infect Immun
72:2272–2279. https://doi.org/10.1128/IAI.72.4.2272-2279.2004.
213. Han YW, Ikegami A, Bissada NF, Herbst M, Redline RW, Ashmead GG.
2006. Transmission of an uncultivated Bergeyella strain from the oral
cavity to amniotic ﬂuid in a case of preterm birth. J Clin Microbiol
44:1475–1483. https://doi.org/10.1128/JCM.44.4.1475-1483.2006.
214. Han YW, Fardini Y, Chen C, Iacampo KG, Peraino VA, Shamonki JM,
Redline RW. 2010. Term stillbirth caused by oral Fusobacterium nuclea-
tum. Obstet Gynecol 115:442–445. https://doi.org/10.1097/AOG
.0b013e3181cb9955.
215. Fardini Y, Chung P, Dumm R, Joshi N, Han YW. 2010. Transmission of
diverse oral bacteria to murine placenta: evidence for the oral micro-
biome as a potential source of intrauterine infection. Infect Immun
78:1789–1796. https://doi.org/10.1128/IAI.01395-09.
216. Dasanayake AP, Li Y, Wiener H, Ruby JD, Lee MJ. 2005. Salivary Acti-
nomyces naeslundii genospecies 2 and Lactobacillus casei levels pre-
dict pregnancy outcomes. J Periodontol 76:171–177. https://doi.org/10
.1902/jop.2005.76.2.171.
217. Perez PF, Dore J, Leclerc M, Levenez F, Benyacoub J, Serrant P, Segura-
Roggero I, Schiffrin EJ, Donnet-Hughes A. 2007. Bacterial imprinting of
the neonatal immune system: lessons from maternal cells? Pediatrics
119:e724–e732. https://doi.org/10.1542/peds.2006-1649.
218. McGuire MK, Meehan CL, McGuire MA, Williams JE, Foster J, Sellen DW,
Kamau-Mbuthia EW, Kamundia EW, Mbugua S, Moore SE, Prentice AM,
Kvist LJ, Otoo GE, Brooker SL, Price WJ, Shaﬁi B, Placek C, Lackey KA,
Robertson B, Manzano S, Ruiz L, Rodriguez JM, Pareja RG, Bode L. 2017.
What’s normal? Oligosaccharide concentrations and proﬁles in milk
produced by healthy women vary geographically. Am J Clin Nutr
105:1086–1100. https://doi.org/10.3945/ajcn.116.139980.
219. Kumazaki T, Yoshida A. 1984. Biochemical evidence that secretor gene,
Se, is a structural gene encoding a speciﬁc fucosyltransferase. Proc Natl
Acad Sci U S A 81:4193–4197. https://doi.org/10.1073/pnas.81.13.4193.
220. Viverge D, Grimmonprez L, Cassanas G, Bardet L, Solere M. 1990.
Discriminant carbohydrate components of human milk according to
donor secretor types. J Pediatr Gastroenterol Nutr 11:365–370. https://
doi.org/10.1097/00005176-199010000-00014.
221. Johnson PH, Watkins WM. 1992. Puriﬁcation of the Lewis blood-group
gene associated alpha-3/4-fucosyltransferase from human milk: an en-
zyme transferring fucose primarily to type 1 and lactose-based oligo-
saccharide chains. Glycoconj J 9:241–249. https://doi.org/10.1007/
BF00731136.
222. Thurl S, Henker J, Siegel M, Tovar K, Sawatzki G. 1997. Detection of four
human milk groups with respect to Lewis blood group dependent
oligosaccharides. Glycoconj J 14:795–799. https://doi.org/10.1023/
A:1018529703106.
223. Chaturvedi P, Warren CD, Altaye M, Morrow AL, Ruiz-Palacios G, Pick-
ering LK, Newburg DS. 2001. Fucosylated human milk oligosaccharides
vary between individuals and over the course of lactation. Glycobiol-
ogy 11:365–372. https://doi.org/10.1093/glycob/11.5.365.
224. Stahl B, Thurl S, Henker J, Siegel M, Finke B, Sawatzki G. 2001. Detection
of four human milk groups with respect to Lewis-blood-group-
dependent oligosaccharides by serologic and chromatographic analy-
sis. Adv Exp Med Biol 501:299–306. https://doi.org/10.1007/978-1-4615
-1371-1_37.
225. Thurl S, Munzert M, Henker J, Boehm G, Muller-Werner B, Jelinek J, Stahl
B. 2010. Variation of human milk oligosaccharides in relation to milk
groups and lactational periods. Br J Nutr 104:1261–1271. https://doi
.org/10.1017/S0007114510002072.
226. Xu Z, Vo L, Macher BA. 1996. Structure-function analysis of human
alpha1,3-fucosyltransferase. Amino acids involved in acceptor substrate
speciﬁcity. J Biol Chem 271:8818–8823.
227. Ward RE, Ninonuevo M, Mills DA, Lebrilla CB, German JB. 2006. In vitro
fermentation of breast milk oligosaccharides by Biﬁdobacterium infan-
tis and Lactobacillus gasseri. Appl Environ Microbiol 72:4497–4499.
https://doi.org/10.1128/AEM.02515-05.
228. Ward RE, Ninonuevo M, Mills DA, Lebrilla CB, German JB. 2007. In vitro
fermentability of human milk oligosaccharides by several strains of
biﬁdobacteria. Mol Nutr Food Res 51:1398–1405. https://doi.org/10
.1002/mnfr.200700150.
229. LoCascio RG, Ninonuevo MR, Freeman SL, Sela DA, Grimm R, Lebrilla CB,
Mills DA, German JB. 2007. Glycoproﬁling of biﬁdobacterial consump-
tion of human milk oligosaccharides demonstrates strain speciﬁc, pref-
erential consumption of small chain glycans secreted in early human
lactation. J Agric Food Chem 55:8914–8919. https://doi.org/10.1021/
jf0710480.
230. Locascio RG, Ninonuevo MR, Kronewitter SR, Freeman SL, German JB,
Lebrilla CB, Mills DA. 2009. A versatile and scalable strategy for glyco-
proﬁling biﬁdobacterial consumption of human milk oligosaccharides.
Microb Biotechnol 2:333–342. https://doi.org/10.1111/j.1751-7915.2008
.00072.x.
231. Garrido D, Ruiz-Moyano S, Lemay DG, Sela DA, German JB, Mills DA.
2015. Comparative transcriptomics reveals key differences in the re-
sponse to milk oligosaccharides of infant gut-associated biﬁdobacteria.
Sci Rep 5:13517. https://doi.org/10.1038/srep13517.
232. Sela DA, Chapman J, Adeuya A, Kim JH, Chen F, Whitehead TR, Lapidus
A, Rokhsar DS, Lebrilla CB, German JB, Price NP, Richardson PM, Mills
DA. 2008. The genome sequence of Biﬁdobacterium longum subsp.
infantis reveals adaptations for milk utilization within the infant micro-
biome. Proc Natl Acad Sci U S A 105:18964–18969. https://doi.org/10
.1073/pnas.0809584105.
233. Lin AE, Autran CA, Szyszka A, Escajadillo T, Huang M, Godula K, Prudden
AR, Boons GJ, Lewis AL, Doran KS, Nizet V, Bode L. 2017. Human milk
oligosaccharides inhibit growth of group B Streptococcus. J Biol Chem
https://doi.org/10.1074/jbc.M117.789974.
234. Gonia S, Tuepker M, Heisel T, Autran C, Bode L, Gale CA. 2015. Human
milk oligosaccharides inhibit Candida albicans invasion of human pre-
mature intestinal epithelial cells. J Nutr 145:1992–1998. https://doi.org/
10.3945/jn.115.214940.
235. Fridkin SK, Kaufman D, Edwards JR, Shetty S, Horan T. 2006. Changing
incidence of Candida bloodstream infections among NICU patients in
the United States: 1995-2004. Pediatrics 117:1680–1687. https://doi
.org/10.1542/peds.2005-1996.
236. Ruiz-Palacios GM, Cervantes LE, Ramos P, Chavez-Munguia B, Newburg
DS. 2003. Campylobacter jejuni binds intestinal H(O) antigen (Fuc alpha
1, 2Gal beta 1, 4GlcNAc), and fucosyloligosaccharides of human milk
inhibit its binding and infection. J Biol Chem 278:14112–14120. https://
doi.org/10.1074/jbc.M207744200.
237. Morrow AL, Ruiz-Palacios GM, Altaye M, Jiang X, Guerrero ML, Meinzen-
Derr JK, Farkas T, Chaturvedi P, Pickering LK, Newburg DS. 2004. Human
milk oligosaccharides are associated with protection against diarrhea in
breast-fed infants. J Pediatr 145:297–303. https://doi.org/10.1016/j
.jpeds.2004.04.054.
238. Manthey CF, Autran CA, Eckmann L, Bode L. 2014. Human milk oligosac-
Milani et al. Microbiology and Molecular Biology Reviews
December 2017 Volume 81 Issue 4 e00036-17 mmbr.asm.org 58
 o
n
 August 20, 2018 by guest
http://m
m
br.asm
.org/
D
ow
nloaded from
 
charides protect against enteropathogenic Escherichia coli attachment in
vitro and EPEC colonization in suckling mice. J Pediatr Gastroenterol Nutr
58:165–168. https://doi.org/10.1097/MPG.0000000000000172.
239. Jantscher-Krenn E, Lauwaet T, Bliss LA, Reed SL, Gillin FD, Bode L. 2012.
Human milk oligosaccharides reduce Entamoeba histolytica attach-
ment and cytotoxicity in vitro. Br J Nutr 108:1839–1846. https://doi
.org/10.1017/S0007114511007392.
240. Eiwegger T, Stahl B, Haidl P, Schmitt J, Boehm G, Dehlink E, Urbanek R,
Szepfalusi Z. 2010. Prebiotic oligosaccharides: in vitro evidence for
gastrointestinal epithelial transfer and immunomodulatory properties.
Pediatr Allergy Immunol 21:1179–1188. https://doi.org/10.1111/j.1399
-3038.2010.01062.x.
241. Civardi E, Garofoli F, Tzialla C, Paolillo P, Bollani L, Stronati M. 2013.
Microorganisms in human milk: lights and shadows. J Matern Fetal
Neonatal Med 26(Suppl 2):S30–S34. https://doi.org/10.3109/14767058
.2013.829693.
242. Urbaniak C, Angelini M, Gloor GB, Reid G. 2016. Human milk microbiota
proﬁles in relation to birthing method, gestation and infant gender.
Microbiome 4:1. https://doi.org/10.1186/s40168-015-0145-y.
243. Hunt KM, Foster JA, Forney LJ, Schutte UM, Beck DL, Abdo Z, Fox LK,
Williams JE, McGuire MK, McGuire MA. 2011. Characterization of
the diversity and temporal stability of bacterial communities in
human milk. PLoS One 6:e21313. https://doi.org/10.1371/journal
.pone.0021313.
244. Jost T, Lacroix C, Braegger C, Chassard C. 2013. Assessment of bacterial
diversity in breast milk using culture-dependent and culture-
independent approaches. Br J Nutr 110:1253–1262. https://doi.org/10
.1017/S0007114513000597.
245. Fernandez L, Langa S, Martin V, Maldonado A, Jimenez E, Martin R,
Rodriguez JM. 2013. The human milk microbiota: origin and potential
roles in health and disease. Pharmacol Res 69:1–10. https://doi.org/10
.1016/j.phrs.2012.09.001.
246. Milani C, Mangifesta M, Mancabelli L, Lugli GA, James K, Duranti S,
Turroni F, Ferrario C, Ossiprandi MC, van Sinderen D, Ventura M. 2017.
Unveiling biﬁdobacterial biogeography across the mammalian branch
of the tree of life. ISME J https://doi.org/10.1038/ismej.2017.138.
247. Urashima T, Saito T, Nakamura T, Messer M. 2001. Oligosaccharides of
milk and colostrum in non-human mammals. Glycoconj J 18:357–371.
https://doi.org/10.1023/A:1014881913541.
248. Saito T, Itoh T, Adachi S, Suzuki T, Usui T. 1981. The chemical structure
of neutral and acidic sugar chains obtained from bovine colostrum
kappa-casein. Biochim Biophys Acta 678:257–267. https://doi.org/10
.1016/0304-4165(81)90215-4.
249. Urashima T, Saito T, Ohmisya K, Shimazaki K. 1991. Structural determi-
nation of three neutral oligosaccharides in bovine (Holstein-Friesian)
colostrum, including the novel trisaccharide; GalNAc alpha 1-3Gal beta
1-4Glc. Biochim Biophys Acta 1073:225–229. https://doi.org/10.1016/
0304-4165(91)90207-W.
250. Martinez-Ferez A, Rudloff S, Guadix A, Henkel CA, Pohlentz G, Boza JJ,
Guadix EM, Kunz C. 2006. Goats’ milk as a natural source of lactose-
derived oligosaccharides: isolation by membrane technology. Int Dairy
J 16:173–181. https://doi.org/10.1016/j.idairyj.2005.02.003.
251. Nakajima K, Kinoshita M, Matsushita N, Urashima T, Suzuki M, Suzuki A,
Kakehi K. 2006. Capillary afﬁnity electrophoresis using lectins for the
analysis of milk oligosaccharide structure and its application to bovine
colostrum oligosaccharides. Anal Biochem 348:105–114. https://doi
.org/10.1016/j.ab.2005.10.010.
252. Tao N, Ochonicky KL, German JB, Donovan SM, Lebrilla CB. 2010.
Structural determination and daily variations of porcine milk oligosac-
charides. J Agric Food Chem 58:4653–4659. https://doi.org/10.1021/
jf100398u.
253. Goto K, Fukuda K, Senda A, Saito T, Kimura K, Glander KE, Hinde K,
Dittus W, Milligan LA, Power ML, Oftedal OT, Urashima T. 2010. Chem-
ical characterization of oligosaccharides in the milk of six species of
New and Old World monkeys. Glycoconj J 27:703–715. https://doi.org/
10.1007/s10719-010-9315-0.
254. Tao N, Wu S, Kim J, An HJ, Hinde K, Power ML, Gagneux P, German JB,
Lebrilla CB. 2011. Evolutionary glycomics: characterization of milk oli-
gosaccharides in primates. J Proteome Res 10:1548–1557. https://doi
.org/10.1021/pr1009367.
255. Gilbert SF. 2014. A holobiont birth narrative: the epigenetic transmis-
sion of the human microbiome. Front Genet 5:282. https://doi.org/10
.3389/fgene.2014.00282.
256. Wikoff WR, Anfora AT, Liu J, Schultz PG, Lesley SA, Peters EC, Siuzdak G.
2009. Metabolomics analysis reveals large effects of gut microﬂora on
mammalian blood metabolites. Proc Natl Acad Sci U S A 106:
3698–3703. https://doi.org/10.1073/pnas.0812874106.
257. McFall-Ngai M, Hadﬁeld MG, Bosch TC, Carey HV, Domazet-Loso T,
Douglas AE, Dubilier N, Eberl G, Fukami T, Gilbert SF, Hentschel U, King
N, Kjelleberg S, Knoll AH, Kremer N, Mazmanian SK, Metcalf JL, Nealson
K, Pierce NE, Rawls JF, Reid A, Ruby EG, Rumpho M, Sanders JG, Tautz
D, Wernegreen JJ. 2013. Animals in a bacterial world, a new imperative
for the life sciences. Proc Natl Acad Sci U S A 110:3229–3236. https://
doi.org/10.1073/pnas.1218525110.
258. Funkhouser LJ, Bordenstein SR. 2013. Mom knows best: the universality
of maternal microbial transmission. PLoS Biol 11:e1001631. https://doi
.org/10.1371/journal.pbio.1001631.
259. Moran NA. 2007. Symbiosis as an adaptive process and source of
phenotypic complexity. Proc Natl Acad Sci U S A 104:8627–8633.
https://doi.org/10.1073/pnas.0611659104.
260. Conroy ME, Shi HN, Walker WA. 2009. The long-term health effects of
neonatal microbial ﬂora. Curr Opin Allergy Clin Immunol 9:197–201.
https://doi.org/10.1097/ACI.0b013e32832b3f1d.
261. Dotterud CK, Avershina E, Sekelja M, Simpson MR, Rudi K, Storro O,
Johnsen R, Oien T. 2015. Does maternal perinatal probiotic supple-
mentation alter the intestinal microbiota of mother and child? J
Pediatr Gastroenterol Nutr 61:200–207. https://doi.org/10.1097/
MPG.0000000000000781.
262. Arumugam M, Raes J, Pelletier E, Le Paslier D, Yamada T, Mende DR,
Fernandes GR, Tap J, Bruls T, Batto JM, Bertalan M, Borruel N, Casellas
F, Fernandez L, Gautier L, Hansen T, Hattori M, Hayashi T, Kleerebezem
M, Kurokawa K, Leclerc M, Levenez F, Manichanh C, Nielsen HB, Nielsen
T, Pons N, Poulain J, Qin J, Sicheritz-Ponten T, Tims S, Torrents D, Ugarte
E, Zoetendal EG, Wang J, Guarner F, Pedersen O, de Vos WM, Brunak S,
Dore J, Meta HITC, Antolin M, Artiguenave F, Blottiere HM, Almeida M,
Brechot C, Cara C, Chervaux C, Cultrone A, Delorme C, Denariaz G, et al.
2011. Enterotypes of the human gut microbiome. Nature 473:174–180.
https://doi.org/10.1038/nature09944.
263. Avershina E, Storro O, Oien T, Johnsen R, Pope P, Rudi K. 2014. Major
faecal microbiota shifts in composition and diversity with age in a
geographically restricted cohort of mothers and their children. FEMS
Microbiol Ecol 87:280–290. https://doi.org/10.1111/1574-6941.12223.
264. Duranti S, Lugli GA, Mancabelli L, Armanini F, Turroni F, James K,
Ferretti P, Gorfer V, Ferrario C, Milani C, Mangifesta M, Anzalone R, Zolfo
M, Viappiani A, Pasolli E, Bariletti I, Canto R, Clementi R, Cologna M,
Crifò T, Cusumano G, Sedi S, Gottardi S, Innamorati C, Masè C, Postai D,
Savoi D, Sofﬁati M, Tateo S, Pedrotti A, Segata N, Van Sinderen D,
Ventura M. 2017. Maternal inheritance of biﬁdobacterial communities
and biﬁdophages in infants through vertical transmission. Microbiome
5:66. https://doi.org/10.1186/s40168-017-0282-6.
265. Milani C, Mangifesta M, Mancabelli L, Lugli GA, James K, Duranti S,
Turroni F, Ferrario C, Ossiprandi MC, Van Sinderen D, Ventura M. 22
August 2017. Unveiling biﬁdobacterial biogeography across the mam-
malian branch of the tree of life. ISME J https://doi.org/10.1038/ismej
.2017.138.
266. Cheng J, Ringel-Kulka T, Heikamp-de Jong I, Ringel Y, Carroll I, de Vos
WM, Salojarvi J, Satokari R. 2016. Discordant temporal development of
bacterial phyla and the emergence of core in the fecal microbiota of
young children. ISME J 10:1002–1014. https://doi.org/10.1038/ismej
.2015.177.
267. Hollister EB, Riehle K, Luna RA, Weidler EM, Rubio-Gonzales M, Mistretta
TA, Raza S, Doddapaneni HV, Metcalf GA, Muzny DM, Gibbs RA,
Petrosino JF, Shulman RJ, Versalovic J. 2015. Structure and function of
the healthy pre-adolescent pediatric gut microbiome. Microbiome 3:36.
https://doi.org/10.1186/s40168-015-0101-x.
268. Ottman N, Smidt H, de Vos WM, Belzer C. 2012. The function of our
microbiota: who is out there and what do they do? Front Cell Infect
Microbiol 2:104. https://doi.org/10.3389/fcimb.2012.00104.
269. Palmer C, Bik EM, DiGiulio DB, Relman DA, Brown PO. 2007. Develop-
ment of the human infant intestinal microbiota. PLoS Biol 5:e177.
https://doi.org/10.1371/journal.pbio.0050177.
270. Dogra S, Sakwinska O, Soh SE, Ngom-Bru C, Bruck WM, Berger B,
Brussow H, Lee YS, Yap F, Chong YS, Godfrey KM, Holbrook JD, GUSTO
Study Group. 2015. Dynamics of infant gut microbiota are inﬂuenced
by delivery mode and gestational duration and are associated with
subsequent adiposity. mBio 6:e02419-14. https://doi.org/10.1128/mBio
.02419-14.
271. Fan W, Huo G, Li X, Yang L, Duan C. 2014. Impact of diet in shaping gut
The Infant Gut Microbiota Microbiology and Molecular Biology Reviews
December 2017 Volume 81 Issue 4 e00036-17 mmbr.asm.org 59
 o
n
 August 20, 2018 by guest
http://m
m
br.asm
.org/
D
ow
nloaded from
 
microbiota revealed by a comparative study in infants during the six
months of life. J Microbiol Biotechnol 24:133–143. https://doi.org/10
.4014/jmb.1309.09029.
272. Fan W, Huo G, Li X, Yang L, Duan C, Wang T, Chen J. 2013. Diversity of
the intestinal microbiota in different patterns of feeding infants by
Illumina high-throughput sequencing. World J Microbiol Biotechnol
29:2365–2372. https://doi.org/10.1007/s11274-013-1404-3.
273. Gensollen T, Iyer SS, Kasper DL, Blumberg RS. 2016. How colonization
by microbiota in early life shapes the immune system. Science 352:
539–544. https://doi.org/10.1126/science.aad9378.
274. Hansen CH, Nielsen DS, Kverka M, Zakostelska Z, Klimesova K, Hudcovic
T, Tlaskalova-Hogenova H, Hansen AK. 2012. Patterns of early gut
colonization shape future immune responses of the host. PLoS One
7:34043. https://doi.org/10.1371/journal.pone.0034043.
275. Sommer F, Backhed F. 2013. The gut microbiota—masters of host
development and physiology. Nat Rev Microbiol 11:227–238. https://
doi.org/10.1038/nrmicro2974.
276. Clarke G, O’Mahony SM, Dinan TG, Cryan JF. 2014. Priming for health:
gut microbiota acquired in early life regulates physiology, brain and
behaviour. Acta Paediatr 103:812–819. https://doi.org/10.1111/apa
.12674.
277. Diaz Heijtz R, Wang S, Anuar F, Qian Y, Bjorkholm B, Samuelsson A,
Hibberd ML, Forssberg H, Pettersson S. 2011. Normal gut microbiota
modulates brain development and behavior. Proc Natl Acad Sci U S A
108:3047–3052. https://doi.org/10.1073/pnas.1010529108.
278. Neuman H, Debelius JW, Knight R, Koren O. 2015. Microbial
endocrinology: the interplay between the microbiota and the endo-
crine system. FEMS Microbiol Rev 39:509–521. https://doi.org/10.1093/
femsre/fuu010.
279. Nylund L, Satokari R, Salminen S, de Vos WM. 2014. Intestinal microbi-
ota during early life—impact on health and disease. Proc Nutr Soc
73:457–469. https://doi.org/10.1017/S0029665114000627.
280. Moon C, Baldridge MT, Wallace MA, Burnham CA, Virgin HW, Stappen-
beck TS. 2015. Vertically transmitted faecal IgA levels determine extra-
chromosomal phenotypic variation. Nature 521:90–93. https://doi.org/
10.1038/nature14139.
281. Fujimura KE, Sitarik AR, Havstad S, Lin DL, Levan S, Fadrosh D, Panzer
AR, LaMere B, Rackaityte E, Lukacs NW, Wegienka G, Boushey HA,
Ownby DR, Zoratti EM, Levin AM, Johnson CC, Lynch SV. 2016. Neonatal
gut microbiota associates with childhood multisensitized atopy and T
cell differentiation. Nat Med 22:1187–1191. https://doi.org/10.1038/nm
.4176.
282. Kalliomaki M, Collado MC, Salminen S, Isolauri E. 2008. Early differences
in fecal microbiota composition in children may predict overweight.
Am J Clin Nutr 87:534–538.
283. Kalliomaki M, Kirjavainen P, Eerola E, Kero P, Salminen S, Isolauri E.
2001. Distinct patterns of neonatal gut microﬂora in infants in whom
atopy was and was not developing. J Allergy Clin Immunol 107:
129–134. https://doi.org/10.1067/mai.2001.111237.
284. Simonyte Sjodin K, Vidman L, Ryden P, West CE. 2016. Emerging
evidence of the role of gut microbiota in the development of allergic
diseases. Curr Opin Allergy Clin Immunol 16:390–395. https://doi.org/
10.1097/ACI.0000000000000277.
285. Al-Asmakh M, Zadjali F. 2015. Use of germ-free animal models in
microbiota-related research. J Microbiol Biotechnol 25:1583–1588.
https://doi.org/10.4014/jmb.1501.01039.
286. Olszak T, An D, Zeissig S, Vera MP, Richter J, Franke A, Glickman JN,
Siebert R, Baron RM, Kasper DL, Blumberg RS. 2012. Microbial exposure
during early life has persistent effects on natural killer T cell function.
Science 336:489–493. https://doi.org/10.1126/science.1219328.
287. Kristof K, Kocsis E, Nagy K. 2009. Clinical microbiology of early-onset
and late-onset neonatal sepsis, particularly among preterm babies.
Acta Microbiol Immunol Hung 56:21–51. https://doi.org/10.1556/AMicr
.56.2009.1.2.
288. Stewart CJ, Embleton ND, Marrs EC, Smith DP, Nelson A, Abdulkadir B,
Skeath T, Petrosino JF, Perry JD, Berrington JE, Cummings SP. 2016.
Temporal bacterial and metabolic development of the preterm gut
reveals speciﬁc signatures in health and disease. Microbiome 4:67.
https://doi.org/10.1186/s40168-016-0216-8.
289. Ward DV, Scholz M, Zolfo M, Taft DH, Schibler KR, Tett A, Segata N,
Morrow AL. 2016. Metagenomic sequencing with strain-level resolution
implicates uropathogenic E. coli in necrotizing enterocolitis and mor-
tality in preterm infants. Cell Rep 14:2912–2924. https://doi.org/10
.1016/j.celrep.2016.03.015.
290. Leach ST, Lui K, Naing Z, Dowd SE, Mitchell HM, Day AS. 2015. Multiple
opportunistic pathogens, but not pre-existing inﬂammation, may be
associated with necrotizing enterocolitis. Dig Dis Sci 60:3728–3734.
https://doi.org/10.1007/s10620-015-3830-6.
291. Sim K, Shaw AG, Randell P, Cox MJ, McClure ZE, Li MS, Haddad M,
Langford PR, Cookson WO, Moffatt MF, Kroll JS. 2015. Dysbiosis antic-
ipating necrotizing enterocolitis in very premature infants. Clin Infect
Dis 60:389–397. https://doi.org/10.1093/cid/ciu822.
292. Mai V, Young CM, Ukhanova M, Wang X, Sun Y, Casella G, Theriaque D,
Li N, Sharma R, Hudak M, Neu J. 2011. Fecal microbiota in premature
infants prior to necrotizing enterocolitis. PLoS One 6:e20647. https://
doi.org/10.1371/journal.pone.0020647.
293. Morrow AL, Lagomarcino AJ, Schibler KR, Taft DH, Yu Z, Wang B, Altaye
M, Wagner M, Gevers D, Ward DV, Kennedy MA, Huttenhower C,
Newburg DS. 2013. Early microbial and metabolomic signatures predict
later onset of necrotizing enterocolitis in preterm infants. Microbiome
1:13. https://doi.org/10.1186/2049-2618-1-13.
294. Torrazza RM, Ukhanova M, Wang X, Sharma R, Hudak ML, Neu J, Mai V.
2013. Intestinal microbial ecology and environmental factors affecting
necrotizing enterocolitis. PLoS One 8:e83304. https://doi.org/10.1371/
journal.pone.0083304.
295. Warner BB, Deych E, Zhou Y, Hall-Moore C, Weinstock GM, Sodergren E,
Shaikh N, Hoffmann JA, Linneman LA, Hamvas A, Khanna G, Rouggly-
Nickless LC, Ndao IM, Shands BA, Escobedo M, Sullivan JE, Radmacher
PG, Shannon WD, Tarr PI. 2016. Gut bacteria dysbiosis and necrotising
enterocolitis in very low birthweight infants: a prospective case-control
study. Lancet 387:1928–1936. https://doi.org/10.1016/S0140-6736
(16)00081-7.
296. Stewart CJ, Nelson A, Treumann A, Skeath T, Cummings SP, Embleton
ND, Berrington JE. 2016. Metabolomic and proteomic analysis of serum
from preterm infants with necrotising entercolitis and late-onset sepsis.
Pediatr Res 79:425–431. https://doi.org/10.1038/pr.2015.235.
297. Gough EK, Stephens DA, Moodie EE, Prendergast AJ, Stoltzfus RJ,
Humphrey JH, Manges AR. 2015. Linear growth faltering in infants is
associated with Acidaminococcus sp. and community-level changes in
the gut microbiota. Microbiome 3:24. https://doi.org/10.1186/s40168
-015-0089-2.
298. Blanton LV, Charbonneau MR, Salih T, Barratt MJ, Venkatesh S, Ilkaveya
O, Subramanian S, Manary MJ, Trehan I, Jorgensen JM, Fan YM, Hen-
rissat B, Leyn SA, Rodionov DA, Osterman AL, Maleta KM, Newgard CB,
Ashorn P, Dewey KG, Gordon JI. 2016. Gut bacteria that prevent growth
impairments transmitted by microbiota from malnourished children.
Science 351:aad3311. https://doi.org/10.1126/science.aad3311.
299. Charbonneau MR, O’Donnell D, Blanton LV, Totten SM, Davis JC, Barratt
MJ, Cheng J, Guruge J, Talcott M, Bain JR, Muehlbauer MJ, Ilkayeva O,
Wu C, Struckmeyer T, Barile D, Mangani C, Jorgensen J, Fan YM, Maleta
K, Dewey KG, Ashorn P, Newgard CB, Lebrilla C, Mills DA, Gordon JI.
2016. Sialylated milk oligosaccharides promote microbiota-dependent
growth in models of infant undernutrition. Cell 164:859–871. https://
doi.org/10.1016/j.cell.2016.01.024.
300. Schwarzer M, Makki K, Storelli G, Machuca-Gayet I, Srutkova D, Her-
manova P, Martino ME, Balmand S, Hudcovic T, Heddi A, Rieusset J,
Kozakova H, Vidal H, Leulier F. 2016. Lactobacillus plantarum strain
maintains growth of infant mice during chronic undernutrition. Science
351:854–857. https://doi.org/10.1126/science.aad8588.
301. Blanton LV, Barratt MJ, Charbonneau MR, Ahmed T, Gordon JI. 2016.
Childhood undernutrition, the gut microbiota, and microbiota-
directed therapeutics. Science 352:1533. https://doi.org/10.1126/
science.aad9359.
302. Houghteling PD, Walker WA. 2015. Why is initial bacterial coloniza-
tion of the intestine important to infants’ and children’s health? J
Pediatr Gastroenterol Nutr 60:294–307. https://doi.org/10.1097/
MPG.0000000000000597.
303. Johnson CC, Ownby DR. 2017. The infant gut bacterial microbiota and
risk of pediatric asthma and allergic diseases. Transl Res 179:60–70.
https://doi.org/10.1016/j.trsl.2016.06.010.
304. Johnson CC, Ownby DR. 2016. Allergies and asthma: do atopic disor-
ders result from inadequate immune homeostasis arising from infant
gut dysbiosis? Expert Rev Clin Immunol 12:379–388. https://doi.org/10
.1586/1744666X.2016.1139452.
305. Kalliomaki M, Salminen S, Arvilommi H, Kero P, Koskinen P, Isolauri E.
2001. Probiotics in primary prevention of atopic disease: a randomised
placebo-controlled trial. Lancet 357:1076–1079. https://doi.org/10
.1016/S0140-6736(00)04259-8.
Milani et al. Microbiology and Molecular Biology Reviews
December 2017 Volume 81 Issue 4 e00036-17 mmbr.asm.org 60
 o
n
 August 20, 2018 by guest
http://m
m
br.asm
.org/
D
ow
nloaded from
 
306. Bjorksten B, Sepp E, Julge K, Voor T, Mikelsaar M. 2001. Allergy devel-
opment and the intestinal microﬂora during the ﬁrst year of life. J
Allergy Clin Immunol 108:516–520. https://doi.org/10.1067/mai.2001
.118130.
307. Penders J, Thijs C, van den Brandt PA, Kummeling I, Snijders B, Stelma
F, Adams H, van Ree R, Stobberingh EE. 2007. Gut microbiota compo-
sition and development of atopic manifestations in infancy: the KOALA
Birth Cohort Study. Gut 56:661–667. https://doi.org/10.1136/gut.2006
.100164.
308. Penders J, Stobberingh EE, Thijs C, Adams H, Vink C, van Ree R, van den
Brandt PA. 2006. Molecular ﬁngerprinting of the intestinal microbiota of
infants in whom atopic eczema was or was not developing. Clin Exp
Allergy 36:1602–1608. https://doi.org/10.1111/j.1365-2222.2006.02599.x.
309. Wang M, Karlsson C, Olsson C, Adlerberth I, Wold AE, Strachan DP,
Martricardi PM, Aberg N, Perkin MR, Tripodi S, Coates AR, Hesselmar B,
Saalman R, Molin G, Ahrne S. 2008. Reduced diversity in the early fecal
microbiota of infants with atopic eczema. J Allergy Clin Immunol
121:129–134. https://doi.org/10.1016/j.jaci.2007.09.011.
310. Ismail IH, Oppedisano F, Joseph SJ, Boyle RJ, Licciardi PV, Robins-
Browne RM, Tang ML. 2012. Reduced gut microbial diversity in early life
is associated with later development of eczema but not atopy in
high-risk infants. Pediatr Allergy Immunol 23:674–681. https://doi.org/
10.1111/j.1399-3038.2012.01328.x.
311. Abrahamsson TR, Jakobsson HE, Andersson AF, Bjorksten B, Engstrand
L, Jenmalm MC. 2012. Low diversity of the gut microbiota in infants
with atopic eczema. J Allergy Clin Immunol 129:434–440. https://doi
.org/10.1016/j.jaci.2011.10.025.
312. Nylund L, Nermes M, Isolauri E, Salminen S, de Vos WM, Satokari R.
2015. Severity of atopic disease inversely correlates with intestinal
microbiota diversity and butyrate-producing bacteria. Allergy 70:
241–244. https://doi.org/10.1111/all.12549.
313. Azad MB, Kozyrskyj AL. 2012. Perinatal programming of asthma: the
role of gut microbiota. Clin Dev Immunol 2012:932072. https://doi.org/
10.1155/2012/932072.
314. Chung H, Pamp SJ, Hill JA, Surana NK, Edelman SM, Troy EB, Reading
NC, Villablanca EJ, Wang S, Mora JR, Umesaki Y, Mathis D, Benoist C,
Relman DA, Kasper DL. 2012. Gut immune maturation depends on
colonization with a host-speciﬁc microbiota. Cell 149:1578–1593.
https://doi.org/10.1016/j.cell.2012.04.037.
315. Hill DA, Siracusa MC, Abt MC, Kim BS, Kobuley D, Kubo M, Kambayashi
T, Larosa DF, Renner ED, Orange JS, Bushman FD, Artis D. 2012.
Commensal bacteria-derived signals regulate basophil hematopoiesis
and allergic inﬂammation. Nat Med 18:538–546. https://doi.org/10
.1038/nm.2657.
316. Sudo N, Sawamura S, Tanaka K, Aiba Y, Kubo C, Koga Y. 1997. The
requirement of intestinal bacterial ﬂora for the development of an IgE
production system fully susceptible to oral tolerance induction. J Im-
munol 159:1739–1745.
317. Russell SL, Gold MJ, Hartmann M, Willing BP, Thorson L, Wlodarska
M, Gill N, Blanchet MR, Mohn WW, McNagny KM, Finlay BB. 2012.
Early life antibiotic-driven changes in microbiota enhance suscepti-
bility to allergic asthma. EMBO Rep 13:440–447. https://doi.org/10
.1038/embor.2012.32.
318. Chu S, Yu H, Chen Y, Chen Q, Wang B, Zhang J. 2015. Periconceptional
and gestational exposure to antibiotics and childhood asthma. PLoS
One 10:e0140443. https://doi.org/10.1371/journal.pone.0140443.
319. Lapin B, Piorkowski J, Ownby D, Freels S, Chavez N, Hernandez E,
Wagner-Cassanova C, Pelzel D, Vergara C, Persky V. 2015. Relationship
between prenatal antibiotic use and asthma in at-risk children. Ann
Allergy Asthma Immunol 114:203–207. https://doi.org/10.1016/j.anai
.2014.11.014.
320. Ong MS, Umetsu DT, Mandl KD. 2014. Consequences of antibiotics and
infections in infancy: bugs, drugs, and wheezing. Ann Allergy Asthma
Immunol 112:441–445 e1. https://doi.org/10.1016/j.anai.2014.01.022.
321. Arrieta MC, Stiemsma LT, Dimitriu PA, Thorson L, Russell S, Yurist-
Doutsch S, Kuzeljevic B, Gold MJ, Britton HM, Lefebvre DL, Subbarao P,
Mandhane P, Becker A, McNagny KM, Sears MR, Kollmann T, Investiga-
tors CS, Mohn WW, Turvey SE, Finlay BB. 2015. Early infancy microbial
and metabolic alterations affect risk of childhood asthma. Sci Transl
Med 7: 307ra152. https://doi.org/10.1126/scitranslmed.aab2271.
322. Abrahamsson TR, Jakobsson HE, Andersson AF, Bjorksten B, Engstrand
L, Jenmalm MC. 2014. Low gut microbiota diversity in early infancy
precedes asthma at school age. Clin Exp Allergy 44:842–850. https://
doi.org/10.1111/cea.12253.
323. Stiemsma LT, Arrieta MC, Dimitriu PA, Cheng J, Thorson L, Lefebvre DL,
Azad MB, Subbarao P, Mandhane P, Becker A, Sears MR, Kollmann TR,
Canadian Healthy Infant Longitudinal Development Study Investiga-
tors, Mohn WW, Finlay BB, Turvey SE. 2016. Shifts in Lachnospira and
Clostridium sp. in the 3-month stool microbiome are associated with
preschool age asthma. Clin Sci (Lond) 130:2199–2207. https://doi.org/
10.1042/CS20160349.
324. van Nimwegen FA, Penders J, Stobberingh EE, Postma DS, Koppelman
GH, Kerkhof M, Reijmerink NE, Dompeling E, van den Brandt PA,
Ferreira I, Mommers M, Thijs C. 2011. Mode and place of delivery,
gastrointestinal microbiota, and their inﬂuence on asthma and atopy. J
Allergy Clin Immunol 128:948–955.e1–3. https://doi.org/10.1016/j.jaci
.2011.07.027.
325. Dzidic M, Abrahamsson TR, Artacho A, Bjorksten B, Collado MC, Mira A,
Jenmalm MC. 2017. Aberrant IgA responses to the gut microbiota during
infancy precede asthma and allergy development. J Allergy Clin Immunol
139:1017–1025.e14. https://doi.org/10.1016/j.jaci.2016.06.047.
326. Reinhardt C, Reigstad CS, Backhed F. 2009. Intestinal microbiota during
infancy and its implications for obesity. J Pediatr Gastroenterol Nutr
48:249–256. https://doi.org/10.1097/MPG.0b013e318183187c.
327. Koleva PT, Bridgman SL, Kozyrskyj AL. 2015. The infant gut microbiome:
evidence for obesity risk and dietary intervention. Nutrients
7:2237–2260. https://doi.org/10.3390/nu7042237.
328. Scheepers LE, Penders J, Mbakwa CA, Thijs C, Mommers M, Arts IC.
2015. The intestinal microbiota composition and weight development
in children: the KOALA Birth Cohort Study. Int J Obes (Lond) 39:16–25.
https://doi.org/10.1038/ijo.2014.178.
329. Kerr CA, Grice DM, Tran CD, Bauer DC, Li D, Hendry P, Hannan GN. 2015.
Early life events inﬂuence whole-of-life metabolic health via gut micro-
ﬂora and gut permeability. Crit Rev Microbiol 41:326–340. https://doi
.org/10.3109/1040841X.2013.837863.
330. Blustein J, Attina T, Liu M, Ryan AM, Cox LM, Blaser MJ, Trasande L.
2013. Association of caesarean delivery with child adiposity from age 6
weeks to 15 years. Int J Obes (Lond) 37:900–906. https://doi.org/10
.1038/ijo.2013.49.
331. Gohir W, Ratcliffe EM, Sloboda DM. 2015. Of the bugs that shape us:
maternal obesity, the gut microbiome, and long-term disease risk.
Pediatr Res 77:196–204. https://doi.org/10.1038/pr.2014.169.
332. Chang L, Neu J. 2015. Early factors leading to later obesity: interactions
of the microbiome, epigenome, and nutrition. Curr Probl Pediatr Ado-
lesc Health Care 45:134–142. https://doi.org/10.1016/j.cppeds.2015.03
.003.
333. Manco M. 2012. Gut microbiota and developmental programming of
the brain: from evidence in behavioral endophenotypes to novel per-
spective in obesity. Front Cell Infect Microbiol 2:109. https://doi.org/10
.3389/fcimb.2012.00109.
334. Mahana D, Trent CM, Kurtz ZD, Bokulich NA, Battaglia T, Chung J, Muller
CL, Li H, Bonneau RA, Blaser MJ. 2016. Antibiotic perturbation of the
murine gut microbiome enhances the adiposity, insulin resistance, and
liver disease associated with high-fat diet. Genome Med 8:48. https://
doi.org/10.1186/s13073-016-0297-9.
335. Cox LM, Yamanishi S, Sohn J, Alekseyenko AV, Leung JM, Cho I, Kim SG,
Li H, Gao Z, Mahana D, Zarate Rodriguez JG, Rogers AB, Robine N, Loke
P, Blaser MJ. 2014. Altering the intestinal microbiota during a critical
developmental window has lasting metabolic consequences. Cell 158:
705–721. https://doi.org/10.1016/j.cell.2014.05.052.
336. Nobel YR, Cox LM, Kirigin FF, Bokulich NA, Yamanishi S, Teitler I, Chung
J, Sohn J, Barber CM, Goldfarb DS, Raju K, Abubucker S, Zhou Y, Ruiz VE,
Li H, Mitreva M, Alekseyenko AV, Weinstock GM, Sodergren E, Blaser MJ.
2015. Metabolic and metagenomic outcomes from early-life pulsed
antibiotic treatment. Nat Commun 6:7486. https://doi.org/10.1038/
ncomms8486.
337. Li DK, Chen H, Ferber J, Odouli R. 2017. Infection and antibiotic use in
infancy and risk of childhood obesity: a longitudinal birth cohort study.
Lancet Diabetes Endocrinol 5:18–25. https://doi.org/10.1016/S2213
-8587(16)30281-9.
338. Jess T. 2014. Microbiota, antibiotics, and obesity. N Engl J Med 371:
2526–2528. https://doi.org/10.1056/NEJMcibr1409799.
339. Cox LM, Blaser MJ. 2015. Antibiotics in early life and obesity. Nat Rev
Endocrinol 11:182–190. https://doi.org/10.1038/nrendo.2014.210.
340. Turta O, Rautava S. 2016. Antibiotics, obesity and the link to microbes—
what are we doing to our children? BMC Med 14:57. https://doi.org/10
.1186/s12916-016-0605-7.
The Infant Gut Microbiota Microbiology and Molecular Biology Reviews
December 2017 Volume 81 Issue 4 e00036-17 mmbr.asm.org 61
 o
n
 August 20, 2018 by guest
http://m
m
br.asm
.org/
D
ow
nloaded from
 
341. Gulden E, Wong FS, Wen L. 2015. The gut microbiota and type 1 diabetes.
Clin Immunol 159:143–153. https://doi.org/10.1016/j.clim.2015.05.013.
342. de Goffau MC, Fuentes S, van den Bogert B, Honkanen H, de Vos WM,
Welling GW, Hyoty H, Harmsen HJ. 2014. Aberrant gut microbiota
composition at the onset of type 1 diabetes in young children. Diabe-
tologia 57:1569–1577. https://doi.org/10.1007/s00125-014-3274-0.
343. Livanos AE, Greiner TU, Vangay P, Pathmasiri W, Stewart D, McRitchie S,
Li H, Chung J, Sohn J, Kim S, Gao Z, Barber C, Kim J, Ng S, Rogers AB,
Sumner S, Zhang XS, Cadwell K, Knights D, Alekseyenko A, Backhed F,
Blaser MJ. 2016. Antibiotic-mediated gut microbiome perturbation
accelerates development of type 1 diabetes in mice. Nat Microbiol
1:16140. https://doi.org/10.1038/nmicrobiol.2016.140.
344. Paun A, Danska JS. 2016. Modulation of type 1 and type 2 diabetes risk
by the intestinal microbiome. Pediatr Diabetes 17:469–477. https://doi
.org/10.1111/pedi.12424.
345. Kostic AD, Gevers D, Siljander H, Vatanen T, Hyotylainen T, Hamalainen
AM, Peet A, Tillmann V, Poho P, Mattila I, Lahdesmaki H, Franzosa EA,
Vaarala O, de Goffau M, Harmsen H, Ilonen J, Virtanen SM, Clish CB,
Oresic M, Huttenhower C, Knip M, DABIMMUNE Study Group, Xavier RJ.
2015. The dynamics of the human infant gut microbiome in develop-
ment and in progression toward type 1 diabetes. Cell Host Microbe
17:260–273. https://doi.org/10.1016/j.chom.2015.01.001.
346. Schirbel A, Fiocchi C. 2011. Targeting the innate immune system in
pediatric inﬂammatory bowel disease. Expert Rev Gastroenterol Hepa-
tol 5:33–41. https://doi.org/10.1586/egh.10.76.
347. Wang F, Kaplan JL, Gold BD, Bhasin MK, Ward NL, Kellermayer R,
Kirschner BS, Heyman MB, Dowd SE, Cox SB, Dogan H, Steven B, Ferry
GD, Cohen SA, Baldassano RN, Moran CJ, Garnett EA, Drake L, Otu HH,
Mirny LA, Libermann TA, Winter HS, Korolev KS. 2016. Detecting mi-
crobial dysbiosis associated with pediatric Crohn disease despite the
high variability of the gut microbiota. Cell Rep 14:945–955. https://doi
.org/10.1016/j.celrep.2015.12.088.
348. O’Mahony SM, Marchesi JR, Scully P, Codling C, Ceolho AM, Quigley EM,
Cryan JF, Dinan TG. 2009. Early life stress alters behavior, immunity, and
microbiota in rats: implications for irritable bowel syndrome and psy-
chiatric illnesses. Biol Psychiatry 65:263–267. https://doi.org/10.1016/j
.biopsych.2008.06.026.
349. O’Mahony SM, Felice VD, Nally K, Savignac HM, Claesson MJ, Scully P,
Woznicki J, Hyland NP, Shanahan F, Quigley EM, Marchesi JR, O’Toole
PW, Dinan TG, Cryan JF. 2014. Disturbance of the gut microbiota in
early-life selectively affects visceral pain in adulthood without impact-
ing cognitive or anxiety-related behaviors in male rats. Neuroscience
277:885–901. https://doi.org/10.1016/j.neuroscience.2014.07.054.
350. Claesson MJ, Cusack S, O’Sullivan O, Greene-Diniz R, de Weerd H,
Flannery E, Marchesi JR, Falush D, Dinan T, Fitzgerald G, Stanton C, van
Sinderen D, O’Connor M, Harnedy N, O’Connor K, Henry C, O’Mahony D,
Fitzgerald AP, Shanahan F, Twomey C, Hill C, Ross RP, O’Toole PW. 2011.
Composition, variability, and temporal stability of the intestinal micro-
biota of the elderly. Proc Natl Acad Sci U S A 108(Suppl 1):
S4586–S4591. https://doi.org/10.1073/pnas.1000097107.
351. Roger LC, Costabile A, Holland DT, Hoyles L, McCartney AL. 2010.
Examination of faecal Biﬁdobacterium populations in breast- and
formula-fed infants during the ﬁrst 18 months of life. Microbiology
156:3329–3341. https://doi.org/10.1099/mic.0.043224-0.
352. Turroni F, Seraﬁni F, Mangifesta M, Arioli S, Mora D, van Sinderen D,
Ventura M. 2014. Expression of sortase-dependent pili of Biﬁdobac-
terium biﬁdum PRL2010 in response to environmental gut condi-
tions. FEMS Microbiol Lett 357:23–33. https://doi.org/10.1111/1574
-6968.12509.
353. Ventura M, Turroni F, Motherway MO, MacSharry J, van Sinderen D.
2012. Host-microbe interactions that facilitate gut colonization by com-
mensal biﬁdobacteria. Trends Microbiol 20:467–476. https://doi.org/10
.1016/j.tim.2012.07.002.
354. Milani C, Mancabelli L, Lugli GA, Duranti S, Turroni F, Ferrario C,
Mangifesta M, Viappiani A, Ferretti P, Gorfer V, Tett A, Segata N, van
Sinderen D, Ventura M. 2015. Exploring vertical transmission of biﬁdo-
bacteria from mother to child. Appl Environ Microbiol 81:7078–7087.
https://doi.org/10.1128/AEM.02037-15.
355. Ventura M, Turroni F, Zomer A, Foroni E, Giubellini V, Bottacini F,
Canchaya C, Claesson MJ, He F, Mantzourani M, Mulas L, Ferrarini A,
Gao B, Delledonne M, Henrissat B, Coutinho P, Oggioni M, Gupta RS,
Zhang Z, Beighton D, Fitzgerald GF, O’Toole PW, van Sinderen D. 2009.
The Biﬁdobacterium dentium Bd1 genome sequence reﬂects its ge-
netic adaptation to the human oral cavity. PLoS Genet 5:e1000785.
https://doi.org/10.1371/journal.pgen.1000785.
356. Lee JH, O’Sullivan DJ. 2010. Genomic insights into biﬁdobacteria. Microbiol
Mol Biol Rev 74:378–416. https://doi.org/10.1128/MMBR.00004-10.
357. Ventura M, Canchaya C, Tauch A, Chandra G, Fitzgerald GF, Chater KF,
van Sinderen D. 2007. Genomics of Actinobacteria: tracing the evolu-
tionary history of an ancient phylum. Microbiol Mol Biol Rev 71:
495–548. https://doi.org/10.1128/MMBR.00005-07.
358. Lugli GA, Milani C, Turroni F, Duranti S, Ferrario C, Viappiani A, Man-
cabelli L, Mangifesta M, Taminiau B, Delcenserie V, van Sinderen D,
Ventura M. 2014. Investigation of the evolutionary development of the
genus Biﬁdobacterium by comparative genomics. Appl Environ Micro-
biol 80:6383–6394. https://doi.org/10.1128/AEM.02004-14.
359. Duranti S, Mangifesta M, Lugli GA, Turroni F, Anzalone R, Milani C,
Mancabelli L, Ossiprandi MC, Ventura M. 2017. Biﬁdobacterium vansin-
derenii sp. nov., isolated from faeces of emperor tamarin (Saguinus
imperator). Int J Syst Evol Microbiol https://doi.org/10.1099/ijsem.0
.002243.
360. Lugli GA, Milani C, Turroni F, Duranti S, Mancabelli L, Mangifesta M,
Ferrario C, Modesto M, Mattarelli P, Jiri K, van Sinderen D, Ventura M.
2017. Comparative genomic and phylogenomic analyses of the Biﬁdo-
bacteriaceae family. BMC Genomics 18:568. https://doi.org/10.1186/
s12864-017-3955-4.
361. Lamendella R, Santo Domingo JW, Kelty C, Oerther DB. 2008. Biﬁdo-
bacteria in feces and environmental waters. Appl Environ Microbiol
74:575–584. https://doi.org/10.1128/AEM.01221-07.
362. Duranti S, Turroni F, Lugli GA, Milani C, Viappiani A, Mangifesta M,
Gioiosa L, Palanza P, van Sinderen D, Ventura M. 2014. Genomic
characterization and transcriptional studies of the starch-utilizing strain
Biﬁdobacterium adolescentis 22L. Appl Environ Microbiol 80:
6080–6090. https://doi.org/10.1128/AEM.01993-14.
363. Duranti S, Milani C, Lugli GA, Mancabelli L, Turroni F, Ferrario C,
Mangifesta M, Viappiani A, Sanchez B, Margolles A, van Sinderen D,
Ventura M. 2016. Evaluation of genetic diversity among strains of the
human gut commensal Biﬁdobacterium adolescentis. Sci Rep 6:23971.
https://doi.org/10.1038/srep23971.
364. Milani C, Andrea Lugli G, Duranti S, Turroni F, Mancabelli L, Ferrario C,
Mangifesta M, Hevia A, Viappiani A, Scholz M, Arioli S, Sanchez B, Lane
J, Ward DV, Hickey R, Mora D, Segata N, Margolles A, van Sinderen D,
Ventura M. 2015. Biﬁdobacteria exhibit social behavior through carbo-
hydrate resource sharing in the gut. Sci Rep 5:15782. https://doi.org/
10.1038/srep15782.
365. Marcobal A, Barboza M, Sonnenburg ED, Pudlo N, Martens EC, Desai P,
Lebrilla CB, Weimer BC, Mills DA, German JB, Sonnenburg JL. 2011.
Bacteroides in the infant gut consume milk oligosaccharides via
mucus-utilization pathways. Cell Host Microbe 10:507–514. https://doi
.org/10.1016/j.chom.2011.10.007.
366. Bienenstock J, Buck RH, Linke H, Forsythe P, Stanisz AM, Kunze WA.
2013. Fucosylated but not sialylated milk oligosaccharides diminish
colon motor contractions. PLoS One 8:e76236. https://doi.org/10.1371/
journal.pone.0076236.
367. Lewis ZT, Totten SM, Smilowitz JT, Popovic M, Parker E, Lemay DG, Van
Tassell ML, Miller MJ, Jin YS, German JB, Lebrilla CB, Mills DA. 2015.
Maternal fucosyltransferase 2 status affects the gut biﬁdobacterial
communities of breastfed infants. Microbiome 3:13. https://doi.org/10
.1186/s40168-015-0071-z.
368. Wada J, Ando T, Kiyohara M, Ashida H, Kitaoka M, Yamaguchi M,
Kumagai H, Katayama T, Yamamoto K. 2008. Biﬁdobacterium biﬁdum
lacto-N-biosidase, a critical enzyme for the degradation of human milk
oligosaccharides with a type 1 structure. Appl Environ Microbiol 74:
3996–4004. https://doi.org/10.1128/AEM.00149-08.
369. Tailford LE, Crost EH, Kavanaugh D, Juge N. 2015. Mucin glycan forag-
ing in the human gut microbiome. Front Genet 6:81. https://doi.org/
10.3389/fgene.2015.00081.
370. Fujita K, Oura F, Nagamine N, Katayama T, Hiratake J, Sakata K, Kumagai
H, Yamamoto K. 2005. Identiﬁcation and molecular cloning of a novel
glycoside hydrolase family of core 1 type O-glycan-speciﬁc endo-alpha-
N-acetylgalactosaminidase from Biﬁdobacterium longum. J Biol Chem
280:37415–37422. https://doi.org/10.1074/jbc.M506874200.
371. Ashida H, Miyake A, Kiyohara M, Wada J, Yoshida E, Kumagai H,
Katayama T, Yamamoto K. 2009. Two distinct alpha-L-fucosidases from
Biﬁdobacterium biﬁdum are essential for the utilization of fucosylated
milk oligosaccharides and glycoconjugates. Glycobiology 19:
1010–1017. https://doi.org/10.1093/glycob/cwp082.
Milani et al. Microbiology and Molecular Biology Reviews
December 2017 Volume 81 Issue 4 e00036-17 mmbr.asm.org 62
 o
n
 August 20, 2018 by guest
http://m
m
br.asm
.org/
D
ow
nloaded from
 
372. Nishimoto M, Kitaoka M. 2007. Identiﬁcation of N-acetylhexosamine
1-kinase in the complete lacto-N-biose I/galacto-N-biose metabolic
pathway in Biﬁdobacterium longum. Appl Environ Microbiol 73:
6444–6449. https://doi.org/10.1128/AEM.01425-07.
373. Ruas-Madiedo P, Gueimonde M, Fernandez-Garcia M, de los Reyes-
Gavilan CG, Margolles A. 2008. Mucin degradation by Biﬁdobacterium
strains isolated from the human intestinal microbiota. Appl Environ
Microbiol 74:1936–1940. https://doi.org/10.1128/AEM.02509-07.
374. Ruiz L, Gueimonde M, Coute Y, Salminen S, Sanchez JC, de los Reyes-
Gavilan CG, Margolles A. 2011. Evaluation of the ability of Biﬁdobacte-
rium longum to metabolize human intestinal mucus. FEMS Microbiol
Lett 314:125–130. https://doi.org/10.1111/j.1574-6968.2010.02159.x.
375. Turroni F, Bottacini F, Foroni E, Mulder I, Kim JH, Zomer A, Sanchez B,
Bidossi A, Ferrarini A, Giubellini V, Delledonne M, Henrissat B, Coutinho
P, Oggioni M, Fitzgerald GF, Mills D, Margolles A, Kelly D, van Sinderen
D, Ventura M. 2010. Genome analysis of Biﬁdobacterium biﬁdum
PRL2010 reveals metabolic pathways for host-derived glycan foraging.
Proc Natl Acad Sci U S A 107:19514–19519. https://doi.org/10.1073/
pnas.1011100107.
376. Turroni F, Milani C, van Sinderen D, Ventura M. 2011. Genetic strategies
for mucin metabolism in Biﬁdobacterium biﬁdum PRL2010: an example
of possible human-microbe co-evolution. Gut Microbes 2:183–189.
https://doi.org/10.4161/gmic.2.3.16105.
377. Duranti S, Milani C, Lugli GA, Turroni F, Mancabelli L, Sanchez B, Ferrario
C, Viappiani A, Mangifesta M, Mancino W, Gueimonde M, Margolles A,
van Sinderen D, Ventura M. 2015. Insights from genomes of represen-
tatives of the human gut commensal Biﬁdobacterium biﬁdum. Environ
Microbiol 17:2515–2531. https://doi.org/10.1111/1462-2920.12743.
378. O’Connell Motherway M, Fitzgerald GF, van Sinderen D. 2011. Metab-
olism of a plant derived galactose-containing polysaccharide by Biﬁ-
dobacterium breve UCC2003. Microb Biotechnol 4:403–416. https://doi
.org/10.1111/j.1751-7915.2010.00218.x.
379. Pokusaeva K, Fitzgerald GF, van Sinderen D. 2011. Carbohydrate me-
tabolism in Biﬁdobacteria. Genes Nutr 6:285–306. https://doi.org/10
.1007/s12263-010-0206-6.
380. Pokusaeva K, Neves AR, Zomer A, O’Connell-Motherway M, MacSharry
J, Curley P, Fitzgerald GF, van Sinderen D. 2010. Ribose utilization by
the human commensal Biﬁdobacterium breve UCC2003. Microb Bio-
technol 3:311–323. https://doi.org/10.1111/j.1751-7915.2009.00152.x.
381. Pokusaeva K, O’Connell-Motherway M, Zomer A, Fitzgerald GF, van
Sinderen D. 2009. Characterization of two novel alpha-glucosidases
from Biﬁdobacterium breve UCC2003. Appl Environ Microbiol 75:
1135–1143. https://doi.org/10.1128/AEM.02391-08.
382. Ryan SM, Fitzgerald GF, van Sinderen D. 2006. Screening for and
identiﬁcation of starch-, amylopectin-, and pullulan-degrading activi-
ties in biﬁdobacterial strains. Appl Environ Microbiol 72:5289–5296.
https://doi.org/10.1128/AEM.00257-06.
383. Turroni F, Ozcan E, Milani C, Mancabelli L, Viappiani A, van Sinderen D,
Sela DA, Ventura M. 2015. Glycan cross-feeding activities between
biﬁdobacteria under in vitro conditions. Front Microbiol 6:1030. https://
doi.org/10.3389/fmicb.2015.01030.
384. Egan M, O’Connell Motherway M, Ventura M, van Sinderen D. 2014.
Metabolism of sialic acid by Biﬁdobacterium breve UCC2003. Appl Environ
Microbiol 80:4414–4426. https://doi.org/10.1128/AEM.01114-14.
385. Egan M, Motherway MO, Kilcoyne M, Kane M, Joshi L, Ventura M, van
Sinderen D. 2014. Cross-feeding by Biﬁdobacterium breve UCC2003
during co-cultivation with Biﬁdobacterium biﬁdum PRL2010 in a
mucin-based medium. BMC Microbiol 14:282. https://doi.org/10.1186/
s12866-014-0282-7.
386. Egan M, Jiang H, O’Connell Motherway M, Oscarson S, van Sinderen D.
2016. Glycosulfatase-encoding gene cluster in Biﬁdobacterium breve
UCC2003. Appl Environ Microbiol 82:6611–6623. https://doi.org/10
.1128/AEM.02022-16.
387. Pande S, Shitut S, Freund L, Westermann M, Bertels F, Colesie C,
Bischofs IB, Kost C. 2015. Metabolic cross-feeding via intercellular nano-
tubes among bacteria. Nat Commun 6:6238. https://doi.org/10.1038/
ncomms7238.
388. Phelan VV, Liu WT, Pogliano K, Dorrestein PC. 2011. Microbial metabolic
exchange–the chemotype-to-phenotype link. Nat Chem Biol 8:26–35.
https://doi.org/10.1038/nchembio.739.
389. Morris BE, Henneberger R, Huber H, Moissl-Eichinger C. 2013. Microbial
syntrophy: interaction for the common good. FEMS Microbiol Rev
37:384–406. https://doi.org/10.1111/1574-6976.12019.
390. De Vuyst L, Leroy F. 2011. Cross-feeding between biﬁdobacteria and
butyrate-producing colon bacteria explains bifdobacterial competitive-
ness, butyrate production, and gas production. Int J Food Microbiol
149:73–80. https://doi.org/10.1016/j.ijfoodmicro.2011.03.003.
391. Barcenilla A, Pryde SE, Martin JC, Duncan SH, Stewart CS, Henderson C,
Flint HJ. 2000. Phylogenetic relationships of butyrate-producing bac-
teria from the human gut. Appl Environ Microbiol 66:1654–1661.
https://doi.org/10.1128/AEM.66.4.1654-1661.2000.
392. Morrison DJ, Mackay WG, Edwards CA, Preston T, Dodson B, Weaver LT.
2006. Butyrate production from oligofructose fermentation by the
human faecal ﬂora: what is the contribution of extracellular acetate and
lactate? Br J Nutr 96:570–577.
393. Duncan SH, Flint HJ. 2008. Proposal of a neotype strain (A1-86) for
Eubacterium rectale. Request for an opinion. Int J Syst Evol Microbiol
58:1735–1736. https://doi.org/10.1099/ijs.0.2008/004580-0.
394. Falony G, Verschaeren A, De Bruycker F, De Preter V, Verbeke K, Leroy
F, De Vuyst L. 2009. In vitro kinetics of prebiotic inulin-type fructan
fermentation by butyrate-producing colon bacteria: implementation of
online gas chromatography for quantitative analysis of carbon dioxide
and hydrogen gas production. Appl Environ Microbiol 75:5884–5892.
https://doi.org/10.1128/AEM.00876-09.
395. Turroni F, Milani C, Duranti S, Mancabelli L, Mangifesta M, Viappiani A,
Lugli GA, Ferrario C, Gioiosa L, Ferrarini A, Li J, Palanza P, Delledonne M,
van Sinderen D, Ventura M. 2016. Deciphering biﬁdobacterial-mediated
metabolic interactions and their impact on gut microbiota by a multi-
omics approach. ISME J https://doi.org/10.1038/ismej.2015.236.
396. Hidalgo-Cantabrana C, Sanchez B, Milani C, Ventura M, Margolles A,
Ruas-Madiedo P. 2014. Genomic overview and biological functions of
exopolysaccharide biosynthesis in Biﬁdobacterium spp. Appl Environ
Microbiol 80:9–18. https://doi.org/10.1128/AEM.02977-13.
397. Ferrario C, Milani C, Mancabelli L, Lugli GA, Duranti S, Mangifesta M,
Viappiani A, Turroni F, Margolles A, Ruas-Madiedo P, van Sinderen D,
Ventura M. 2016. Modulation of the eps-ome transcription of biﬁdo-
bacteria through simulation of human intestinal environment. FEMS
Microbiol Ecol 92:ﬁw056. https://doi.org/10.1093/femsec/ﬁw056.
398. Fanning S, Hall LJ, Cronin M, Zomer A, MacSharry J, Goulding D,
Motherway MO, Shanahan F, Nally K, Dougan G, van Sinderen D. 2012.
Biﬁdobacterial surface-exopolysaccharide facilitates commensal-host
interaction through immune modulation and pathogen protection.
Proc Natl Acad Sci U S A 109:2108–2113. https://doi.org/10.1073/pnas
.1115621109.
399. O’Connell Motherway M, Zomer A, Leahy SC, Reunanen J, Bottacini F,
Claesson MJ, O’Brien F, Flynn K, Casey PG, Munoz JA, Kearney B,
Houston AM, O’Mahony C, Higgins DG, Shanahan F, Palva A, de Vos
WM, Fitzgerald GF, Ventura M, O’Toole PW, van Sinderen D. 2011.
Functional genome analysis of Biﬁdobacterium breve UCC2003 reveals
type IVb tight adherence (Tad) pili as an essential and conserved
host-colonization factor. Proc Natl Acad Sci U S A 108:11217–11222.
https://doi.org/10.1073/pnas.1105380108.
400. Foroni E, Seraﬁni F, Amidani D, Turroni F, He F, Bottacini F, O’Connell
Motherway M, Viappiani A, Zhang Z, Rivetti C, van Sinderen D, Ventura
M. 2011. Genetic analysis and morphological identiﬁcation of pilus-like
structures in members of the genus Biﬁdobacterium. Microb Cell Fact
10(Suppl 1):S16. https://doi.org/10.1186/1475-2859-10-S1-S16.
401. Turroni F, Seraﬁni F, Foroni E, Duranti S, O’Connell Motherway M,
Taverniti V, Mangifesta M, Milani C, Viappiani A, Roversi T, Sanchez B,
Santoni A, Gioiosa L, Ferrarini A, Delledonne M, Margolles A, Piazza L,
Palanza P, Bolchi A, Guglielmetti S, van Sinderen D, Ventura M. 2013.
Role of sortase-dependent pili of Biﬁdobacterium biﬁdum PRL2010 in
modulating bacterium-host interactions. Proc Natl Acad Sci U S A
110:11151–11156. https://doi.org/10.1073/pnas.1303897110.
402. Freitas F, Alves VD, Reis MA. 2011. Advances in bacterial exopolysaccha-
rides: from production to biotechnological applications. Trends Biotechnol
29:388–398. https://doi.org/10.1016/j.tibtech.2011.03.008.
403. Round JL, Mazmanian SK. 2009. The gut microbiota shapes intestinal
immune responses during health and disease. Nat Rev Immunol
9:313–323. https://doi.org/10.1038/nri2515.
404. Round JL, Lee SM, Li J, Tran G, Jabri B, Chatila TA, Mazmanian SK. 2011.
The Toll-like receptor 2 pathway establishes colonization by a com-
mensal of the human microbiota. Science 332:974–977. https://doi.org/
10.1126/science.1206095.
405. Laws A, Gu Y, Marshall V. 2001. Biosynthesis, characterisation, and design
of bacterial exopolysaccharides from lactic acid bacteria. Biotechnol Adv
19:597–625. https://doi.org/10.1016/S0734-9750(01)00084-2.
406. Lopez P, Monteserin DC, Gueimonde M, de los Reyes-Gavilan CG,
The Infant Gut Microbiota Microbiology and Molecular Biology Reviews
December 2017 Volume 81 Issue 4 e00036-17 mmbr.asm.org 63
 o
n
 August 20, 2018 by guest
http://m
m
br.asm
.org/
D
ow
nloaded from
 
Margolles A, Suarez A, Ruas-Madiedo P. 2012. Exopolysaccharide-
producing Biﬁdobacterium strains elicit different in vitro responses
upon interaction with human cells. Food Res Int 46:99–107. https://doi
.org/10.1016/j.foodres.2011.11.020.
407. Hughes KR, Harnisch LC, Alcon-Giner C, Mitra S, Wright CJ, Ketskemety
J, van Sinderen D, Watson AJ, Hall LJ. 2017. Biﬁdobacterium breve
reduces apoptotic epithelial cell shedding in an exopolysaccharide and
MyD88-dependent manner. Open Biol 7:160155. https://doi.org/10
.1098/rsob.160155.
408. Schiavi E, Gleinser M, Molloy E, Groeger D, Frei R, Ferstl R, Rodriguez-
Perez N, Ziegler M, Grant R, Moriarty TF, Plattner S, Healy S, O’Connell
Motherway M, Akdis CA, Roper J, Altmann F, van Sinderen D, O’Mahony
L. 2016. The surface-associated exopolysaccharide of Biﬁdobacterium
longum 35624 plays an essential role in dampening host proinﬂam-
matory responses and repressing local TH17 responses. Appl Environ
Microbiol 82:7185–7196. https://doi.org/10.1128/AEM.02238-16.
409. Altmann F, Kosma P, O’Callaghan A, Leahy S, Bottacini F, Molloy E,
Plattner S, Schiavi E, Gleinser M, Groeger D, Grant R, Rodriguez Perez N,
Healy S, Svehla E, Windwarder M, Hoﬁnger A, O’Connell Motherway M,
Akdis CA, Xu J, Roper J, van Sinderen D, O’Mahony L. 2016. Genome
analysis and characterisation of the exopolysaccharide produced by
Biﬁdobacterium longum subsp. longum 35624. PLoS One 11:e0162983.
https://doi.org/10.1371/journal.pone.0162983.
410. Bach JF. 2002. The effect of infections on susceptibility to autoimmune
and allergic diseases. N Engl J Med 347:911–920. https://doi.org/10
.1056/NEJMra020100.
411. Ivanov D, Emonet C, Foata F, Affolter M, Delley M, Fisseha M, Blum-
Sperisen S, Kochhar S, Arigoni F. 2006. A serpin from the gut bacte-
rium Biﬁdobacterium longum inhibits eukaryotic elastase-like serine
proteases. J Biol Chem 281:17246–17252. https://doi.org/10.1074/
jbc.M601678200.
412. Turroni F, Foroni E, O’Connell Motherway M, Bottacini F, Giubellini V,
Zomer A, Ferrarini A, Delledonne M, Zhang Z, van Sinderen D, Ventura
M. 2010. Characterization of the serpin-encoding gene of Biﬁdobacte-
rium breve 210B. Appl Environ Microbiol 76:3206–3219. https://doi
.org/10.1128/AEM.02938-09.
413. Alvarez-Martin P, Fernandez M, O’Connell-Motherway M, O’Connell KJ,
Sauvageot N, Fitzgerald GF, MacSharry J, Zomer A, van Sinderen D.
2012. A conserved two-component signal transduction system controls
the response to phosphate starvation in Biﬁdobacterium breve
UCC2003. Appl Environ Microbiol 78:5258–5269. https://doi.org/10
.1128/AEM.00804-12.
414. Bottacini F, Ventura M, van Sinderen D, O’Connell Motherway M. 2014.
Diversity, ecology and intestinal function of biﬁdobacteria. Microb Cell
Fact 13(Suppl 1):S4. https://doi.org/10.1186/1475-2859-13-S1-S4.
415. Christiaen SE, O’Connell Motherway M, Bottacini F, Lanigan N, Casey
PG, Huys G, Nelis HJ, van Sinderen D, Coenye T. 2014. Autoinducer-2
plays a crucial role in gut colonization and probiotic functionality of
Biﬁdobacterium breve UCC2003. PLoS One 9:e98111. https://doi.org/
10.1371/journal.pone.0098111.
416. Xavier KB, Bassler BL. 2003. LuxS quorum sensing: more than just a
numbers game. Curr Opin Microbiol 6:191–197. https://doi.org/10
.1016/S1369-5274(03)00028-6.
417. Milani C, Lugli GA, Duranti S, Turroni F, Bottacini F, Mangifesta M,
Sanchez B, Viappiani A, Mancabelli L, Taminiau B, Delcenserie V, Barr-
angou R, Margolles A, van Sinderen D, Ventura M. 2014. Genomic
encyclopedia of type strains of the genus Biﬁdobacterium. Appl Envi-
ron Microbiol 80:6290–6302. https://doi.org/10.1128/AEM.02308-14.
418. Rainey FA. 2015. Clostridia class. nov. In Bergey’s manual of system-
atics of archaea and bacteria. https://doi.org/10.1002/9781118960608
.cbm00034.
419. Lawson PA, Citron DM, Tyrrell KL, Finegold SM. 2016. Reclassiﬁcation of
Clostridium difﬁcile as Clostridioides difﬁcile (Hall and O’Toole 1935)
Prevot 1938. Anaerobe 40:95–99. https://doi.org/10.1016/j.anaerobe
.2016.06.008.
420. Lakshminarayanan B, Harris HM, Coakley M, O’Sullivan O, Stanton C,
Pruteanu M, Shanahan F, O’Toole PW, Ross RP, ELDERMET Consortium.
2013. Prevalence and characterization of Clostridium perfringens from
the faecal microbiota of elderly Irish subjects. J Med Microbiol 62:
457–466. https://doi.org/10.1099/jmm.0.052258-0.
421. Mevissen-Verhage EA, Marcelis JH, de Vos MN, Harmsen-van Ameron-
gen WC, Verhoef J. 1987. Biﬁdobacterium, Bacteroides, and Clostridium
spp. in fecal samples from breast-fed and bottle-fed infants with and
without iron supplement. J Clin Microbiol 25:285–289.
422. Stackebrandt E, Kramer I, Swiderski J, Hippe H. 1999. Phylogenetic basis
for a taxonomic dissection of the genus Clostridium. FEMS Immunol
Med Microbiol 24:253–258. https://doi.org/10.1111/j.1574-695X.1999
.tb01291.x.
423. Atarashi K, Tanoue T, Oshima K, Suda W, Nagano Y, Nishikawa H,
Fukuda S, Saito T, Narushima S, Hase K, Kim S, Fritz JV, Wilmes P, Ueha
S, Matsushima K, Ohno H, Olle B, Sakaguchi S, Taniguchi T, Morita H,
Hattori M, Honda K. 2013. Treg induction by a rationally selected
mixture of Clostridia strains from the human microbiota. Nature 500:
232–236. https://doi.org/10.1038/nature12331.
424. Atarashi K, Tanoue T, Shima T, Imaoka A, Kuwahara T, Momose Y,
Cheng G, Yamasaki S, Saito T, Ohba Y, Taniguchi T, Takeda K, Hori S,
Ivanov II, Umesaki Y, Itoh K, Honda K. 2011. Induction of colonic
regulatory T cells by indigenous Clostridium species. Science 331:
337–341. https://doi.org/10.1126/science.1198469.
425. Sokol H, Pigneur B, Watterlot L, Lakhdari O, Bermudez-Humaran LG,
Gratadoux JJ, Blugeon S, Bridonneau C, Furet JP, Corthier G, Grangette
C, Vasquez N, Pochart P, Trugnan G, Thomas G, Blottiere HM, Dore J,
Marteau P, Seksik P, Langella P. 2008. Faecalibacterium prausnitzii is an
anti-inﬂammatory commensal bacterium identiﬁed by gut microbiota
analysis of Crohn disease patients. Proc Natl Acad Sci U S A 105:
16731–16736. https://doi.org/10.1073/pnas.0804812105.
426. Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, Edberg S, Medzhitov R.
2004. Recognition of commensal microﬂora by toll-like receptors is
required for intestinal homeostasis. Cell 118:229–241. https://doi.org/
10.1016/j.cell.2004.07.002.
427. Hooper LV, Littman DR, Macpherson AJ. 2012. Interactions between the
microbiota and the immune system. Science 336:1268–1273. https://
doi.org/10.1126/science.1223490.
428. Morotomi M, Nagai F, Sakon H, Tanaka R. 2009. Paraprevotella clara
gen. nov., sp. nov. and Paraprevotella xylaniphila sp. nov., members of
the family ‘Prevotellaceae’ isolated from human faeces. Int J Syst Evol
Microbiol 59:1895–1900. https://doi.org/10.1099/ijs.0.008169-0.
429. Sakamoto M, Ohkuma M. 2012. Bacteroides sartorii is an earlier het-
erotypic synonym of Bacteroides chinchillae and has priority. Int J Syst
Evol Microbiol 62:1241–1244. https://doi.org/10.1099/ijs.0.035659-0.
430. Macfarlane GT, Cummings JH, Allison C. 1986. Protein degradation by
human intestinal bacteria. J Gen Microbiol 132:1647–1656.
431. Narushima S, Itoha K, Miyamoto Y, Park SH, Nagata K, Kuruma K, Uchida
K. 2006. Deoxycholic acid formation in gnotobiotic mice associated
with human intestinal bacteria. Lipids 41:835–843. https://doi.org/10
.1007/s11745-006-5038-1.
432. Krinos CM, Coyne MJ, Weinacht KG, Tzianabos AO, Kasper DL, Com-
stock LE. 2001. Extensive surface diversity of a commensal microorgan-
ism by multiple DNA inversions. Nature 414:555–558. https://doi.org/
10.1038/35107092.
433. Mazmanian SK, Liu CH, Tzianabos AO, Kasper DL. 2005. An immuno-
modulatory molecule of symbiotic bacteria directs maturation of the
host immune system. Cell 122:107–118. https://doi.org/10.1016/j.cell
.2005.05.007.
434. Liu CH, Lee SM, Vanlare JM, Kasper DL, Mazmanian SK. 2008. Regulation
of surface architecture by symbiotic bacteria mediates host coloniza-
tion. Proc Natl Acad Sci U S A 105:3951–3956. https://doi.org/10.1073/
pnas.0709266105.
435. Kuwahara T, Yamashita A, Hirakawa H, Nakayama H, Toh H, Okada N,
Kuhara S, Hattori M, Hayashi T, Ohnishi Y. 2004. Genomic analysis of
Bacteroides fragilis reveals extensive DNA inversions regulating cell
surface adaptation. Proc Natl Acad Sci U S A 101:14919–14924. https://
doi.org/10.1073/pnas.0404172101.
436. Cerdeno-Tarraga AM, Patrick S, Crossman LC, Blakely G, Abratt V,
Lennard N, Poxton I, Duerden B, Harris B, Quail MA, Barron A, Clark L,
Corton C, Doggett J, Holden MT, Larke N, Line A, Lord A, Norbertczak
H, Ormond D, Price C, Rabbinowitsch E, Woodward J, Barrell B, Parkhill
J. 2005. Extensive DNA inversions in the B. fragilis genome control
variable gene expression. Science 307:1463–1465. https://doi.org/10
.1126/science.1107008.
437. Vipperla K, O’Keefe SJ. 2012. The microbiota and its metabolites in
colonic mucosal health and cancer risk. Nutr Clin Pract 27:624–635.
https://doi.org/10.1177/0884533612452012.
438. Solis G, de Los Reyes-Gavilan CG, Fernandez N, Margolles A, Guei-
monde M. 2010. Establishment and development of lactic acid bacteria
and biﬁdobacteria microbiota in breast-milk and the infant gut. Anaer-
obe 16:307–310. https://doi.org/10.1016/j.anaerobe.2010.02.004.
439. Kageyama A, Benno Y, Nakase T. 1999. Phylogenetic and phenotypic
Milani et al. Microbiology and Molecular Biology Reviews
December 2017 Volume 81 Issue 4 e00036-17 mmbr.asm.org 64
 o
n
 August 20, 2018 by guest
http://m
m
br.asm
.org/
D
ow
nloaded from
 
evidence for the transfer of Eubacterium aerofaciens to the genus
Collinsella as Collinsella aerofaciens gen. nov., comb. nov. Int J Syst
Bacteriol 49:557–565. https://doi.org/10.1099/00207713-49-2-557.
440. Nagai F, Watanabe Y, Morotomi M. 2010. Slackia piriformis sp. nov. and
Collinsella tanakaei sp. nov., new members of the family Coriobacteri-
aceae, isolated from human faeces. Int J Syst Evol Microbiol 60:
2639–2646. https://doi.org/10.1099/ijs.0.017533-0.
441. Durand GA, Cadoret F, Lagier JC, Fournier PE, Raoult D. 2017. Descrip-
tion of ‘Gorbachella massiliensis’ gen. nov., sp. nov., ‘Fenollaria ti-
monensis’ sp. nov., ‘Intestinimonas timonensis’ sp. nov. and ‘Collinsella
ihuae’ sp. nov. isolated from healthy fresh stools with culturomics. New
Microbes New Infect 16:60–62. https://doi.org/10.1016/j.nmni.2017.01
.005.
442. Padmanabhan R, Dubourg G, Jean-Christophe l, Nguyen TT, Couderc C,
Rossi-Tamisier M, Caputo A, Raoult D, Fournier PE. 2014. Non-
contiguous ﬁnished genome sequence and description of Collinsella
massiliensis sp. nov. Stand Genomic Sci 9:1144–1158. https://doi.org/
10.4056/sigs.5399696.
443. Bidart GN, Rodriguez-Diaz J, Yebra MJ. 2015. The extracellular wall-
bound beta-N-acetylglucosaminidase from Lactobacillus casei is in-
volved in the metabolism of the human milk oligosaccharide lacto-N-
triose. Appl Environ Microbiol 82:570–577. https://doi.org/10.1128/
AEM.02888-15.
444. Derrien M, Collado MC, Ben-Amor K, Salminen S, de Vos WM. 2008. The
mucin degrader Akkermansia muciniphila is an abundant resident of
the human intestinal tract. Appl Environ Microbiol 74:1646–1648.
https://doi.org/10.1128/AEM.01226-07.
445. Derrien M, Vaughan EE, Plugge CM, de Vos WM. 2004. Akkermansia
muciniphila gen. nov., sp. nov., a human intestinal mucin-degrading
bacterium. Int J Syst Evol Microbiol 54:1469–1476. https://doi.org/10
.1099/ijs.0.02873-0.
446. Collado MC, Derrien M, Isolauri E, de Vos WM, Salminen S. 2007.
Intestinal integrity and Akkermansia muciniphila, a mucin-degrading
member of the intestinal microbiota present in infants, adults, and the
elderly. Appl Environ Microbiol 73:7767–7770. https://doi.org/10.1128/
AEM.01477-07.
447. Everard A, Belzer C, Geurts L, Ouwerkerk JP, Druart C, Bindels LB, Guiot
Y, Derrien M, Muccioli GG, Delzenne NM, de Vos WM, Cani PD. 2013.
Cross-talk between Akkermansia muciniphila and intestinal epithelium
controls diet-induced obesity. Proc Natl Acad Sci U S A 110:9066–9071.
https://doi.org/10.1073/pnas.1219451110.
448. Plovier H, Everard A, Druart C, Depommier C, Van Hul M, Geurts L,
Chilloux J, Ottman N, Duparc T, Lichtenstein L, Myridakis A, Delzenne
NM, Klievink J, Bhattacharjee A, van der Ark KC, Aalvink S, Martinez LO,
Dumas ME, Maiter D, Loumaye A, Hermans MP, Thissen JP, Belzer C, de
Vos WM, Cani PD. 2017. A puriﬁed membrane protein from Akkerman-
sia muciniphila or the pasteurized bacterium improves metabolism in
obese and diabetic mice. Nat Med 23:107–113. https://doi.org/10.1038/
nm.4236.
449. Ottman N, Reunanen J, Meijerink M, Pietila TE, Kainulainen V, Klievink
J, Huuskonen L, Aalvink S, Skurnik M, Boeren S, Satokari R, Mercenier A,
Palva A, Smidt H, de Vos WM, Belzer C. 2017. Pili-like proteins of
Akkermansia muciniphila modulate host immune responses and gut
barrier function. PLoS One 12:e0173004. https://doi.org/10.1371/
journal.pone.0173004.
450. Ottman N. 2015. Host immunostimulation and substrate utilization of
the gut symbiont Akkermansia muciniphila. PhD thesis. Wageningen
University, Wageningen, The Netherlands.
451. Belzer C, de Vos WM. 2012. Microbes inside—from diversity to function:
the case of Akkermansia. ISME J 6:1449–1458. https://doi.org/10.1038/
ismej.2012.6.
452. de Vos WM. 2017. Microbe proﬁle: Akkermansia muciniphila: a con-
served intestinal symbiont that acts as the gatekeeper of our mucosa.
Microbiology https://doi.org/10.1099/mic.0.000444.
453. Flint HJ, Scott KP, Louis P, Duncan SH. 2012. The role of the gut
microbiota in nutrition and health. Nat Rev Gastroenterol Hepatol
9:577–589. https://doi.org/10.1038/nrgastro.2012.156.
454. Gordon JI, Dewey KG, Mills DA, Medzhitov RM. 2012. The human gut
microbiota and undernutrition. Sci Transl Med 4: 137ps12. https://doi
.org/10.1126/scitranslmed.3004347.
455. Le Chatelier E, Nielsen T, Qin J, Prifti E, Hildebrand F, Falony G, Almeida
M, Arumugam M, Batto JM, Kennedy S, Leonard P, Li J, Burgdorf K,
Grarup N, Jorgensen T, Brandslund I, Nielsen HB, Juncker AS, Bertalan
M, Levenez F, Pons N, Rasmussen S, Sunagawa S, Tap J, Tims S,
Zoetendal EG, Brunak S, Clement K, Dore J, Kleerebezem M, Kristiansen
K, Renault P, Sicheritz-Ponten T, de Vos WM, Zucker JD, Raes J, Hansen
T, MetaHIT Consortium, Bork P, Wang J, Ehrlich SD, Pedersen O. 2013.
Richness of human gut microbiome correlates with metabolic markers.
Nature 500:541–546. https://doi.org/10.1038/nature12506.
456. Wopereis H, Oozeer R, Knipping K, Belzer C, Knol J. 2014. The ﬁrst
thousand days—intestinal microbiology of early life: establishing a
symbiosis. Pediatr Allergy Immunol 25:428–438. https://doi.org/10
.1111/pai.12232.
457. Korpela K, Salonen A, Virta LJ, Kekkonen RA, Forslund K, Bork P, de Vos
WM. 2016. Intestinal microbiome is related to lifetime antibiotic use in
Finnish pre-school children. Nat Commun 7:10410. https://doi.org/10
.1038/ncomms10410.
458. DiBartolomeo ME, Claud EC. 2016. The developing microbiome of the
preterm infant. Clin Ther 38:733–739. https://doi.org/10.1016/j.clinthera
.2016.02.003.
459. de Weerth C, Fuentes S, Puylaert P, de Vos WM. 2013. Intestinal
microbiota of infants with colic: development and speciﬁc signatures.
Pediatrics 131:e550–e558. https://doi.org/10.1542/peds.2012-1449.
460. Butel MJ, Suau A, Campeotto F, Magne F, Aires J, Ferraris L, Kalach N,
Leroux B, Dupont C. 2007. Conditions of biﬁdobacterial colonization in
preterm infants: a prospective analysis. J Pediatr Gastroenterol Nutr
44:577–582. https://doi.org/10.1097/MPG.0b013e3180406b20.
461. Tojo R, Suarez A, Clemente MG, de los Reyes-Gavilan CG, Margolles A,
Gueimonde M, Ruas-Madiedo P. 2014. Intestinal microbiota in health
and disease: role of biﬁdobacteria in gut homeostasis. World J Gastro-
enterol 20:15163–15176. https://doi.org/10.3748/wjg.v20.i41.15163.
462. de Meij TG, de Groot EF, Eck A, Budding AE, Kneepkens CM, Benninga
MA, van Bodegraven AA, Savelkoul PH. 2016. Characterization of mi-
crobiota in children with chronic functional constipation. PLoS One
11:e0164731. https://doi.org/10.1371/journal.pone.0164731.
463. Chichlowski M, De Lartigue G, German JB, Raybould HE, Mills DA.
2012. Biﬁdobacteria isolated from infants and cultured on human
milk oligosaccharides affect intestinal epithelial function. J Pediatr
Gastroenterol Nutr 55:321–327. https://doi.org/10.1097/MPG
.0b013e31824fb899.
464. Fukuda S, Toh H, Hase K, Oshima K, Nakanishi Y, Yoshimura K, Tobe T,
Clarke JM, Topping DL, Suzuki T, Taylor TD, Itoh K, Kikuchi J, Morita H,
Hattori M, Ohno H. 2011. Biﬁdobacteria can protect from enteropatho-
genic infection through production of acetate. Nature 469:543–547.
https://doi.org/10.1038/nature09646.
465. Taipale T, Pienihakkinen K, Isolauri E, Larsen C, Brockmann E, Alanen P,
Jokela J, Soderling E. 2011. Biﬁdobacterium animalis subsp. lactis BB-12
in reducing the risk of infections in infancy. Br J Nutr 105:409–416.
https://doi.org/10.1017/S0007114510003685.
466. Vanhoutvin SA, Troost FJ, Kilkens TO, Lindsey PJ, Hamer HM, Jonkers
DM, Venema K, Brummer RJ. 2009. The effects of butyrate enemas on
visceral perception in healthy volunteers. Neurogastroenterol Motil
21:952-e76. https://doi.org/10.1111/j.1365-2982.2009.01324.x.
467. Ogawa K, Ben RA, Pons S, de Paolo MI, Bustos Fernandez L. 1992.
Volatile fatty acids, lactic acid, and pH in the stools of breast-fed and
bottle-fed infants. J Pediatr Gastroenterol Nutr 15:248–252. https://doi
.org/10.1097/00005176-199210000-00004.
468. Haarman M, Knol J. 2006. Quantitative real-time PCR analysis of fecal
Lactobacillus species in infants receiving a prebiotic infant formula.
Appl Environ Microbiol 72:2359–2365. https://doi.org/10.1128/AEM.72
.4.2359-2365.2006.
469. Abe R, Oda S, Sadahiro T, Nakamura M, Hirayama Y, Tateishi Y, Shino-
zaki K, Hirasawa H. 2010. Gram-negative bacteremia induces greater
magnitude of inﬂammatory response than Gram-positive bacteremia.
Crit Care 14:R27. https://doi.org/10.1186/cc8898.
470. Kant R, de Vos WM, Palva A, Satokari R. 2014. Immunostimulatory CpG
motifs in the genomes of gut bacteria and their role in human health
and disease. J Med Microbiol 63:293–308. https://doi.org/10.1099/jmm
.0.064220-0.
471. Young SL, Simon MA, Baird MA, Tannock GW, Bibiloni R, Spencely K,
Lane JM, Fitzharris P, Crane J, Town I, Addo-Yobo E, Murray CS, Wood-
cock A. 2004. Biﬁdobacterial species differentially affect expression of
cell surface markers and cytokines of dendritic cells harvested from
cord blood. Clin Diagn Lab Immunol 11:686–690.
472. Vatanen T, Kostic AD, d’Hennezel E, Siljander H, Franzosa EA, Yassour M,
Kolde R, Vlamakis H, Arthur TD, Hamalainen AM, Peet A, Tillmann V,
Uibo R, Mokurov S, Dorshakova N, Ilonen J, Virtanen SM, Szabo SJ,
Porter JA, Lahdesmaki H, Huttenhower C, Gevers D, Cullen TW, Knip M,
The Infant Gut Microbiota Microbiology and Molecular Biology Reviews
December 2017 Volume 81 Issue 4 e00036-17 mmbr.asm.org 65
 o
n
 August 20, 2018 by guest
http://m
m
br.asm
.org/
D
ow
nloaded from
 
DIABIMMUNE Study Group, Xavier RJ. 2016. Variation in microbiome
LPS immunogenicity contributes to autoimmunity in humans. Cell
165:842–853. https://doi.org/10.1016/j.cell.2016.04.007.
473. Virgin HW. 2014. The virome in mammalian physiology and disease.
Cell 157:142–150. https://doi.org/10.1016/j.cell.2014.02.032.
474. Ray K. 2015. Gut microbiota: a ‘friendly’ gut virus? Nat Rev Gastroen-
terol Hepatol 12:6. https://doi.org/10.1038/nrgastro.2014.220.
475. Hayes S, Mahony J, Nauta A, van Sinderen D. 2017. Metagenomic
approaches to assess bacteriophages in various environmental niches.
Viruses 9:E127. https://doi.org/10.3390/v9060127.
476. Wommack KE, Bhavsar J, Polson SW, Chen J, Dumas M, Srinivasiah S,
Furman M, Jamindar S, Nasko DJ. 2012. VIROME: a standard operating
procedure for analysis of viral metagenome sequences. Stand Genomic
Sci 6:421. https://doi.org/10.4056/sigs.2945050.
477. Reyes A, Haynes M, Hanson N, Angly FE, Heath AC, Rohwer F,
Gordon JI. 2010. Viruses in the faecal microbiota of monozygotic
twins and their mothers. Nature 466:334–338. https://doi.org/10
.1038/nature09199.
478. Reyes A, Semenkovich NP, Whiteson K, Rohwer F, Gordon JI. 2012.
Going viral: next-generation sequencing applied to phage populations
in the human gut. Nat Rev Microbiol 10:607–617. https://doi.org/10
.1038/nrmicro2853.
479. Manrique P, Bolduc B, Walk ST, van der Oost J, de Vos WM, Young MJ.
2016. Healthy human gut phageome. Proc Natl Acad Sci U S A 113:
10400–10405. https://doi.org/10.1073/pnas.1601060113.
480. Lim ES, Zhou Y, Zhao G, Bauer IK, Droit L, Ndao IM, Warner BB, Tarr PI,
Wang D, Holtz LR. 2015. Early life dynamics of the human gut virome
and bacterial microbiome in infants. Nat Med 21:1228–1234. https://
doi.org/10.1038/nm.3950.
481. Reyes A, Blanton LV, Cao S, Zhao G, Manary M, Trehan I, Smith MI, Wang
D, Virgin HW, Rohwer F, Gordon JI. 2015. Gut DNA viromes of Malawian
twins discordant for severe acute malnutrition. Proc Natl Acad Sci
U S A 112:11941–11946. https://doi.org/10.1073/pnas.1514285112.
482. Kapusinszky B, Minor P, Delwart E. 2012. Nearly constant shedding of
diverse enteric viruses by two healthy infants. J Clin Microbiol 50:
3427–3434. https://doi.org/10.1128/JCM.01589-12.
483. Minot S, Sinha R, Chen J, Li H, Keilbaugh SA, Wu GD, Lewis JD, Bushman
FD. 2011. The human gut virome: inter-individual variation and dy-
namic response to diet. Genome Res 21:1616–1625. https://doi.org/10
.1101/gr.122705.111.
484. Canchaya C, Fournous G, Chibani-Chennouﬁ S, Dillmann ML, Brussow
H. 2003. Phage as agents of lateral gene transfer. Curr Opin Microbiol
6:417–424. https://doi.org/10.1016/S1369-5274(03)00086-9.
485. Ogilvie LA, Jones BV. 2015. The human gut virome: a multifaceted
majority. Front Microbiol 6:918. https://doi.org/10.3389/fmicb.2015
.00918.
486. Lugli GA, Milani C, Turroni F, Tremblay D, Ferrario C, Mancabelli L,
Duranti S, Ward DV, Ossiprandi MC, Moineau S, van Sinderen D, Ventura
M. 2016. Prophages of the genus Biﬁdobacterium as modulating
agents of the infant gut microbiota. Environ Microbiol 18:2196–2213.
https://doi.org/10.1111/1462-2920.13154.
487. Sheth RU, Cabral V, Chen SP, Wang HH. 2016. Manipulating bacterial
communities by in situ microbiome engineering. Trends Genet 32:
189–200. https://doi.org/10.1016/j.tig.2016.01.005.
488. Hempel S, Newberry S, Ruelaz A, Wang Z, Miles JN, Suttorp MJ, Johnsen
B, Shanman R, Slusser W, Fu N, Smith A, Roth B, Polak J, Motala A, Perry
T, Shekelle PG. 2011. Safety of probiotics used to reduce risk and
prevent or treat disease. Agency for Healthcare Research and Quality,
Rockville, MD.
489. Stojanovic N, Plecas D, Plesinac S. 2012. Normal vaginal ﬂora, disorders
and application of probiotics in pregnancy. Arch Gynecol Obstet 286:
325–332. https://doi.org/10.1007/s00404-012-2293-7.
490. Gueimonde M, Sakata S, Kalliomaki M, Isolauri E, Benno Y, Salminen S.
2006. Effect of maternal consumption of lactobacillus GG on transfer
and establishment of fecal biﬁdobacterial microbiota in neonates. J
Pediatr Gastroenterol Nutr 42:166–170. https://doi.org/10.1097/01
.mpg.0000189346.25172.fd.
491. Lahtinen SJ, Boyle RJ, Kivivuori S, Oppedisano F, Smith KR, Robins-
Browne R, Salminen SJ, Tang ML. 2009. Prenatal probiotic administra-
tion can inﬂuence Biﬁdobacterium microbiota development in infants
at high risk of allergy. J Allergy Clin Immunol 123:499–501. https://doi
.org/10.1016/j.jaci.2008.11.034.
492. Panigrahi P, Parida S, Pradhan L, Mohapatra SS, Misra PR, Johnson JA,
Chaudhry R, Taylor S, Hansen NI, Gewolb IH. 2008. Long-term coloni-
zation of a Lactobacillus plantarum synbiotic preparation in the neo-
natal gut. J Pediatr Gastroenterol Nutr 47:45–53. https://doi.org/10
.1097/MPG.0b013e31815a5f2c.
493. AlFaleh K, Anabrees J. 2014. Probiotics for prevention of necrotizing
enterocolitis in preterm infants. Cochrane Database Syst Rev https://
doi.org/10.1002/14651858.CD005496.pub4.
494. Kajander K, Hatakka K, Poussa T, Farkkila M, Korpela R. 2005. A probiotic
mixture alleviates symptoms in irritable bowel syndrome patients: a
controlled 6-month intervention. Aliment Pharmacol Ther 22:387–394.
https://doi.org/10.1111/j.1365-2036.2005.02579.x.
495. Lin HC, Su BH, Chen AC, Lin TW, Tsai CH, Yeh TF, Oh W. 2005. Oral
probiotics reduce the incidence and severity of necrotizing enteroco-
litis in very low birth weight infants. Pediatrics 115:1–4. https://doi.org/
10.1542/peds.2004-1463.
496. Braegger C, Chmielewska A, Decsi T, Kolacek S, Mihatsch W, Moreno L,
Piescik M, Puntis J, Shamir R, Szajewska H, Turck D, van Goudoever J,
Nutrition ECo. 2011. Supplementation of infant formula with probiotics
and/or prebiotics: a systematic review and comment by the ESPGHAN
committee on nutrition. J Pediatr Gastroenterol Nutr 52:238–250.
https://doi.org/10.1097/MPG.0b013e3181fb9e80.
497. Cuello-Garcia CA, Brozek JL, Fiocchi A, Pawankar R, Yepes-Nunez JJ,
Terracciano L, Gandhi S, Agarwal A, Zhang Y, Schunemann HJ. 2015.
Probiotics for the prevention of allergy: a systematic review and meta-
analysis of randomized controlled trials. J Allergy Clin Immunol 136:
952–961. https://doi.org/10.1016/j.jaci.2015.04.031.
498. Bergmann H, Rodriguez JM, Salminen S, Szajewska H. 2014. Probiotics
in human milk and probiotic supplementation in infant nutrition: a
workshop report. Br J Nutr 112:1119–1128. https://doi.org/10.1017/
S0007114514001949.
499. Chau K, Lau E, Greenberg S, Jacobson S, Yazdani-Brojeni P, Verma N,
Koren G. 2015. Probiotics for infantile colic: a randomized, double-
blind, placebo-controlled trial investigating Lactobacillus reuteri
DSM 17938. J Pediatr 166:74–78. https://doi.org/10.1016/j.jpeds.2014
.09.020.
500. Szajewska H, Gyrczuk E, Horvath A. 2013. Lactobacillus reuteri DSM
17938 for the management of infantile colic in breastfed infants: a
randomized, double-blind, placebo-controlled trial. J Pediatr 162:
257–262. https://doi.org/10.1016/j.jpeds.2012.08.004.
501. Savino F, Cordisco L, Tarasco V, Palumeri E, Calabrese R, Oggero R, Roos
S, Matteuzzi D. 2010. Lactobacillus reuteri DSM 17938 in infantile colic:
a randomized, double-blind, placebo-controlled trial. Pediatrics 126:
e526–e533. https://doi.org/10.1542/peds.2010-0433.
502. Partty A, Luoto R, Kalliomaki M, Salminen S, Isolauri E. 2013. Effects of
early prebiotic and probiotic supplementation on development of gut
microbiota and fussing and crying in preterm infants: a randomized,
double-blind, placebo-controlled trial. J Pediatr 163:1272–1277.e1–2.
https://doi.org/10.1016/j.jpeds.2013.05.035.
503. Partty A, Isolauri E. 2012. Gut microbiota and infant distress—the
association between compositional development of the gut microbiota
and fussing and crying in early infancy. Microb Ecol Health Dis https://
doi.org/10.3402/mehd.v23i0.18577.
504. Sung V, Hiscock H, Tang ML, Mensah FK, Nation ML, Satzke C, Heine RG,
Stock A, Barr RG, Wake M. 2014. Treating infant colic with the probiotic
Lactobacillus reuteri: double blind, placebo controlled randomised trial.
BMJ 348:g2107. https://doi.org/10.1136/bmj.g2107.
505. Skorka A, Piescik-Lech M, Kolodziej M, Szajewska H. 2017. To add or not
to add probiotics to infant formulae? An updated systematic review.
Benef Microbes https://doi.org/10.3920/BM2016.0233.
506. Mah KW, Chin VI, Wong WS, Lay C, Tannock GW, Shek LP, Aw MM, Chua
KY, Wong HB, Panchalingham A, Lee BW. 2007. Effect of a milk formula
containing probiotics on the fecal microbiota of Asian infants at risk of
atopic diseases. Pediatr Res 62:674–679. https://doi.org/10.1203/PDR
.0b013e31815991d5.
507. Boyle RJ, Bath-Hextall FJ, Leonardi-Bee J, Murrell DF, Tang ML. 2008.
Probiotics for treating eczema. Cochrane Database Syst Rev https://doi
.org/10.1002/14651858.CD006135.pub2.
508. Correa NB, Peret Filho LA, Penna FJ, Lima FM, Nicoli JR. 2005. A
randomized formula controlled trial of Biﬁdobacterium lactis and Strep-
tococcus thermophilus for prevention of antibiotic-associated diarrhea
in infants. J Clin Gastroenterol 39:385–389. https://doi.org/10.1097/01
.mcg.0000159217.47419.5b.
509. Vandenplas Y, Zakharova I, Dmitrieva Y. 2015. Oligosaccharides in
infant formula: more evidence to validate the role of prebiotics. Br J
Nutr 113:1339–1344. https://doi.org/10.1017/S0007114515000823.
Milani et al. Microbiology and Molecular Biology Reviews
December 2017 Volume 81 Issue 4 e00036-17 mmbr.asm.org 66
 o
n
 August 20, 2018 by guest
http://m
m
br.asm
.org/
D
ow
nloaded from
 
510. Jinno S, Toshimitsu T, Nakamura Y, Kubota T, Igoshi Y, Ozawa N, Suzuki
S, Nakano T, Morita Y, Arima T, Yamaide F, Kohno Y, Masuda K, Shimojo
N. 2017. Maternal prebiotic ingestion increased the number of fecal
biﬁdobacteria in pregnant women but not in their neonates aged one
month. Nutrients 9:E196. https://doi.org/10.3390/nu9030196.
511. Kunz C, Rudloff S, Baier W, Klein N, Strobel S. 2000. Oligosaccharides in
human milk: structural, functional, and metabolic aspects. Annu Rev
Nutr 20:699–722. https://doi.org/10.1146/annurev.nutr.20.1.699.
512. Roberfroid M, Gibson GR, Hoyles L, McCartney AL, Rastall R, Rowland I,
Wolvers D, Watzl B, Szajewska H, Stahl B, Guarner F, Respondek F,
Whelan K, Coxam V, Davicco MJ, Leotoing L, Wittrant Y, Delzenne NM,
Cani PD, Neyrinck AM, Meheust A. 2010. Prebiotic effects: metabolic
and health beneﬁts. Br J Nutr 104(Suppl 2):S1–S63. https://doi.org/10
.1017/S0007114510003363.
513. Firmansyah A, Chongviriyaphan N, Dillon DH, Khan NC, Morita T,
Tontisirin K, Tuyen LD, Wang W, Bindels J, Deurenberg P, Ong S,
Hautvast J, Meyer D, Vaughan EE. 2016. Fructans in the ﬁrst 1000 days
of life and beyond, and for pregnancy. Asia Pac J Clin Nutr 25:652–675.
https://doi.org/10.6133/apjcn.092016.02.
514. Veereman-Wauters G, Staelens S, Van de Broek H, Plaskie K, Wesling
F, Roger LC, McCartney AL, Assam P. 2011. Physiological and biﬁ-
dogenic effects of prebiotic supplements in infant formulae. J Pe-
diatr Gastroenterol Nutr 52:763–771. https://doi.org/10.1097/MPG
.0b013e3182139f39.
515. Knol J, Scholtens P, Kafka C, Steenbakkers J, Gro S, Helm K, Klarczyk M,
Schopfer H, Bockler HM, Wells J. 2005. Colon microﬂora in infants fed
formula with galacto- and fructo-oligosaccharides: more like breast-fed
infants. J Pediatr Gastroenterol Nutr 40:36–42. https://doi.org/10.1097/
00005176-200501000-00007.
516. Ben XM, Li J, Feng ZT, Shi SY, Lu YD, Chen R, Zhou XY. 2008. Low level
of galacto-oligosaccharide in infant formula stimulates growth of in-
testinal biﬁdobacteria and lactobacilli. World J Gastroenterol 14:
6564–6568.
517. Rinne MM, Gueimonde M, Kalliomaki M, Hoppu U, Salminen SJ, Isolauri
E. 2005. Similar biﬁdogenic effects of prebiotic-supplemented partially
hydrolyzed infant formula and breastfeeding on infant gut microbiota.
FEMS Immunol Med Microbiol 43:59–65. https://doi.org/10.1016/j
.femsim.2004.07.005.
518. Sierra C, Bernal MJ, Blasco J, Martinez R, Dalmau J, Ortuno I, Espin B,
Vasallo MI, Gil D, Vidal ML, Infante D, Leis R, Maldonado J, Moreno JM,
Roman E. 2015. Prebiotic effect during the ﬁrst year of life in healthy
infants fed formula containing GOS as the only prebiotic: a multicentre,
randomised, double-blind and placebo-controlled trial. Eur J Nutr 54:
89–99. https://doi.org/10.1007/s00394-014-0689-9.
519. Scalabrin DM, Mitmesser SH, Welling GW, Harris CL, Marunycz JD,
Walker DC, Bos NA, Tolkko S, Salminen S, Vanderhoof JA. 2012. New
prebiotic blend of polydextrose and galacto-oligosaccharides has a
biﬁdogenic effect in young infants. J Pediatr Gastroenterol Nutr 54:
343–352. https://doi.org/10.1097/MPG.0b013e318237ed95.
520. Gonzalez R, Klaassens ES, Malinen E, de Vos WM, Vaughan EE. 2008.
Differential transcriptional response of Biﬁdobacterium longum to hu-
man milk, formula milk, and galactooligosaccharide. Appl Environ Mi-
crobiol 74:4686–4694. https://doi.org/10.1128/AEM.00122-08.
521. Kapiki A, Costalos C, Oikonomidou C, Triantafyllidou A, Loukatou E,
Pertrohilou V. 2007. The effect of a fructo-oligosaccharide supple-
mented formula on gut ﬂora of preterm infants. Early Hum Dev 83:
335–339. https://doi.org/10.1016/j.earlhumdev.2006.07.003.
522. Luoto R, Ruuskanen O, Waris M, Kalliomaki M, Salminen S, Isolauri E.
2014. Prebiotic and probiotic supplementation prevents rhinovirus
infections in preterm infants: a randomized, placebo-controlled trial. J
Allergy Clin Immunol 133:405–413. https://doi.org/10.1016/j.jaci.2013
.08.020.
523. Nayfach S, Rodriguez-Mueller B, Garud N, Pollard KS. 2016. An inte-
grated metagenomics pipeline for strain proﬁling reveals novel pat-
terns of bacterial transmission and biogeography. Genome Res 26:
1612–1625. https://doi.org/10.1101/gr.201863.115.
524. Dominguez-Bello MG, De Jesus-Laboy KM, Shen N, Cox LM, Amir A,
Gonzalez A, Bokulich NA, Song SJ, Hoashi M, Rivera-Vinas JI, Mendez K,
Knight R, Clemente JC. 2016. Partial restoration of the microbiota of
cesarean-born infants via vaginal microbial transfer. Nat Med 22:
250–253. https://doi.org/10.1038/nm.4039.
525. Dezateux C, Colson D, Brocklehurst P, Elias P. 2016. ‘Life after Life
Study’: report of a scientiﬁc meeting held at The Royal College
of Physicians, 14th January 2016. https://doi.org/10.14324/000.rp
.1485681.
526. Gomez-Gallego C, Garcia-Mantrana I, Salminen S, Collado MC. 2016.
The human milk microbiome and factors inﬂuencing its composition
and activity. Semin Fetal Neonatal Med 21:400–405. https://doi.org/10
.1016/j.siny.2016.05.003.
527. Jaeggi T, Kortman GA, Moretti D, Chassard C, Holding P, Dostal A,
Boekhorst J, Timmerman HM, Swinkels DW, Tjalsma H, Njenga J,
Mwangi A, Kvalsvig J, Lacroix C, Zimmermann MB. 2015. Iron fortiﬁca-
tion adversely affects the gut microbiome, increases pathogen abun-
dance and induces intestinal inﬂammation in Kenyan infants. Gut
64:731–742. https://doi.org/10.1136/gutjnl-2014-307720.
528. Subramanian S, Huq S, Yatsunenko T, Haque R, Mahfuz M, Alam MA,
Benezra A, DeStefano J, Meier MF, Muegge BD, Barratt MJ, VanAren-
donk LG, Zhang Q, Province MA, Petri WA, Jr, Ahmed T, Gordon JI. 2014.
Persistent gut microbiota immaturity in malnourished Bangladeshi
children. Nature 510:417–421. https://doi.org/10.1038/nature13421.
529. Tissier H. 1900. Recherches sur la ﬂore intestinale normale et
pathologique du nourisson. Thesis. University of Paris, Paris, France.
530. Logan WR. 1913. The intestinal ﬂora of infants and young children. J
Pathol Bacteriol 18:527–551. https://doi.org/10.1002/path.1700180154.
531. Norton RC, Shohl AT. 1926. The hydrogen ion concentration of the
stools of new-born infants. Am J Dis Child 32:183–191.
532. Ventura M, Turroni F, van Sinderen D. 2012. Probiogenomics as a tool
to obtain genetic insights into adaptation of probiotic bacteria to the
human gut. Bioeng Bugs 3:73–79.
533. Hemsell DL, Obregon VL, Heard MC, Nobles BJ. 1989. Endometrial
bacteria in asymptomatic, nonpregnant women. J Reprod Med 34:
872–874.
The Infant Gut Microbiota Microbiology and Molecular Biology Reviews
December 2017 Volume 81 Issue 4 e00036-17 mmbr.asm.org 67
 o
n
 August 20, 2018 by guest
http://m
m
br.asm
.org/
D
ow
nloaded from
 
